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Abstract 
Biological methylation is defined as the transfer of a methyl group from 
S-adenosyl-L-methionine (SAM) to one of a wide range of potential acceptors such 
as DNA, RNA, protein, hormones and neurotransmitters. Protein arginine 
methylation is a common post-translational modification facilitated by protein 
arginine methyltransferases (e. g. PRMTI). The roles of these enzymes in vivo are 
currently poorly understood. 
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The focus of the project is design and synthesis of PRMT inhibitors with the ultimate 
goal of evaluating their activities in cells. Preliminary work toward the synthesis of 
S-adenosyl-trifluoromethyl-L-homocysteine 69 and adenosyl 5'-[2-(tert-butoxycarbo- 
nylam ino)ethyl-tri fluorom ethyl] thiophenium 70 is described. The temary crystal 
2 
structure of PRMTI in complex with S-adenoSyl-L-homocysteine (SAH) and an 
arginine containing peptide (PBD IOR8) was used to design a series of potential 
bisubstrate inhibitors of PRMTI. The prototypical SAM analogues bearing guanidine 
group were sought to replace the reactive sulfonium centre with nitrogen. Analogue 
synthesis proceeded via successive reductive arnination of Y-arnino-Y-deoxy- 
adenosine and deprotection in good overall yields. An alkyne SAM analogue, 
5'-[(S-3-amino-3-carboxypropyl)-propargylaminol-5'-deoxyadenosine 77 was 
prepared, which underwent efficient Cu (1) catalysed Huisgen reaction to yield a 
triazole derived SAM analogue 5'-[(S-3-amino-3-carboxypropyl)-[I-(2-guanidino- 
ethyl)- I H- 1,2,3-triazol-4-yl]methyl-amino]-5'-deoxyadenosine 78. Preliminary 
biological evaluation of the compounds by collaborators Professor Steve Ward and 
Dr Richard Parry at the University of Bath, confirmed that 5'-[(S-3-amino-3-carboxy- 
propyl)-3-guanidinopropyl-amino]-5'-deoxyadenosine 74a and 5-[(S-3-amino-3- 
carboxypropyl)-5-guanidinopentyl-amino]-5'-deoxyadenosine 74c are potent 
inhibitors of PRMTI but not the lysine methyltransferase SET7. A related N-6 
modified SAM analogue 5'-[(S-3-amino-3-carboxypropyl)-3-guanidinopropyl- 
amino]-5'-deoxy-N6-(l I 
-azido-3,6,9-trioxaundecane)-amino adenosine 79 bearing an 
azide tether was developed with the aim of allowing facile introduction of biolin or 
fluorescent dyes, using either Staudinger ligation, or Cu (1) catalysed Huisgen 
reaction to provide compounds that can be used for affinity purification of the target 
protein or study of its localisation in cells respectively. 
Finally, progress toward a novel, rapid and enantioselective synthesis of the natural 
3 
product (+)-sinefungin is reported. Key dihydropyridazine intermediates were 
generated from adenosyl 5'-propaldehyde, commercially available azodicarboxylate 
derivatives and ester substituted vinyltriphenylphosphonium salt by successful 
extension of methodology first reported by Ley and co-workers. Deprotection and 
ring opening of clihydropyridazine Compounds was attempted, and unfortunately we 
were not able to generate (+)-sinefungin, although it is hoped that this route can be 
developed to achieve this in the future. 
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ADMA asymmetric dimethylarginine 
AlBN azobisisobutyronitrile 
ATP adenosine triphosphate 
BAIB (bis(acetoxy)-iodo)benzene 
Boc tert-butoxycarbonyl 
Bz benzoyl 
BzCI benzoyl chloride 
CARMI coactivator associated arginine methyltransferase I 
Cbz benzyloxycarbonyl 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC N, Y-dicyclohexyl-carbodiimide 
DEAD diethyl azodicarboxylate 
DIAD diisopropyl azodicarboxylate 
DIBAL diisobutylaluminiurn hydride 
DIPEA N, Ný-diisopropylethylamine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DMAP 4-dimethylaminopyridine 
DNA deoxyribonucleic acid 
DPPA diphenyl phosphorazide 
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EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride 
Fmoc 9H-fluoren-9-ylmethyl carbonyl 
hnRNP heterogeneous nuclear ribonucleoprotein 
HIV human immunodeficiency virus 
HOBt hydroxybenzotriazole 
LDA lithium diisopropylamide 
MES morpholinomethanesulfonic acid 
MetJ methionine repressor protein 
MMA monomethylarginine 
NBS N-bromosuccinimide 
PKMTs protein lysine methyltransferases 
PRMTs protein arginine methyltransferases 
Py pyridine 
PyBOP benzotriazol-1-yloxytripyrrolidinophosphonium 
hexafluorophosphate 
rpS2 ribosome protein S2 
RNA ribonucleic acid 
SAH S-adenosyl-L-homocysteine 
SAM S-adenosyl-L-methionine 
SDMA symmetric dimethylarginine 
snRNP small nuclear ribonucleoprotein 
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TBAF tetrabutylarnmonium fluoride 
TEMPO 2,2,6,6-tetramethylpiperidine- I 
-oxyl 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TMSBr bromotrimethylsi lane 
TMSCI trimcthylsilylcholride 
TSCI p-toluenesulfonyl chloride 
TsOH p-toluenesulfonate acid 
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Chapter I 
Introduction 
1.1. Biological methylation and S-adenOSyl-L-methionine (SAM) 
Biological methylation refers to the transfer of one or more methyl groups from a 
donor to a substrate in living organisms, usually under the control of enzymes called 
methyltransferases. 1 Biomethylation is an important step in the regulation of a 
number of cellular processes in both prokaryotes and eukaryotes, providing the 
signal for processes, such as control of interactions with other macromolecules. 2 
S-adenosyl-L-methionine (SAM, Figure 1) was discovered in 1952 by Cantoni and 
emerged as the major methyl group carrier in cells. 3 SAM is claimed to be the second 
most abundant co-substrate in cells after ATp4 with an intracellular concentration of 
approximately 0.04mM5 and is responsible for a wide range of biological 
transformations in addition to methylation. 6 The biosynthesis of SAM involves 
reaction between ATP and L-methionine catalysed by ATP: L-methionine 
S-adenosyltransferase (EC 2.5.1.6) (Figure 1). 6 
SAM dependent methyltransferases. catalyse the transfer of a methyl group from the 
sulfonium centre at SAM to a wide range of substrates, including DNA, RNA, 
proteins, hormones and neurotransmitters. 7 The transfer of the methyl group from 
SAM to a nucleophilic atom of the substrate presumably occurs Via SN2 nucleophilic 
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displacement, leading to the by-product S-adenosyl-L-homocysteine (SAH). SAH is 
actually a strong inhibitor of methyltransferases and must then be displaced from the 
binding site before being hydrolysed into adenosine and L-homocysteine by the 
enzyme SAH hydrolase (EC 3.3.1.1) (Figure 1). 6 Each SAM dependent 
methyltransferase is necessarily adapted to display a substrate specific binding site in 
order to achieve selectivity fdr individual methyl acceptors. 
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Figure 1: Biosynthesis of SAM, methyltransfer, and SAH's metabolism 
Methylation is a common post-translational modification of proteins, and any 
potentially nucleophilic atom including nitrogen, oxygen, sulfur and carbon can be 
transformed, leading to new physical properties that may be recognised by other 
proteins potentially allowing signal transfer. 8 The most common post-translational 
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methylations occur at oxygen or nitrogen functional groups. The transformation of 
side chain carboxylates of glutamates and aspartates into methyl esters is a common 
example of the former methyl transformation"O that has an obvious impact on 
charge as well as the size of the functional group. 9 Obviously, such changes can be 
easily reversed by hydrolysis, thus offering modulation of target proteins. " 
Methylation at nitrogen atoms, such as the c-amino group of lysine, the guanidine 
moiety of arginine, the imidazole ring of histidine, or the amide side chain of 
glutamine and asparagine is generally less easily reversed! Methylation of nitrogen 
atoms can occur up to three times (mono-, di- and trimcthylation) in the c-amino 
group of lysine, leading to a substantial increase in the size and hydrophobicity at 
that position, potentially disrupting protein-protein interactions, and the mono- 
methylation of lysine can lead to a increase in the pK. value, 12 yet the overall charge 
may remain unaltered. 13 In addition, It is not surprising that protein methylation is as 
important for regulating key cellular events, including regulation of transcription, 
stress response, ageing and protein repair, T-cell activation, nuclear transport, 
neuronal differentiation, ion channel function and cytokine signaling as other 
better-known post-translational modifications, such as phosphory ation. 14 
The primary focus of this thesis is on protein arginine methyltransferases (PRMTs), 
which catalyse methylation of nitrogen atoms on the guanidine moiety of arginine 
residues of protein substrates. 
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1.2. Protein arginine methyltransferases (PRMTs) and protein arginine 
methylation 
Protein arginine methyltransferases (PRMTs, EC 2.1.1.125) catalyse the methylation 
of arginine residues of a variety of proteins involved in cell signaling, RNA splicing 
and gene regulation such as histones 1-12A, H3 and H4.15 In common with the general 
pathway outlined above, all PRMTs utilise SAM as the methyl group donor. 15 Cheng 
and co-workers described a possible catalytic mechanism of PRMTI and PRMT3 
based on the structural features of the active sites of these two enzymes. 16-1 8 Two 
invariant glutamate residues (E144 and E153 of PRMTI and E326 and E335 of 
PRMT3) located at the substrate arginine binding site are essential for methylation to 
occur. There is an electrostatic interaction between the substrate guanidine and E 153 
of PRMTI (or E335 of PRMT3), while another glutamate residue E144 of PRMTI 
(or E326 of PRMT3) acts as a general base, thus liberating a lone pair of electrons on 
the guanidine group that undergoes SN2 reaction with SAM to generate the 
methylated arginine (Figure 2). 16 Similar pairs of glutamate residue are conserved 
among all PRMTs, suggesting the common mechanism for PRIVIT catalysis. 16 
15 
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Figure 2: The possible catalysed mechanism of PRMTs and their classification based 
on product type: Type I generating MMA and ADMA, and Type 11 generating MMA 
and SDMA, Type III only generating MMA and Type IV generating 6-N-MMA. 
In general, PRMTs are categorised as Type 1, Type 11, Type III and Type IV enzymes 
(Figure 2). Type 1,11 and III enzymes catalyse the formation of monomethylarginine 
(MMA) at the terminal guanidine nitrogen atom. Type I and Type 11 enzymes may 
promote further methylation of MMA substrates, either at the previously methylated 
nitrogen to generate asymmetric dimethylarginine (ADMA) or the unsubstituted 
amine leading to symmetric dimethylarginine (SDMA) respectively. In addition, 
Type IV enzyme catalyse the monomethylation at the internal (or 8) guanidine 
nitrogen atom to generate 6-N-monomethylarginine. 9"9 At present, 9 mammalian 
PRMTs have been identified, of which PRMTI, 3,4,6 and 8 belong to Type I 
enzymes, PRMT5,7 are Type 11 enzymes, while PRMT2, and 9 are not classified 
because their exact enzymatic activity has not been demonstrated. 19 In addition, 
16 
FBXOII and FBXOIO, a second family of putative enzymes related to the F 
box-only proteins have been suggested to be PRMT: s, but their biochemical 
characterisation remains to be verified. 20 
In general, PRMTs influence a number of important cellular processes including 
cellular growth, nuclear or cytoplasmic protein shuttling, differentiation and 
embryogenesis, RNA splicing and transport, and post-transcriptional gene 
regulation 
. 
21 The following discussion provides a very brief outline of some known 
biological roles for specific PRMTs, although this information continues to emerge. 
PRMTI, a predominant Type I PRIVIT in mammalian cells, is one of the best studied 
PRMTs at the cellular level. The central role of PRMTI is to provide regulation of 
protein function, for example methylation of heterogeneous nuclear 
ribonucleoprotein (hnRNP) molecules leads to shuttling of these proteins between 
the cytoplasm and the nucleUS. 
22 PRMTI can also methylate histone H4, providing 
modification as a transcriptional activation mark that may regulate gene expression, 
and thus contribute to what is called the "histone code". 23,24 Although PRMT2 does 
not seem to have enzymatic activity, it does appear to function as a coactivator for 
the estrogen receptor. 25 PRMT3's unique character is that it is located exclusively in 
the cytoplasm and harbors a zinc-finger domain at its N-terminal, which acts as a 
substrate recognition module. 26 In fact, PRMT3 seems to be associated with 
ribosome protein S2 (rpS2), because in the absence of PRMT3, rpS2 is 
hypornethylated. 27 The modification of rpS2 with PRMT3 may therefore play a role 
in the regulation of protein synthesiS. 27 PRMT4 binds with the steroid coactivators 
17 
and has apparent transcriptional co-activity itself, and is consequently also named as 
1). 28 pp coactivator associated arginine methyltransferase I (CARM MT4 is a 
coactivator for nuclear receptors and its over-expression is correlated with human 
prostate and breast cancers. 19 PRMT5, the major Type 11 enzyme, methylates histone 
H2A, H3 and H4 and localises to both the cytoplasm and nucleus. 20 In the cytoplasm, 
methylation of Sm protein by PRMT5 is implicated in small nuclear 
ribonucleoprotein (snRNP) biogenesiS. 29 Nuclear PRMT5 associates with regulators 
of transcriptional elongation 30 and can also complex with the hSWI/SNF 
ATP-dependent chromatin remodelling proteins, presumably acting as a 
transcriptional coactivator. 31 PRMT6 is a nuclear enzyme and seems to have the 
ability to methylate itself. " PRMT6 specific substrates include the nuclear scaffold 
protein, histone H3 and H4, DNA polymerase P and HIV proteinS. 20 PRMT7 has 
been described as having Type 11 activity to form SDN4A and Type III activity to 
form MMA on different substrates. 20 PRMT8, is mainly limited to the brain and is 
the only PRIVIT known to be membrane associated, being attached to the plasma 
membrane via N-terminal myristoylation. 32 PRMT9 (4q3 1) was identified based on 
homology with other family members as a product of a gene on human chromosome 
4q3 1.32 It has not been biochemically characterised to date and its N-terminal has a 
TPR repeat, which may modulate protein-protein interactions. 19 FBXO 11, referred to 
as PRMT9, was identified from a "forced" alignment of its amino acid sequence to 
the PRMT family. 33 Its enzymic activity is not clear, because FLAG-tagged 
hFBXO II has been reported to have Type 11 activity, 33 but HA-tagged hFBXO II and 
18 
its C elegans orthologue have no PRIVIT actiVity. 
34 FBXOlO has been temporarily 
identified as PRMT 11, but no biological characterisation has been reported to date. 9 
Besides their important roles in maintaining normal cellular function, PRMT 
activities are dysregulated in some human diseases, such as cardiovascular diseases 
and cancer. 21 PRMTI has recently emerged as a potentially new target for the 
development of a novel therapeutic for heart disease, due to its overexpression in 
35 
patients with coronary heart disease. Moreover, PRMTI appears to be responsible 
for generating the majority of the ADMA in cells, whose plasma levels are 
apparently directly related to heart diseases. 21 Raised plasma levels of free ADMA is 
indeed detected in patients with atherosclerosis, hypercholesterolernia and heart 
failure. 21 Therefore, an efficient therapy for cardiovascular disease may be targeted 
toward the inhibition of PRMTI. Additionally, PRMT4/CARMI targeted 
therapeutics may also provide a novel treatment for a variety of human cancers, 
because this enzyme acts as a transcriptional co-activator for multiple nuclear 
receptor family members including androgen and estrogen receptors and 
dysregulation of nuclear receptor signalling, which are features of hormone 
dependent cancers, such as prostate and breast cancer. 21,35 
The possible relationship between dysregulated PRMT functions with human 
diseases has stimulated interest in the design and synthesis of selective inhibitors for 
PRMT: s. PRMTI was identified as the predominant Type I PRMT in mammalian 
cells, consequently it is one of the best studied PRMTs at the cellular level and its 
19 
x-ray crystal structure is available, 16 for this reason our initial efforts are focused on 
developing specific inhibitors for this protein. 
1.3. Crystal structure of PRMTl 
The X-ray crystal structure of rat PRMTI in complex with SAH, the by-product of 
SAM, and a 19 residues peptide substrate containing three arginines can be accessed 
from the Protein Data Bank (PDB I OR8). 16 The overall structure of PRMTI can be 
divided into four parts: N-terminal, SAM binding domain, P barrel domain and 
climerisation arm (Figure 3). The SAM binding domain resembles other 
methyltransferases, whereas, the P barrel domain is unique to the PRMT family. In 
fact, PRMT: s have a hydrophobic interface that enables dimerisation and even though 
the precise crystal structure of the dimer is not currently known, it is apparent that 
this dimer interface is formed between the dimerisation. arm and the outer surface of 
SAM binding site. Furthermore, dimerisation is believed to be essential for 
methylation activity and the formation of the asymmetric dimethylarginine product. ' 6 
The crystal structure reveals that the cofactor product, SAH is surrounded by amino 
acid residues that are conserved throughout the PRMT family (Figure 3). 16 Various 
electrostatic and hydrogen bonding interactions between SAH and PRMTI include: 
the homocysteine carboxylate, group and R54; the ribose dihydroxyl group and E 100; 
one of the ribose hydroxyl group and H45; the adenine ring amino group and E129; 
the adenine ring and V128 (Figure 4). 16 
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Figure 3: Overall monomeric structure of PRMTI in complex with SAH (tube) and 
substrate arginine peptide (ARGý ball and stick) was visualised by software Visual 
Molecular Dynamics (VMD). 36 
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Figure 4: SAH (black) bound with PRMTl residues (blue) by hydrogen bonds. 
Dashed lines indicate hydrogen bonds. 
Most PRMTI substrates contain glycine- and arginine-rich sequences, " and bind 
with the substrate binding site which is expected to be acidic (Figure 5) and located 
21 
Dimerisation Arm 
in a deep pocket between the SAM binding domain and the P barrel domain (Figure Zý 
3). 16 The residues that make up the substrate binding site are also conserved in the 
PRMT family, and include two glutamates E144 and E153 which form two hydrogen 
bonds with the substrate arginine and stabilise the substrate arginine in the binding 
pocket via electrostatic interactions, thus, are important for the catalysed methylation 
(Figure 5). 16,18 
Figure 5: Active site of PRMTI (solid electrostatic surface) in complex with SAH 
(yellow tube) and substrate arginine (ball and stick). Key glutarnates residues E144 
36 
and 153 are the red areas surrounding the target arginine 
. 
However, the major protein methylation sites within cells are not only on arginine 
residues but also on the c-amino group of lysine. Protein lysine methyltransferases 
(PKMTs, EC 2.1.1.43) catalyse the methyl group transfer from SAM to protein 
lysine residues, including K4, K9, K27, K36 and K79 in histone H3, K20, K59 in 
histone H4, K26 in histone HIB. 37 Almost all PKMTs contain a SET domain with the 
22 
DOTI family as one known exception. 37 In fact, the active site of PKMTs differ from 
PRMTs mainly in SET domain by comparing the X-ray crystal structure of human 
SET7/9 in complex with SAH (SAM cofactor) and mono-methylated lysine 4 on 
histone H3 (PDB 109S)38 with X-ray crystal structure of PRMTI (PDB IOR8), 
which has been described above. 
Figure 6: Active site of SET7/9 (solid electrostatic surface) in complex with SAH 
(yellow tube) and substrate lysine (ball and stick). There is a narrow channel passing 
through the enzyme that connects the substrate lysine and SAH binding sites. 36 
The crystal structure of human SET7/9 revealed that the peptide substrate and SAH 
are located on opposite sides of the SET domain and there is a narrow channel 
passing through the enzyme that connects the peptide and cofactor binding surfaces. 
The target lysine residue of the substrate accesses the methyl group donor, SAM by 
inserting its side chain into this narrow channel (Figure 6). 38 At the lysine binding 
23 
site, the channel surface is fonned by hydrophobic residues that engage in van der 
Waals interactions with the lysine side chain. In addition, two tyrosine residues (Tyr 
245 and Tyr 305) at the lysine binding site hydrogen bond to the lysine c-amino 
group, aligning it for reaction with SAM. 38 
The X-ray crystal structure of PRMTI confirms that its substrate arginine binding 
surface is hydrophilic, which reinforces the possibility of discovering specific 
inhibitors that might bind with PRMTI selectivelY, but not with PKMTs. 
1.4. Inhibitors of PRMTs 
Even though PRMT: s are known to play physiologically important roles in numerous 
cellular processes, their general function in vivo is still not well understood. Global 
inhibitors of methyltransferases that have so far been used for the study of biological 
role of protein arginine methylation in vivo fall into two general types: the first are 
analogues of SAM that compete at the binding site, such as SAH, 
methylthioadenosine 1 and (+)-sinefungin 2 (Figure 7); the second are small 
molecules such as adenosine dialdehyde 3 that inhibit SAH hydrolase, thus causing 
intracellular accumulation of SAH and feedback inhibition of most methylation 
reactions (Figure 7) 
. 
39 However, use of such broad-spectrum inhibitors is 
problematic, because PRMTs are inhibited along with lysine methyltransferases, 
DNA methyltransferases and other SAM-dependent enzymes, thus it is difficult to 
assign specific cellular functions to a distinct methylation event. 40,41 
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Figure 7: Chemical structure of reported inhibitors for PRMTs 
Development of specific inhibitors of PRMTs will therefore be very attractive for the 
study of PRMT biological activities in vivo. Chemical interference offers exquisite 
control over biological pathways since various concentrations of inhibitors can be 
added, or withdrawn at any time in a biological process. There is resurgent interest in 
protein arginine methylation, but there are relatively few chemical probes with which 
to dissect the biological significance of this pathway, creating strong demand for 
such compounds. Development of novel therapeutics is a related but distant ambition 
when compared to the attempt to address this initial demand for such chemical 
probes. The design of specific PRMT inhibitors faces a number of common, but 
important challenges: 1) selective inhibition of PRMTs in the presence of a wide 
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range of SAM utilising enzymes and 2) competition with the high intracellular 
concentration of SAM (0.04mM). 5 
The first specific inhibitor of PRMTs, AMI-I 4 (Figure 7) was discovered to 
selectively inhibit arginine methylation, but not lysine methylation in vitro in 2004 
by Bedford and co-workersýo through the screening of a random compound library. 
Furthermore, AMI-I is cell permeable and can prevent protein arginine methylation 
in cells and has been shown to act as a brake on the action of certain hormones in 
vivo. For example, AMI- I can modulate nuclear receptor regulated transcription from 
estrogens and androgen response elements. This molecule does not compete at the 
SAM/SAH binding site, and is presumed to insert into the arginine binding pocket, 
although this remains to be established. If true, then this might explain the reason 
that this compound displayed the suggested specificity for PRMTs. Although there is 
no crystal structural data available to prove this hypothesis, it is possible that the urea. 
functionality of AMI-I resembles the guanidine group, while the hydrophobic 
40 
naphthalene ring system is of similar length to the alkyl chain of arginine. On the 
other hand, AMI-I is a dye and resembles sulfonated ureas of the Suramin type 
which have been reported to be pleiotropic drugs that target many proteins, 42 so it is 
not an attractive candidate for the therapeutics and the possibility that AMl- I targets 
other proteins required further investigation 
. 
43 Nonetheless, AMI-I provides the first 
indications that selective chemical modulation of PRMTs over other 
methyltransferases is possible and how such probes might be used to give an 
indication of biological processes controlled by PRMTs. The longer term goal of 
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developing compounds that are able to selectively modulate individual PRMTs 
requires compounds that are rationally designed to exploit individual variations 
between the binding sites of individual PRMTs. 
Subsequently, a target-based approach for the rational design of PRMT inhibitors 
was described by Jung and co-workers. 42,43 Virtual screening of a compound library 
lead to the identification of three compounds, stilbamidine 5, allantodapsone 6 and 7 
(Figure 7), and importantly compound 7 showed no inhibitory effect on lysine 
methyltransferase SET7/9.43 These inhibitors were later found to cause cellular 
hypornethylation and a block of estrogen receptor activation, offering a potential 
drug strategy for the treatment of hormone dependent cancer, such as breast cancer. 43 
In addition, a "bump and hole" approach has been developed in an attempt to resolve 
the problem of improving selectivity of potential chemical probes. This strategy 
creates an ligand-mutant receptor pair in which the SAM binding site is genetically 
modified to feature a "hole" that complements the shape of a "bumped" ligand that is 
too large to bind with the wild-type enzyme (Figure 8). 44 The "bump and hole" 
approach was firstly used by Schreiber and co-workers to describe an engineered 
cyclosporin and cyclophilin interface 45 and then successfully implemented with 
46 kinases, nuclear hormone receptors and human growth hormone receptors. In fact, 
the most important function of the "bump and hole" approach is generating a 
chemical probe to selectively regulate transcription, apoptosis, genetic recombination, 
signal transduction for the manipulation and study of biological systems. 44 
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Figure 8: Explanation of "bump and hole" approach. The nature ligand (inhibitor or 
substrate) can bind with protein (wide-type enzyme) and bumped ligand with mutant 
protein respectively. 
Therefore, Gray and co-workers attempted to deliver substrates for specific PRMT 
mutants using the "bump and hole" strategy in which a mutation introduced to yeast 
arginine methyltransferase (Rmtl) binding site is designed to complement a 
46 
chemically modified version of the co-substrate, in this case SAM 
. 
During these 
studies, benzyl-SAH 8 and naphthylmethyl-SAH 9 analogues (Figure 9) were 
identified to selectively inhibit mutant Rmtl and not the wild-type enzyme in vitro 
due to their structure being complementary to the expanded SAM binding site. SAM 
analogue 10 (Figure 9) was found to be preferentially utilised by the mutant Rmtl as 
methyl group donor and not by the wide-type enzyme 
. 
46 Such target-selective 
substrates or inhibitors may be useful as a chemical tool to study the function and 
perhaps identify the substrates of specific PRMTs in vivo. Even though the "bump 
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and hole" derivatives can inhibit the mutant protein arginine methyltransferases, they 
do not inhibit the wild type PRMTs and they require significant manipulation of the 
model organism. 
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Figure 9: Chemical structure of "bump and hole" derivatives, SAH analogues (8 and 
9) as selective inhibitors and SAM analogues (10) as selective substrate to the mutant 
yeast RmtI respectively. 
This thesis concentrates on the rational design of a series of potential inhibitors of 
PRMTI which hopefully can be used for the study of PRMT function in vivo and as 
prototype compounds that would ideally lead to novel therapeutic strategies as well. 
1.5. Chemical synthesis and stability of SAM 
There are a number of important factors that need to be taken into account when 
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developing SAM analogues. In particular, the sulfonium centre of SAM is chiral and 
it has been demonstrated that the (-)-isomer is required for biomethylation. 
Unfortunately, the sulfonium centre undergoes slow pyramidal inversion, leading to 
the inactive (+)-isomer (Scheme 1). Moreover, the sulfonium centre can act as an 
efficient leaving group and degradation may occur by a range of routes, for example 
at high pH the nucleophilic carboxylate may displace the sulfoniurn centre, leading to 
the formation of methylthioadenosine 1 and lactone 11 (Scheme 1). Wong reported 
studies that revealed that large counteranions, such as sulfates are able to stabilise the 
sulfonium centre of SAM against cpimerisation and decomposition over a pH range 
of 3.5 to 5.5 to some extent. 47 
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In addition, SAM is very sensitive to mild alkaline conditions resulting in the 
cleavage of the glycosidic bond. Borchardt reported the mechanism of this alkaline 
hydrolysis of SAM as outlined in Scheme 2.48 In the first stage, cleavage of the 
glycosidic bond occurs with base catalysed elimination between C-4 and C-5, 
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leading to removal of purine ring at C- I to form the alkene 12 and purine 13. Next, 
nucleophilic addition to the aldehyde at C-1 proceeds with conjugate addition to the 
vinyl sulfonium to form sugar 14 with loss of stereochernistry at C-4. 
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Reagents and conditions: 
a) CH31, formic acid, 80%. 49 
Even though the sulfonium centre of SAM is unstable, Borchardt reported a chemical 
synthesis of SAM (Scheme 3). 49 Treatment of SAH with methyl iodide and formic 
acid in the dark for 5 days delivered SAM as a mixture of diastereoisomers in 80% 
yield after purification by Amberlite IRC-5 0 ion exchange resin. 
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Recently an industrial manufacture of SAM leading to enriched (SS)-isomer has 
been reported (Scheme 4). 50 Treatment of adenosine 15 with thionyl. chloride and 
pyridine in acetonitrile gave 5'-chloro adenosine 16 in 94% yield. L-Hornocysteine 
sodium salt was produced by treatment of commercially available L-methionine with 
sodium metal in the presence of liquid ammonia. SAH was then obtained by 
condensing 5'-chloro adenosine 16 and L-homocysteine sodium salt in the presence 
of potassium iodide and water in 75% yield, and SAH was finally subject to 
methylation using Meerwein's salt 17 in the presence of trifluoroacetic acid to afford 
SAM with enrichment of (SS)-iomer in the yield of 60-65%. 
1.6. Stable nitrogen analogues of SAM 
Because of the relative instability of SAM and its analogues, it is attractive to replace 
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the sulfonium centre with another more stable functional group, which would allow 
for a more robust inhibitor analogue. A series of nitrogen analogues of SAM was 
reported by Nelson and Eclick recently. ", 52 Nitrogen analogues of SAM, named 
AzaAdoMet 18 and MeAzaAdoMet 19, in which the sulfoniurn moiety is replaced by 
a tertiary amine or quaternary ammonium centre respectively have been reported 
originally by Blackburn and co-workers (Figure 10). 53 
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Figure 10: Structure of SAM nitrogen analogues: AzaAdoMet 18 and 
MeAzaAdoMet 19. 
The tertiary amine at the Y-position of adenosine was generated by initial alkylation 
of methylarnine with adenosyl 5-tosylate 20 in 80% yield, then subsequently 
alkylated with either the oxazolidinone protected iodide (S isomer) 22 or the racemic 
N-Boc and 0-methylester protected bromide 23 to generate the protected precursors 
24 and 25 respectively (Scheme 5). 53 
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Unfortunately, this second alkylation to introduce the side chain needed long reaction 
times (2-4 days) and produced the desired products in a disappointing yield (5 1% and 
31% respectively). If strong base, such as sodium hydride was used in the second 
alkylation, the yield presumably would be improved, but the deprotonation of the 
secondary amine occurred at the same time as the purinyl amine in adenosine leading 
to alkylation on the N-6 position as by-product. 53 Moreover, deprotection of either 
precursor 24 with BF3-EtSH complex, or precursor 25 with bromotrimethylsilane 
(TMSBr) proved to be problematic and resulted in partial deprotection in both 
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cases. 53 This problematic and quite lengthy synthesis highlights the fact that 
development of a new, more efficient synthetic route toward bisubstrate inhibitors 
based on this tertiary amine motif would be highly desirable. 
Blackburn reported that AzoAdoMet 18 had a relatively low pK,, 
- 
7.08, which meant 
that switching 18 into its protonated form requires a pH below 6.5, which may be 
unsuitable for some proteins. So MeAzoAdoMet 19, a quaternary dimethyl- 
ammonium analogue was developed, which bears a permanent positive charge at 
Y-position that is independent of pH. 53 
In fact, a racernic form of AzoAdoMet 18 was previously reported by Kenyon to 
potentially inhibit E. coli transfer RNA uracil-5-methyltransferase and E-coli B 
methionine synthase. 54 Consequently, Blackburn reported that the protonated form of 
homochiral AzoAdoMet 18 was a potent inhibitor of the E. coli methionine repressor 
protein (MetJ), binding more tightly than SAM and indeed the crystal structure of the 
resulting MetJ-AzoAdoMet 18 complex was reported. 55 Moreover, the quaternary 
ammonium compound, MeAzaAdoMet 19 was competitive with SAM in the 
inhibition of DNA methyltransferase Hhal at nanomolar concentrations. Therefore, 
these highly promising biological results promoted us to design and prepare modified 
nitrogen SAM analogues that might be expected to act as specific bisubstrate 
inhibitors of PRMTI. 
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1.7. The natural (+)-sincfungin as a potent inhibitor of methyltransferascs 
1.7.1. Biological activity of (+)-sinefungin 
The natural product (+)-sinefungin 2 (Figure 7) was isolated in 1971 from a strain of 
Streptomyces grisoleus at Lilly Research LaboratorieS56 as a nucleoside antibiotic 
with broad biological activities, " such as anti-fungal activity especially against 
Candida albicans, anti-viral activity including strong activity against HIV, 58 
anti-parasitic activity particularly against several species of Leishmania and 
anti-tumor activity. The biological properties of (+)-sinefungin all derive from 
inhibition of SAM dependent proteins because of its structural similarity with SAM, 
in that it preserves all of the structure of the co-substrate, but replaces the sulfonium 
centre with an amine side-chain that is presumably protonated at physiological pH 
thus supplying a positive charge at a similar location to the sulfonium centre. 
Unfortunately, clinical use of (+)-sinefungin is limited due to its known in vivo 
toxicity, which is not surprising given its general activity. The total synthesis and 
structural modifications of (+)-sinefungin have been attractive to many researchers. 
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1.7.2. Background of (+)-sinefungin total synthesis 
56,57,59-63 A number of total synthetic routes to (+)-sinefungin have been published 
. 
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Four of the synthetic procedures produce a mixture of epimers at the C-6 position, 
while other routes generate the correct stereochernistry at C-6, but over many steps. 
Of these approaches Barton's route using radical chemistry is perhaps the most 
elegant (Scheme 6). 57 
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Reagents and conditions: 
a) N-methylmorpholine, isobutyl chloroformate, N-hydroxyl-2-thiopyridone, then 
olefin 28,45%; b) BU3SnH, AIBN, 36% (30) and 38% (31); c) (CF3CO2)2lC6H5, PY, 
DMF/H20; ii) (BOC)20, Et3N, DMF, 66%; d) i) H2. Pd/C; ii) NH3/MeOH; iii) 
TFAM20,80%. 57 
The N-hydroxyl-2-thiopyridyl ester 27 was synthesised from adenosyl 5'-carboxylic 
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acid 26, then treated with initiator, resulting in the generation of the radical at C4 
position which then reacted with electron deficient olefin 28 and the resulting C-6 
radical quenched by further reaction with thiocarbonyl compound to provide the 
sinefungin precursor 29 as a mixture of d iastereo isomers in 45% yield. Reduction of 
precursor 29 with tributyltin hydride furnished amides 30 and 31 which were isolated 
separately as R and S isomers at C-6 position in a yield of 36% and 38% respectively. 
Finally, precursor 31 was transformed into (+)-sinefungin by Hoffmann 
rearrangement and deprotection in 80% yield. Although very concise, the synthesis 
lacks efficiency as the yields for the key reactions are poor and there is no control 
over the C-6 stereocenter. 
Other routes to sinefungin have also been reported. Fourrey and co-workers reported 
a synthesis of (+)-sinefungin by forming the C-6 and C-7 carbon bond via 
Homer-Emmons reaction (Scheme 7) 
. 
56 The key Homer-Emmons condensation of 
phosphonate 32 and aldehyde 33 produced a 1: 1 mixture of unsaturated nitriles 34 
and N-6-debenzoylated derivative in a total yield of 72%. Reduction of the alkene 34 
using magnesium in methanol afforded the nitriles 35 as a diastereoisomeric mixture 
at C-6 in 84% yield. Hydration of the nitriles 35 with hydrogen peroxide afforded the 
corresponding amides in a disappointing yield of 22% for the two epimers 36 and 37, 
and the single diastereoisomer was isolated by HPLC. Consequently, sinefungin was 
synthesised from the key precursor 37 by Hoffmann rearrangement and deprotection. 
Although short, Fourrey's procedure is limited due to the poor yielding nitrile 
hydration and the use of HPLC which make large scale synthesis unattractive. 
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Reagent and conditions: 
a) Mg(OCH3)2, aldehyde 33, CH30H, 72%; b) Mg, CH30H, 84%; c) H202, NaOH, 
CH30H, 22% as two epimers (36 an 37). 56 
Moffatt and co-workers reported successive nitroaldol reactions to form the C-5 and 
C-6 bond, C-6 and C-7 bond of sinefungin (Scheme 8). 59 The adenosyl 5'-aldehyde 
38 was reacted with nitromethanc and potassium terl-butoxide to generate 
5'-hydroxyl compound 39 in 91% yicid, this was dcoxygcnated by acctylation and 
reduction to afford the nitro compound 40 in 55% yield. Next, the second nitroaldol 
reaction and deoxygenation were carried out with nitro compound 40 and aldehyde 
41 using the previous procedures to afford the nitro precursor 43 as a mixture of 
epimers. Deprotection and reduction produced (+)-sinefungin from the precursor 43 
in 22% yield, which was purified by preparative reverse HPLC- 
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Reagents and conditions: 
a) CH3NO2. t-BuOK, t-BuOH, 91%; b) i. AC20, HC1047 ii. NaBH4, EtOH/FHF, 55%; 
c) t-BuOK, i-BuOH, aldehyde 41,69%; d) i. AC20, DMAP, THF, ii. NaBH4. 
EtOH/'FHF, 77%; e) i. 90%TFA, ii. H2. Pd/C, MeOH, Pt02,22%. 59 
Another approach depending on the nitroaldol reaction was reported by Buchanan 
which provides sinefungin in fewer steps (Scheme 9). 63 Key to this route is the 
formation of C-5 and C-6 bond using a single nitroaldol reaction conditions. The 
adenosyl 5'-aldehyde 38 and lysine derived nitro 44 were combined in the presence 
of tetrabutylammonium fluoride (TBAF) as base to generate the 5'-hydroxyl 
intermediate, which was deoxygenated using standard conditions to furnish the nitro 
compound 45 as a 1: 1 mixture of two C-6 epimers in 70% over three steps. 
Subsequently, deprotection and reduction of nitro with Raney Ni gave (+)-sinefungin 
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and its C-6 epimer 46 in 32% yield. Although this route is short, they did not report 
the synthesis of stereochemically pure sinefungin. 
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a) i. TBAF, THF, ii. AC20, DMAP, iii. NaBH4, EtOH, 70% (1: 1 C6-epimers); b) i. 
63 ZnBr2, MeOH, ii. 800/oTFA, iii. Raney Ni, MeOH, 32% 
. 
The four approaches to synthesise (+)-sinefungin as described above cannot generate 
C-6 (S) epimer selectively, but Rapoport and co-workers reported a stereoselective 
route to generate the C-6 (S) epimer again using a nitroaldol reaction (Scheme 10). 60 
The ribose derived 5'-aldehyde 47 was treated with nitro side chain 48 and potassium 
fluoride to generate the nitro alcohol, and then dehydrated with dicYclohexyl- 
carbodiimide (DCQ and copper chloride to give nitro alkene 49 as a cis and trans 
mixture in a yield of 83% over two steps. Reduction with zinc and acetic acid 
produced the oxime 50 in 84% yield, which was then oxidatively hydrolysed with 
ceric ammonium nitrate (CAN) to afford the ketone 51 in 81% yield. 
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a) i. KF, CH3CN, ii. DCC, CuCl, MeOH, 83%; b) Zn, 4M HOAc, THF, 84%; c) CAN, 
0.5M 14N03, EtOH, 81%; d) i. L-selectride, THF, 80%, ii. Ts2O, py, 63%; e) NaN3, 
DMF, 100%. 60 
Selective reduction of the ketone 51 using L-selectride gave the desired alcohol in 
80% yield as the major diastereoisomer (92% de), which was subsequently treated 
with toluenesulfonic acid anhydride to furnish the tosylate 52 as a single 
diastereoisomer after recrystallisation in 63% yield. The azide group was introduced 
into the C-6 position by SN2 nucleophilic displacement with obvious inversion of 
stereochernistry to produce the key precursor 53 in quantitative yield. Finally, 
(+)-sinefungin was synthesised by installing the adenine ring, reduction of azide and 
deprotection. 
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Ghosh and co-workers published another criantioselective synthesis of (+)-sinefungin 
at C-6 and C-9 positions in many steps (Scheme 11). 61 The key diastereoselective 
alkylation at the C-6 position was achieved using the chiral auxiliary 55 which was 
generated by following Evan's protocol. 64 Oxazolidinone 55 was deprotonated with 
n-butyllithium and then treated with the anhydride formed from the D-ribose derived 
acid 54 and tert-butyl choloroformate in the presence of triethylamine to give imide 
56 in 70% yield. Next, imide 56 was converted to the lithium enolate with lithium 
hexamethyldisilazane ((TMS)2NLi) and then treated with allyl iodide to afford the 
allylation product 57 as a single diastereoisomer in 78% yield. Hydrolysis of the 
chiral auxiliary was achieved using lithium hydroperoxide to provide the chiral acid 
58 in near quantitative yield. 
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Subsequently, stereochernical control at the C-9 position was achieved by 
asymmetric hydrogenation using a chiral rhodiurn catalyst (Scheme 12). Chiral acid 
58 was converted to the protected amine derivative 59 by Curtius rearrangement 
using diphenyl phosphorazide (DPPA), triethylarnine and benzyl alcohol in refluxing 
toluene, then benzylation. Introduction of C-9 amino acid species was achieved by 
oxidation and Homer-Emmons reaction of protected amine derivative 59. Ozonolysis 
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of alkene 59, followed by reductive workup with dimethyl sulfide produced the 
intermediate aldehyde, which was reacted with phosphonate 60 and potassium 
tert-butoxide to produce a 1: 5 mixture of E and Z enamides 61 and 62 in 74% yield. 
Asymmetric hydrogenation of the mixture of enamides 61 and 62 in the presence of 
the rhodium catalyst [Rh(COD)(R, R-DIPAMP)21+BF4- generated 63 selectively as S 
isomer in C-9 position with good yield. 
The diastereoselective allylation and asymmetric hydrogenation successfully 
installed the correct stereochernistry at C-6 and C-9 position. The remaining total 
synthesis of (+)-sinefungin involved the installation of the adenine ring and 
deprotection over several steps. Even though Ghosh's synthesis is enantioselective, 
the control of the stereoselectivity at C-6 and C-9 position is achieved through a 
quite lengthy route from the starting material. Therefore, we were interested in 
developing an efficient, flexible, rapid and stereoselective synthesis of 
(+)-sinefungin. 
1.7.3. Structural modifications of (+)-sinefungin 
Although sinefungin shows strong bioactivity against fungi, viruses, parasites and 
tumors, when tested with larger mammals, it caused fatalities, probably due to its in 
vivo toxic side effects. Therefore, development of new therapeutic agents 
maintaining sinefungin's bioactivity without toxic side effects to humans continues 
to be of considerable interest. Barton reported the sinefungin analogues 64 and 65 
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(Figure 11) bearing uracil or dihydrouracil groups instead of the adenine fragment65 
and Robertgero published the sinefungin analogues 66 and 67 (Figure 11), lacking 
the amino moiety at C-9 and the terminal carboxylate respectiVely. 66 The biological 
tests as anti-parasite showed that all of the analogues 64-67 have a lower affinity 
with protein carboxylmethyltransferase of leishmanial promastigotes than sinefungin 
leading to decreased inhibition of growth of Leishmania donovani prornastigotes in 
vitro. As a result of these studies it can be concluded that the adenine fragment and 
the C-9 terminal amino acid group are important for binding to carboxylmethyl- 
transferase and for the growth inhibitory effect. Moreover, inspired by the potent 
antiviral activity of natural carbocyclic nucleosides, Miller recently reported the 
synthesis of a carbocyclic analogue 68 (Figure 11), which contains an isosteric 
replacement of the ribosyl oxygen for a methylene unit. 67 However, there are no 
reported biological results for carbocyclic analogue 68 in detail. 
In addition, the structure-activity relationships studied of (+)-sinefungin and its 
derivatives have shown that some functional groups are necessary to retain 
methyltransferases inhibition including the L configuration of the terminal amino 
acid group, the three-carbon linker between the S carbon atom and the terminal 
amino acid group, and either the 2' or 3' hydroxyl groups on the ribosyl ring. 67 
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Figure 11: Chemical structure of sinefungin analogues: uracil or dihydrouracil 
analogues (64,65), dearnino at C-9 analogue (66), decarboxylate analogue (67), 
carbocyclic analogue (68). 
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Chapter 2 
Project Aims and Objectives 
This project is broadly focused on improving on the very small number of chemical 
tools available for the evaluation of protein arginine methylation in cells and can be 
defined in four aims: 1) development of general inhibitors of methyltransferases; 2) 
design and synthesis of specific inhibitors of protein arginine methyltransferases 
(such as PRMTI); 3) synthesis of a N-6 modified S-adcnosyl-L-methionine (SAM) 
analogue for possible affinity purification of the target protein; 4) development of a 
novel, rapid and enantioselective synthesis of natural product (+)-sinefungin and its 
analogues. 
2.1 Design and synthesis of trifluoromethyl SAM analogue toward general 
methyltransferases inhibition 
Altering the electronic nature of the methyl group might be expected to influence the 
kinetics of biomethylation. Consequently, simple replacement of the methyl group of 
SAM with a trifluoromethyl group as in analogue 69 was envisaged (Figure 12); 
model compound 70 was useful for evaluating the reaction conditions required for 
installation of the trifluoromethylsulfonium centre. If SAM analogue 69 can compete 
with SAM at the receptor binding site of a methyltransferases then the electron 
withdrawing nature of the three fluorines might be expected to slow down the 
48 
methylation reaction and thereby influence the progress of the biological reaction, so 
providing a preliminary point for the development of a new inhibitor. On the other 
hand, trifluoromethyl-SAM 69 might act as a substrate, allowing potentially specific 
transfer of a trifluoromethyl group to biological targets. Trifluoromethylation of 
proteins and DNA might be attractive because 19F has spin V2 and 100% natural 
abundance making it a powerful probe for NMR, whereas the addition of 54 mass 
units compared to the native methyl group might be useful for target identification by 
mass spectrometry. 
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Figure 12: Chemical structure of trifluoromethyl SAM analogue 70 and model 
compound 71. 
2.2. Design and synthesis of specific inhibitors of PRMTI 
2.2.1. Guanidine containing SAM analogues with different carbon linkers 
SAM is claimed to be the second most widely used substrate in enzymatic reactions 
p4 So after AT 9 it is a significant challenge to achieve selective inhibition between 
PRMT: s and other SAM utilising proteins. We chose to explore the potential of 
bisubstrate inhibitors that might achieve greatest binding by targeting both SAM and 
arginine substrate binding sites, while potentially being excluded from the substrate 
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of other proteins due to poor fit arising from the extra functionality compared to 
SAM. The crystal structure of PRMTI complexed with the product of methylation, 
S-adenosyl-L-homocysteine (SAH) and a substrate arginine bearing peptide (PDB 
I OR8) 16 shows that the arginine binding site includes two negatively charged 
glutamate residues (E144 and E153) which are believed to directly bind to arginine 
and be essential for catalysis, being a conserved feature across the known PRMTs. 16 
Therefore, the selective inhibition for PRMTs might be achieved by incorporating a 
guanidine group into the intended SAM analogues so that they could bind at both 
SAM binding site and the glutamate residues that form part of the arginine substrate 
binding site (Figure 13). Presumably the bisubstrate inhibitors could inhibit PRMTI 
selectively as individual chemical tools to probe the process of protein arginine 
methylation or candidate drugs for the therapeutic of some diseases, such as cancer. 
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Figure 13: General concept for the design of bisubstrate inhibitors (black) for 
PRMTI, which presumably could interact with SAM binding site (blue) and two 
glutarnates residues E 144 and E 15 3 (red). 
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SAM analogues 71,74(a-c) and 75 (Figure 14) were designed to include 
functionality that mimics the guanidine portion of the arginine substrate side chain 
joined by short linkers that bridge between the SAM and substrate arginine binding 
sites. Improved potency and selectivity is expected to be achieved by further rational 
improvement of the functionalities appended to the rest of the nucleoside core. 
Additionally, SAH analogues 72 and 73 bearing guanidine moieties derived from the 
precursor of SAM analogue 71 were designed as a tool to investigate further the 
inhibition for PRMTI. 
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2.2.2. Guanidine containing SAM analogue with triazole linker 
Cu (1) catalysed [3+2] Huisgen reaction between azides and terminal alkynes is an 
exceedingly facile and high yielding reaction that is a popular method for assembling 
architectures from simple precursors. OccasionallY, protein binding sites have been 
used to accelerate the reaction instead of copper, leading to a template induced 
synthesis of potential inhibitors. 68 Azide SAM analogue 76 and alkyne SAM 
derivative 77 were designed as potential inhibitor fragments with the additional aim 
of attempting PRMT-templated synthesis (Figure 15). 
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Figure 15: Chemical structure of azide SAM analogue 76 and alkyne SAM analogue 
77 and triazole linker SAM analogue 78. 
In principle, only the best-fit combination of azide SAM analogue 76 with alkyne 
derivatives that target the arginine binding site, or alkyne SAM analogue 77 with 
corresponding azides will be selected from an array of potential coupling partners to 
undergo Huisgen reaction at the target biding site, thus revealing inhibitors that may 
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be detected at typical experimental concentration using HPLC and mass spectrometry. 
Such an experiment is an attractive long term goal that also requires expression and 
purification of substantial quantities of protein. In the near term, SAM derived 
bisubstrate inhibitor, containing triazole linkers, such as 78, can easily be generated 
using the Cu (1) catalysed [3+2] Huisgen reaction and then tested as a selective 
inhibitor of PRMTI (Figure 15). 
23. Design and synthesis of N-6 azide side chain SAM analogue 
The function of PRMTs is currently poorly understood, thus modification of 
inhibitors to facilitate labeling of proteins, or affinity purification of their targets and 
associated proteins are desirable. Introduction of an azide side chain at the N-6 
adenosine position of the SAM analogue 79 was expected to retain the inhibition for 
PRMTs by extending into space away from the binding pocket, yet allow easy 
attachment of biotin or fluorescent dyes via Staudinger ligation, or Cu (1) catalysed 
[3+21 Huisgen reaction as described (Figure 16)69 
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Figure 16: Chemical structure of N-6 modified SAM analogue 79 
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2.4. Total synthesis of (+)-sinefungin 
The natural product (+)-sinefungin 2 (Figure 17) displays a wide variety of 
biological activities, being potent against various fungi, viruses, parasites and tumors 
57 
as a result of its very potent, but not specific inhibition for methyltransferases. This 
potency arises from its close similarity of the structure of sinefungin and SAM. 
Presumably, the primary amine connected to C-6 of sinefungin is protonated at 
physiological pH and resembles the sulfonium centre of SAM to achieve strong 
binding, but not turnover at target methyltransferases. We were attracted by the 
possibility of using sinefungin as an alternative scaffold for inhibitor development 
and sought a novel and rapid synthetic method for the total synthesis of 
(+)-sinefungin. In addition, we aimed to design and synthesise sinefungin analogue 
80 (Figure 17), bearing a guanidine group which is connected to the C-6 amino group 
by a carbon linker, as bisubstrate inhibitor toward the selective inhibition for PRMT I, 
perhaps without cytotoxicity. 
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Chapter 3 
Results and Discussion 
3.1 Preparation of trifluoromethyl SAM analogue 
Synthesis of the trifluoromethyl SAM analogue 69 (Figure 12) was attempted with 
the aim of exploring how the highly electron withdrawing fluorine atoms might 
affect the properties of SAM. The compound 69 might compete with SAM at the 
binding site, but would be expected to turn over slowly, therefore providing a 
preliminary point for the development of new general inhibitors of 
methyltransferases. Alternatively, if compound 69 was able to act as a substrate, the 
transfer of trifluoromethyl group to some biological targets might be attractive for 
either NMR spectroscopy due to the strong signal arising from 19F, which is present 
in 100% abundance, or mass spectrometry studies where trifluoromethyl groups can 
be identified at 54 Da higher than equivalent methylated substrates. 
3.1.1. The synthetic strategy 
As illustrated in Scheme 13, the sulfonium centre could be formed by three routes: 1) 
trifluoromethylation of thioether 81 using trifluoromethylation reagent (route a); 2) 
nucleophilic displacement of 5'-halogen modified adenosine 83 (or other leaving 
groups) with a thioether 82 containing a trifluoromethyl group (route b); 3) 
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alkylation of 5'-trifluoromethylthioadenosine 85 with an appropriate electrophile 84 
(route c). We initially explored this trifluoromethylation chemistry using the readily 
available model compound 70 (Figure 12). 
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3.1.2. Synthesis of the model compound 
In the beginning, we explored direct trifluoromethylation of thioether 81 utilising 
70 
trifluoromethylation reagent 86 (Scheme 14). It was recognised that there is a fine 
energetic balance between the target sulfonium 70 and the reagent 86, but we were 
enticed by the simplicity of this potential route. Following a known protocol, 7 the 
5'-chloro-5'-deoxyadenosine 16 was generated by the treatment of adenosine 15 with 
thionyl chloride and pyridine in acetonitrile in quantitative yield, which was purified 
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by ion exchange resin chromatography on Dowex Ix 2-100 (OH-). Subsequently, 
N-protection of 2-aminoethanethiol with Boc anhydride was attempted in the 
presence of base, sodium hydride or triethylamine. In fact, the sodium hydride 
method 71 provided a mixture of the desired compound 88 and a large amount of 
disulfide impurity. Although the disulfide can be reduced by some reagents, such as 
72 
tributylphosphine 
, 
it was most practical to employ a milder base, such as 
triethylamine, 73 which gave protected amino thiol 88 in a satisfactory isolated yield. 
Nucleophilic displacement of the 5'-chloro-5-deoxyadenosine 16 with thiolate 
generated by protected amino thiol 88 and sodium hydroxide 7 furnished the desired 
thioether 81 in 56% yield. 
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The electrophilic trifluoromethylation reagent 86 has been developed by Urnernoto. 70 
Alkanethiolate 90 was trifluoromethylated by the reagent 86 to give the 
trifluoromethyl alkane thioether 91 (Scheme 15). The possible reaction mechanism is 
bimolecular ionic substitution by the kinetic study, which refers a side-on attack to 
the S-CF3 bond, not the conventional SN2 attack mechanism, since the CF3 carbon 
atom is covered by three electron withdrawing fluorine atoms of larger size than 
hydrogen atoms (scheme 16). 74 
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Unfortunately, all attempts to carry out electrophilic trifluoromethylation of the 
model thioether 81 in DMF were unsuccessful (Scheme 14). Presumably the sulfur 
atom in thioether 81 is less nucleophilic than thiolate 90, so the displacement of 
trifluoromethyl group from the reagent 86 could be difficult. 
We next sought to generate the sulfonium centre by alkylation of a trifluoromehtyl 
thioether precursor (Scheme 17). Deprotonation of thiol 88 with sodium hydride and 
treatment with the trifluoromethylation reagent 86 in THF produced the side chain 82 
in poor yield of 42%, alongside significant amounts of the dimer. Unfortunately, 
attempts to subsequently alkylate the trifluoromethyl thioether 82 by displacement at 
5'-chloro-5'-deoxyadenosine 16 in acetonitrile using a combination of sodium iodide 
and silver perchloride 75 for in situ generation of the more reactive iodide did not 
deliver the desired product. 
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The polarity of the sulfonium product means that its purification is as much of an 
issue as the reactions to generate it. Therefore, sulfonium centre formation was 
attempted with the protected 5'-iodo-5'-deoxyadenosine 93 with the intention that the 
product could be more easily purified by silica column chromatography (Scheme 18). 
2', 3'-Isopropylidene adenosine 92 was treated with m ethyl phenoxyphosphon ium 
iodide in dry CH2CI2 to fumish protected 5'-iodo-5'-deoxyadenosine 93 in 48% 
yield. 76 Reaction of the resulting iodide 93 with the trifluoromethyl thioether 82 in 
the presence of silver perchloride 75 in acetonitrile, did result in consumption of 
starting material as monitored by TLC. However, purification from the complex 
reaction mixture proved difficult, so the desired product 94 could not be obtained. 
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a) methylphenoxyphosphoniurn iodide, CH202, -70'C-r. t., 48%; b) compound 82, 
AgCI04, CH3CN, r. t. 
In summary, the approaches to generate the desired trifluoromethyl sulfonium centre 
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for the model compound 70 failed. In fact, it may be possible to find conditions to 
effect this transformation in the future, such as alkylation of 5'-trifluoromethyl- 
thioadenosine 85, but we decided to turn our attention to a more readily achievable 
strategy for the exploration of the bisubstrate inhibitors concept. 
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3.2. Preparation of putative bisubstrate inhibitors: SAM analogues containing 
guanidine with carbon linkers 
SAM is the second most abundant co-substrate after ATp. 4 So it is a significant 
challenge to achieve selective inhibition of PRMT: s over all other SAM utilising 
proteins. We sought to explore whether this PRMT selective inhibition might be 
achieved by linking guanidine functionality to SAM analogues with the idea that 
such selective binding for PRMT: s but not with other methyltransferases might be 
achieved. 
3.2.1. Guanidine containing SAM analogue 
The failed synthesis of trifluoromethyl sulfonium centre for the model compound 70 
lead us to examine a different route toward generation of the sulfonium centre 
involving alkylation at 5'-thio-5'-deoxy-adenosine 96. Additionally, the sulfonium 
centre can result in decomposition via attack of carboxylate at high pH environment, 
as described in Chapter 1. Therefore, the synthetic strategy of guanidine containing 
SAM analogue 71 would include the protection of the amino acid side chain 97 (or 
98) prior to the generation of sulfonium centre, and then the stable amino acid might 
be obtained by deprotection in carefully controlled pH environment (Scheme 19). 
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Initially, we sought to make the protected guanidine containing thioether 96. 
Generally, the classical method of preparing protected guanidine derivatives is the 
treatment of amines with various guanidinylating reagents, such as protected thiourea 
or S-methylisothiourea. 77 Consequently, two approaches were explored: one involved 
reaction of a guanidine containing side chain with 5'-chloro-5'-deoxyadenosine 16, or 
the related iodide 93 (Scheme 20); the other involved late stage guanidinylation of a 
modified adenosine 81 (Scheme 21). Protected guanidine, containing compounds 
were sought as they would be sufficiently hydrophobic to allow normal purification 
until a final, ideally global deprotection step to liberate the highly polar target 
compounds. 
As illustrated in Scheme 20, thiourea 99 was reacted with Boc anhydride and sodium 
hydride to produce the protected guanidinylating agent 100 in 59% yield. 78 
Subsequent reaction with cysteamine hydrochloride in the presence of triethylamine 
in DMF proceeded to give the side chain 101 in a disappointing yield of 34%. Of 
course, the reactivity of protected thiourea 100 could be increased with the utility of 
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mercury (11) chloride 
'79 but the cysteamine hydrochloride's thiol group might also be 
affected by such reaction conditions, thus we accepted the poor yield at this stage. 
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The subsequent deprotonation of thiol 101 using either sodium hydroxide or 
potassium tert-butoxide, and reaction with 5-chloro-5-deoxyadenosine 16 
unfortunately failed. Similarly, attempts to react thiol 101 with the more hydrophobic 
acetonide protected 5'-iodo-5'-deoxyadenosine 93 in the presence of bases, such as 
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caesiurn carbonate and DBU also failed. Instead the mass spectrometry analysis 
which showed a major peak at 289 indicated that presumably the alternative product 
was the elimination compound 103 bearing an alkene at the C-4 and C-5 position. 
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Ultimately, the guanidine containing thioether 96 was generated by late stage 
guanidine formation using the cysteamine modified adenosine 81 (Scheme 21). 
Removal of the Boc protecting groups with TFA, followed by direct treatment of the 
resulting salt with guanidinylating reagent 100 in the presence of triethylamine and 
mercury (11) chloride gave the desired compound 96 in 56% yield, which was easily 
purified by silica gel column chromatography. This reaction was also attempted in 
the absence of mercury (11) chloride, but the rate of reaction was quite slow. 
Therefore, the key intermediate, guanidine containing thioether 96 was synthesised 
through three potentially simple steps, including the formation of alkyl chloride, 
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alkylation with thiolate and guanidinylation, which may be scaled up to larger 
quantities if required. In addition, this intermediate 96 can be used to evaluate 
subsequent formation of the sulfonium centre of the target bisubstrate SAM analogue 
71, leading to a guanidine containing SAH analogue 72 via deprotection as a 
potential inhibitor of PRMTs. 
Next, the Boc protected guanidine containing compound 96 was treated with TFA, 
and the reaction mixture adjusted to pH 9 with ammonia solution to get the target 
compound 72 as the free base in a good yield of 78%, which was then purified using 
ion exchange resin chromatography on Dowex Ix 2-100 (OH-) in order to remove 
residual trifluoroacetic acid ammonium salt. We subsequently uncovered that 
compound 72 was claimed in a patent as a poor inhibitor for DNA methyltransferases 
(IC50 
- 
40ýtM). 80 While it was a little disappointing to find that the compound has 
been previously described, it might have potential activity of the inhibitor for PRMT; s 
and suggests that the planned synthesis can be applied to the synthesis of other 
guanidine containing analogues. 
We next sought to adapt this route to generate more hydrophobic analogues, such as 
those containing a cycloethyl guanidine (Scheme 22). Originally, late formation of 
the cycloethyl guanidine was attempted following the procedure described above. 
Thus, Boc deprotection of thioether 81 and treatment of the TFA salt with 2-methyl- 
thio-2-imidazolium iodide in aqueous sodium hydroxide solution, was attempted but 
81 
unfortunately this did not lead to the formation of desired compound 73. 
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Reagents and conditions: 
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a) i. 4M HCI/dioxane, ii. 2-methylthio-2-imidazolium iodide, NaOH, r. t. 
-85"C. 
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H2N 
'-"-"S'S-"ý'NH2 2HCI a) FmocHN 'ýý"'SH 
104 105 
N NH2 N ý\ 
NH2 
FmocHN,,,. 
--,, 
0 N--( N 
NN ----J 
6 -0 00 X< ýK 
93 106 
N NH2 
N, 0N 
---------- 
HH 
N 
N 
ýYN 
00 Y< 
107 
Reagents and conditions: 
a) i. FmocCl, DIPEA, DMF, OOC, ii. BU3P. MeOH, r. t., 88%; b) compound 105, 
CS2CO3 or DIPEA, DMF, r. t. 
In fact, purification of the highly polar target compound 73 presented a significant 
problem. Therefore, a route incorporating two protecting groups, the acid sensitive 
acetonide and the base labile Fmoc group was explored (Scheme 23). Thus 
cYstamine dihydrochloride 104 was reacted with Fmoc chloride and Honig's base in 
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DMF to give the protected disulfide in quantitative yield, which could be used 
without further purification. Subsequent reduction with tributylphosphine 72 in 
methanol gave Fmoc protected thiol 105 in a good yield of 88%. Unfortunately, the 
alkylation of thiol 105 with protected 5'-iodo-5'-deoxyadenosine 93 in the presence 
of either caesium carbonate or HUnig's base did not deliver the precursor 106, and it 
was difficult to find a suitable base that could affect thiol alkylation without causing 
cleavage of Fmoc group (as detected by TLC and mass spectrometry). 
We next sought to explore guanidinylation with protected thiomethyl-2-imidazoline 
111 or imidazolidine-2-thione 113 (Scheme 24). Firstly, the two guanidinylating 
reagents 111 and 113 were prepared following known procedureS. 82'83 Thus, the 
protected thiomethyl-2-imidazoline 111 produced by treatment of methylthio-2- 
imiclazolium iodide 110 with Boc anhydride and triethylamine in quantitative yield 83 
and protected 2-imidazolidinthione 113 was generated from 2-imidazolidinthione 112 
with Boc anhydride and sodium hydride in 57% yield. 82 Consequently, the two 
guanidinylating agents were progressed toward formation of desired cycloethyl 
guanidine. Deprotection of compound 81 with TFA and direct treatment with 
guanidinylating reagents, either 111 or 113 in the presence of triethylamine and 
mercury (II) chloride in DMF produced only a trace of the cycloethyl guanidine 108 
or 109 which were detected by mass spectrometry at peak 494 and 594, and much of 
the starting amine remained. Therefore, these reactions did not work well on scale up, 
but it indicates the possibility of forming cycloethyl guanidine containing analogues 
73. Essentially, we had to improve the overall yields for this route, so we turned our 
68 
attention to investigate the key bromoethane or iodoethane side chain 97 (or 98), 
required for the formation of the guanidine containing SAM analogue 71. 
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Reagents and conditions: 
a) i. TFA, CH2CI2.0"C-r. t., ii. compound 111, Et3N, HgC12, DMF, 80"C; b) i. TFA, 
CH202, OOC-r. t.; ii. compound 113, Et3N, HgC12, DMF, 80'C; c) (BOC)20, Et3N, 
CH2CI2. OOC-r-t., 98%; d) (Boc)20, NaH, THF, 0"C-r. t., 57%. 
Initially, we attempted to synthesise the bromide 97 from racemic methionine 
(Scheme 25). The key lactone 115 was prepared as the hydrobromide salt in one step 
from racemic methionine 114 by treatment with bromoacetic acid in water, 
isopropanol and acetic acid in 65% yield. 84 Alternatively, the equivalent 
hydrochloride salt 117 was synthesised in two steps from methionine 114, by 
treatment with methyl iodide in aqueous methanol to provide the sulfonium salt 116 
in 87% yield, which was then cyclised in the presence of aqueous sodium hydrogen 
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81,86 
carbonate to give the lactone 117 in 60% yield. Obviously, the former approach 
for the fonnation of lactone hydrobromide 115 was more direct than the latter route 
involving discrete methylation and cyclisation to lactone hydrochloride 117. 
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a) BrCH2COOH, H20/isopropanol/ CH3COOH, 50-85*C, 65%; b) HBr/CH3COOH; 
C) CH31, MeOH/li2O, 35'C, 87%; d) NaHC03, H20, reflux, 60%; e) HBr/CH3COOH; 
0 CH3COOI-Bu, H2SO4, CH3COOH, and then (BOC)20, NaHC03, EtOAc/H20, 
opening of lactone 115 (or 117) using hydrobromic acid in acetic acid under a 
variety of conditions was attempted, as described in table 1,84,86.87 but it proved 
difficult to isolate the pure desired product 118 due to contamination of the product 
with the lactone starting material as observed by 1H NMR spectroscopy. 
Unfortunately, attempts to prepare a protected version of the bromo amino acid 98 84 
by treating the crude mixture with fert-butyl acetate and sulphuric acid in acetic acid 
and then Boc anhydride and sodium hydrogen carbonate also failed. 
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Table I 
Entry Reaction conditions 
Crude 
Yield' Purityb 
I 100'C, 5.5h; then r. t. overnight 53 
Mixture 
(Lactone and product) 
2 50'C, 20h 84 Mixture (Lactone and product) 
3 Scaled tube, 65'C, 6h; then r. t. 42 Mixture 
overnight (Lactone and product) 
'Yield before the purification; b Estimated purity based on 1 HNM R spectroscopy. 
An alternative approach to generate the iodoethane derived amino acid 98 via 
L-aspartic aid was successful (Scheme 26). Treatment of L-aspartic acid 119 with 
thionyl chloride in dry methanol provided selective esterification of the y-L-aspartate 
carboxylic acid 120 in 68% yield. 88 Installation of the Boe group at the amine and the 
remaining tert-butyl ester protecting groups using two approaches was investigated. 
In the first, the Boc group was installed at the amine using standard conditions to 
89 
provide compound 121 in 56% yield, then the tert-butyl ester was subsequently 
formed with the general method of dry tert-butanol, 4-dimethylaminopyridine 
(DMAP), NiV-dicyclohexyl-carbodiimide (DCC) to afford the desired protected 
aspartate 122 in 53% yield 
. 
89 However, an alternative one pot protocol gave superior 
overall yields, thus treatment of compound 120 with tert-butyl acetate in perchloric 
acid, 90 then Boc anhydride and sodium hydrogen carbonate directly gave the 
protected aspartate 122 in 61% yield. Saponification of this fully protected aspartate 
derivative 122 provided y-carboxylic acid 123 which was then isolated in 88% yield 
after recrystallisation. 89 The target iodide 98 was then obtained using a one pot 
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procedure which proceeded in 55% overall yield from the carboxylic acid 123, thus 
treatment with ethyl chloroformate and triethylamine provided the corresponding 
anhydride which was reduced in situ with sodium borohydride to generate an 
intermediate alcohol89 that was finally converted into the iodide 98 by treatment with 
iodine, triphenylphosphine and imidazole. 91 
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H3CO Y"'y COOH 
0 NHBoc 
121 
HO, lr, -yCOOH 
0 NH2HCI 
119 
Reagents and conditions: 
0 d) T0 
ot-Bu 
HOýr,, 
-, 
ýOt_13U 
NHBoc 0 NHBoc 
98 123 
0 
H3CO 
-ffý COOH b) H3CO 
0 NH2HCI 
-ryl Ot-Bu 
0 NHBoc 
120 122 
C) 
I 
a) SOC12, dry MeOH, -10"C, 68%; b) HC104, CH3COOt-Bu, O'C-rt, and then 
(Boc)20, NaHC03, H20/ THF, O'C-rt, 61%; c) IM NaOH, acetone/H20, O'C, 8 8%; d) 
CICOOC2H5, Et3N, dry THF, 
-50C-rt, NaBH4/li2O, O'C-rt, and then 12, Ph3Pq 
imidazole, CH2C12. OT, 55%; e) (BOC)20, Na2C03, dioxane/H20, O'C-rt, 56%; 
t-BuOH, DMAP, DCC, dry CH2CI2. OOC-rt, 53%. 
Reliable access to the iodoethane side chain 98 permitted investigation into 
alkylation of the thioether 96 that would ultimately lead to the desired sulfonium 
compound 95 (Scheme 27). Unfortunately, all attempts to alkylate the thioether 
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intermediate 96 failed, such as performing the reaction in the presence of silver 
perchlorate or silver tetrafluoroborate. As indicated in section 3.1, formation of the 
trifluoromethyl substituted sulfonium centre was also difficult to access and 
represents a significant barrier to the formation of sulfonium centre based SAM 
analogues. 
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Reagents and conditions: 
a) iodide compound 98, AgCI04, CH3CN, OOC-rt; b) iodide compound 98, AgBF49 
CH3CN, O'C-rt. 
3.2.2. Nitrogen SAM analogues containing guanidine 
Access to the guanidine containing SAM analogue 71 (Figure 14) was unsuccessful, 
and formation of the desired sulfonium centre still faces a number of problems, 
including decomposition pathways, such as intramolecular nucleophilic displacement 
by the amino acid carboxylate group or slow pyramidal inversion of the sulfonium 
centre under physiological conditions. Wong reported" that the inversion of the 
sulfoniurn centre, can be slowed by maintaining pH between 3.5 and 5.5 and using an 
excess of large, non-nucleophilic counter ions such as sulfate, but it is still likely to 
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be difficult to maintain this sulfoniurn centre throughout the planned deprotection 
steps at the end of the synthesis. In light of these problems, our attention turned to 
the more accessible nitrogen containing SAM analogues 74(a-c) and 75 (Figure 14). 
The target compounds feature a nitrogen atom at the 5'-adenosine position which, 
like the sulfonium centre can support a positive charge, moreover they were expected 
to be much easier to handle and manipulate. 
Initially, introduction of nitrogen at the Y-position of adenosine, was explored by 
nucleophilic displacement of 5'-iodo-5'-deoxyadenosine 93 with an amine 126 
carrying the protected guanidine prepared using the standard guanidinylating 
conditions (Scheme 28) 
. 
7' Reaction of ethylenediamine 124 and protected 
S-methylisothiourea 125 in the presence of mercury (II) chloride and triethylamine 
produced the desired amine in 48% yield. Alternatively the reaction between 
ethylenediamine 124 and protected S-methylisothiourea 125 was performed in THF 
and water (20/1) solvent to give the desired amine 126 in a better yield of 56%. 92 
Attempts to alkylate the resulting amine 126 with 5'-iodo-5'-deoxyadenosine 93 in 
the presence of NJW-diisopropylethylamine (DIPEA) in DMF did not provide the 
target compound 127, instead presumably leading to the elimination product 103, as 
detected by mass spectrometry which showed the peak at 289. Generally, alkylation 
of amines is complicated by mixtures due to the increased nucleophilicity of the 
product secondary amine. A synthesis involving successive reductive arninations 
would be expected to proceed in higher overall yields. 
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THF/H20,50*C, 56%; b) DIPEA, DMF, rt. 
Consequently, installation of nitrogen to Y-position adenosine and introduction of 
subsequent fragments using such a reductive amination strategy was envisaged, 80 
This route required preparation of 5-amino-5'-deoxy adenosine and two aldehydes 
129 and 132(a-c) bearing amino acid and protected guanidine side chains 
respectively. As shown in Scheme 29, amino acid derived aldehyde 129 was 
generated as a single enantiorner by oxidation of alcohol 128, which itself could be 
cfficiently prepared by reduction of y-carboxylic acid 123 as described earlier. Two 
oxidation reactions were examined for generation of aldchyde 129, thus Swern 
oxidation provided superior yield of 82% for this transformation, 93 compared to 
chromium oxide and pyridine (57%). 94 
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a) CICOOC2Hs, Et3N, dry THF, 
-5'C-rt, NaBH4/H20, O'C-rt, 84%; b) Cr3O, py, 
CH2CI2, rt, 57%; c) dry DMSO, oxalyl chloride, Et3N, dry CH2C12, rt, 82%. 
Meanwhile, the guanidine containing aldehydes 132(a-c) were synthesised using the 
standard guanidinylation reaction follwed by Swern oxidation. Thus, amino alcohols 
130(a-c) were treated with protected S-methylisothiourea 125, triethylaminc and 
mercury (11) chloride to give the corresponding alcohols 131(a-c) in a satisfactory 
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yield (92-95%). Subsequent oxidation of the corresponding alcohols 131(a-c) using 
Swern conditions proceeded smoothly to provide aldehydes 132(a-c) in moderate to 
good yields (Scheme 30). 93 
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Reagents and conditions: 
a) compound 125, Et3N, HgC12, DMF, rt, 92-95%; b) oxalyl chloride, dry DMSO, 
Et3N, dry CH2CI2,40-71%; 
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Reagents and conditions: 
a) DIAD, phthalimide, Ph3P, dry THF, rt, and then hydrazine hydrate, CAM 
reflux, 60%; b) aldehyde 129, NaBH(OAc)3, DCE, rt, 73%; 0 aldehydes 132(a-c), 
NaBH(OAc)3, DCE, rt, 34-89%; d) 90% TFA, rt, 67-90%; 
5'-Amino-5'-deoxy adenosine 133 was generated following the Gabriel synthesis 
described by Townsend (Scheme 3 1). 95 A Mitsunobu reaction was used to convert the 
protected adenosine 92 into the phthalimide, which could be directly obtained from 
the reaction mixture by filtration then treated with hydrazine hydrate in ethanol to 
afford the protected 5'-amino-5'-deoxy adenosine 133 in 60% overall yield. 
Aldehydes 129 and 132(a-c) were then incorporated by sequential reductive 
amination to generate the respective precursors 135(a-c). Reductive alkylation of 
protected 5'-amino-5'-deoxy adenosine 133 with aldehyde 129 using sodium 
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triacetoxyborohydride in 1,2-dichloroethane smoothly provided compound 134 in 
73% yield, which was immediately treated with the respective guanidine containing 
aldehydes 132(a-c) using the same conditions to provide the protected tertiary 
amines 135(a-c) in yields of 34-89%. Finally, global deprotection of the precursors 
using 90% TFA in water generated the target compounds 74(a-c) which were purified 
with Amberlite IRA 400 (CI) ion-exchange resin as hygroscopic hydrochloride salts 
in yields that ranged between 67-90%. 
Therefore, a series of guanidine containing SAM analogues 74(a-c), bearing the 
different carbon linkers, was produced in four concise steps, including an one-pot 
Mitsunobu-Gabriel synthesis, two successive reductive arninations and deprotection 
in satisfactory overall yields. Blackburn's original synthesis of AzoAdoMet 18 relied 
on an alkylation strategy, that proved inefficient for the second alkylation and 
problematic in the deprotection step. 53 We are able to access a protected form of 
AzaAdoMet 18 using a more efficient and robust route, and then access guanidine 
containing SAM analogues 74(a-c) using a subsequent reductive arnination and an 
efficient final global deprotection. Moreover, the intermediate, second amine 134 can 
be easily produced on a large scale, which can be used for the production of other 
bisubstrate inhibitors bearing different functional ities, such as cycloethyl guanidine 
for the development of further specific PRMT inhibitors. 
Subsequently, further guanidine derivatives featuring potentially hydrophobic 
substituents, cycloethyl compound 75, were sought with the idea of exploring 
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potential binding at the arginine binding site and synthesising more bisubstrate 
inhibitors for PRMTs. Following with the successful route for the sYnthesis of 
guanidine containing SAM analogues 74(a-c), it became necessary to prepare key 
aldehydes 138 or 139 from their respective alcohols 136 or 137. Consequently, two 
approaches to oxidise 3-amino propanol were attempted (Scheme 32). In fact, 
treatment of 3-amino propanol with guanidinylating agent 113 in the presence of 
triethylamine and mercury (11) chloride afforded compound 136 in a very poor 5% 
yield. 82 An alternative approach involving treatment of 3-aminopropanol with 
methylthio-2-imidazoline 110 in ethanol, then Boc protection also furnished 
compound 137 in an impractical yield of 8%. 96 There is clearly room for improving 
synthesis of the substituted guandiniums which can be explored in the future. 
Scheme 32 
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C2H50H, rcflux, and then (BOC)20, THF/H20, OOC-rt, 8%. 
In summary, although the guanidine containing SAM analogue 71 could not be 
obtained because of the challenges of forming the sulfonium center, the guanidine 
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containing compound 72 was generated 
. 
In addition, the cycloethyl guanidine 
containing compound 73 was difficult to obtain in realistic yields. 
It is important that a series of nitrogen SAM analogues 74(a-c) were achieved in a 
high yielding four steps synthesis. This reductive arnination strategy offers a 
significant improvement to the overall yields obtained by Blackburn's original 
synthesis of AzoAdoMet 18, and while we have not carried out deprotection of 
intermediate 134, our experience of the later analogues justified this claim. 
Production of the key amine intermediate 134 is convenient and can be produced on 
large scale that is amenable to the generation of a range of potential bisubstrate 
inhibitors. The results of biological evaluation of nitrogen SAM analogues 74(a-c) 
for inhibition PRMTI, which were carried out by Professor Steve Ward and Dr 
Richard Parry at the University of Bath will be described in Chapter 4 in this thesis. 
Unfortunately, it was difficult to generate the more hydrophobic cycloethyl guanidine 
analogues 75 because of the impractical yields of the key inten-nediates 136 and 137. 
So the investigation of exploring the conditions for the synthesis of cycloethyl 
guanidine is necessary for the compound 75, and improved routes to these 
compounds must be explored in the future. 
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3.3. Preparation of triazole linker SAM analogue with click chemistry 
Huisgen cycloaddition between azides and terminal alkynes is particularly attractive 
for fragment based inhibitor design because it offers very fast and efficient 
condensation reaction while the triazole products may gain positive interaction with 
their biological targets through hydrogen bonding and dipole interactions. 68 As 
illustrated in Scheme 33, a mixture of both regioisomers, syn and anti isomers can be 
obtained by thermal cycloaddition, alternatively the regioisomerically pure 
1,4-disubstituted triazole, anti isomer can be prepared by the Cu (1) catalysiS. 97 
Scheme 33 
N=N 
I Cu (1) N 2 Rl' 
RI-N 
--R2 
anti 
3 
N=N N=N 
n8 0- 
ýrC 
+ R' eat, qn Rl' 
N21 
anti R2 
syn 
In fact, Sharpless reported that the binding site of some proteins can be used to 
promote Huisgen cycloaddition in the absence of Cu (1) due to the proximity of the 
reactive components (positive template) and therefore promote the reaction to form 
the pure 1,4-triazole regioisomer. 98 For instance, some inhibitors of HIV-1 protease 
have been developed using this method (Scheme 34). 98 The building blocks, alkyne 
140 and azide 141 were incubated in the presence of HIV-1 protease, SF-2-Pr, in a 
morpholinomethanesulfonic acid (MES) and sodium chloride buffer solution at 23*C 
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for 24 hours, and only the anti triazole 142 was detected by HPLC and mass 
spectrometry. 
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In principle, only the best-fit combination of the azide SAM analogue 76 with other 
alkynes or the alkyne SAM analogue 77 with other azides could be selected from an 
array of potential coupling partners to undergo Huisgen reaction at the target site, 
thus revealing inhibitors as detected by HPLC and mass spectrometry. A SAM 
analogue featuring either azide or alkyne functionality attached to nitrogen atom 
capable of mimicking the positively charged sulfonium centre might be useful for the 
rapid synthesis of bisubstrate inhibitors for a range of methyl transferases, including 
PRMT: s. Theoretically, such compounds could also be used to explore PRMT 
templated synthesis, for example alkyne derived SAM analogue might bind to PRMT 
and only react with azides bearing guanidiniums with an appropriately sized linker. 
Tlierefore, SAM analogues bearing an azide 76 and alkyne 77 (Figure 15) were 
envisaged. 
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The azide containing SAM analogue 76 could, in principle, be generated from known 
I 
-azidopropanal and secondary amine 134 by reductive arnination, but it is likely to 
be difficult to handle the potentially explosive low molecular weight I 
-azidopropanal. 
Instead, the azide functionality could be installed at a much later stage with the view 
that higher molecular weight azide should be more stable (Scheme 35). To this end, 
3-propanediol 143 was treated with toluenesulfonyl chloride in the presence of 
triethylarnine and 4-dimethylarninopyridine (DMAP) to give tosylate 144 in 73% 
yield, 99 however attempts to oxidise the remaining alcohol to aldehyde 145 using 
Swem conditions failed and this route had to be abandoned for the time being. 
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In the meantime, the synthesis of alkyne bearing SAM analogue 77 was also pursued. 
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It was envisaged that reductive arnination of the secondary amine 134 with 
2-propynal might provide the appropriate precursor with the minimum distance to the 
tertiary amine that might mimic the sulfonium centre of SAM. Unfortunately, a 
literature method to oxidise commercially available propargyl alcohol (Scheme 36), 
was unsuccessful because it was difficult to get pure 2-propynal by distillation. 100 
However, an alternative method involving simple alkylation of secondary amine 134 
with commercially available propargyl bromide in the presence of potassium 
carbonate proceeded smoothly to produce the alkyne precursor 148 in 71% yield, 
which could be deprotected with 98% TFA to give the alkyne bearing SAM analogue 
77 after purification with Dowex 50WX4400 ion-exchange resin in 91% yield. This 
alkyne derived SAM analogue will be used to explore PRMT or other 
methyltransferase templated synthesis toward identification of new inhibitors. 
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We next attempted Cu (1) catalysed synthesis of the related triazole containing SAM 
analogue 78 from the respective alkyne 148 and guanidine containing azide 154. 
Initially, synthesis of the azide side chain 154 was envisaged to proceed by 
Mitsunobu reaction from the alcohol 150 generated by guanidinylation of 2-amino 
ethanol 149 (Scheme 37). '0' Unfortunately, treatment of alcohol 150 with 
diphenylphosphoryl azide (DPPA), triphenylphosphine and diisopropyl 
azodicarboxylate (DIAD) did not provide the corresponding azide 154. Alternatively, 
conversion of the alcohol 150 to its corresponding tosylate was attempted using 
toluenesulfonyl chloride, triethylamine and 4-dimethylaminopyridine (DMAP), but 
no tosylate 151 was observed. 
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a) compound 125, Et3N, HgC12, DMF, rt., 99%; b) DPPA, Ph3P, DIAD, dry THF; c) 
TsCl, Et3N, DMAP, dry CH2CI2, rt; d) L TSCI, Et3N, DNIAP, dry CH202, rt, ii. NaN3. 
DMF, 601C, 71%; e) i. TFA, CH2CI2, ii. compound 125, Et3N, HgC12, DMF, rt, 78%. 
Subsequently, the Boc protected ethanolamine 152 was first converted into the 
tosylate, and replaced by nucleophilic displacement to give the azide derivative 153 
85 
99,102 in 71% overall yield 
. 
TFA in CH202 was used to remove the remaining Boc 
protecting group and the resulting amine was subject to the standard guanidinylation 
conditions to provide the target protected guanidine containing azide side chain 154 
in a yield of 78%. 
77 
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a) azide compound 154, CUS04'5H20, C6H706Na, MeOH/H20, rt, 70%; b) 98%TFA, 
rt, 95%. 
Afterwards, synthesis of the triazole ring was performed using Huisgen cycloaddition 
catalysed by Cu (1) generated in situ from copper sulfate and sodium ascorbate 
according to a known protocol (Scheme 38). 103 The treatment of the protected alkyne 
148 and the azide side chain 154 with copper sulfate and sodium ascorbate in 
acetonitrile and water afforded the precursor 155 in a yield of 70% with formation of 
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the anti isomer only. Global deprotection of this precursor 155 using the same 
synthetic approach as the amine compounds 74(a-c) achieved the target triazole 78 as 
a hygroscopic hydrochloride salt with 95% yield. 
Briefly, the azide SAM analogue 76 could not be generated because of difficulty with 
the formation of the side chain 145, but the alkyne SAM analogue 77 was 
synthesised successfully from the protected adenosine in four simple steps. It is 
expected that the alkync SAM analogue 77 can be used in the future to explore 
templated synthesis of potential inhibitors of PRMT: s or other methyltransferases. 
The subsequent triazole derived SAM analogue 78 was efficiently realised using the 
Cu (1) catalysed Huisgen reaction to deliver a potential bisubstrate inhibitor of 
PRMTs. Both of these compounds were evaluated for PRMT inhibition by 
collaborators, Professor Steve Ward and Dr Richard Parry at the University of Bath, 
and the results will be described in Chapter 4 in this thesis. 
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3.4. Preparation of N-6 azide side chain SAM analogue 
Cu (1) catalysed Huisgen reaction between azide and terminal alkynes is so efficient 
that it has been exploited for the labeling of biornolecules using fluorescent dyes or 
biotin for the purpose of either localisation or affinity purification of target proteins 
because the resulting triazole is small and easily produced in protein compatible 
conditionS. 69 Unfortunately, the copper promoted Huisgen reaction is not compatible 
with live cells due to the toxicity of copper. An alternative, biologically compatible 
reaction for azides has been developed by Bertozzi and co-workers who have 
optimised the reaction condition for the phosphine promoted conversion of azides 
into amides, now known as Staudinger ligation 
. 
69 This transformation has been used 
to effectively manipulate exogenously applied azides within live cells, confirming 
the relatively benign nature of the reagents and their potential utility for synthetic 
manipulation of compounds within a relative biological setting. 69 
Ideally, any reactive functionality presented on any inhibitor should be remote from 
its binding site so that it does not interfere with binding site. The crystal structure of 
PRMTI in complex with SAH (PDB I OR8, Figure 5) shows that the N-6 position of 
the adenine ring is relatively exposed in a shallow binding site for this co-enzyme. 
Therefore, N-6 modification of adenosine to incorporate azide functionality via a 
long tether was sought in order to explore the potential of such SAM analogues 
75(a-c). It is anticipated that the flexible linker might ensure that the reactive azide 
functionality is presented in a remote position away from the protein, thus offering 
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maximum opportunity for Huisgen reaction or Staudinger ligation. 
The azide linker 159 was formed following the approach shown in Scheme 39. 
Tetraethylene glycol 156 was converted to the bis-tosylate 157 using tosylate 
chloride in the presence of sodium hydroxide as base in THIF and water in 71% 
yield. 104 Displacement of both esters with sodium azide in dry DMF provided the 
bis-azide 158 in an excellent yield of 96%. 102 Desymmetrisation of bis-azide 158 was 
achieved in high yield using a biphasic variation of the Staudinger reaction, ' 02 thus 
treatment with triphenylphosphine in ethyl acetate/IM aqueous HCI (511) afforded 
the monoamine 159 in 75% yield after purification by silica gel chromatography. 
Exclusive reduction of onlY one of the azide groups was achieved because the water 
soluble ammonium hydrochloride formed after the first reduction was transported to 
the aqueous water layer, thus removing the remaining azide from further 
triphenylphosphine which is only soluble in the organic layer. 
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Installing the azide tether 159 at the N-6 position of adenosine was attempted using 
two approaches hown in Scheme 40. Ribofuranose tetraacetate 160 was treated with 
6-chloropurine in the presence of Lewis acid, tin tetrachloride, in acetonitrile to give 
the protected 6-chloride adenosine analogue 161 in 78% yield. 105 The purinyl 
chloride was then displaced with the amine tether 159 in the presence of 
triethylamine in dry DMF to form the desired compound 162 in a disappointing yield 
of 43%. Finally, sodium methoxide in dry methanol was used to cleave the acetate 
protecting groups, leading to a polar intermediate, which was directly reacted with 
2,2-dimethoxyl propane in the presence of toluenesulfonic acid and acetone to give 
the acetonide protected compound 165 in 51% yield. 
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a) SnC14,6-chloropurine, CH3CN, rt, 78%; b) compound 159, Et3N, dry DMF, 
rt-601C, 43%; c) NaOCH3, dry MeOH, rt, and then TsOH, 2,2-dimethoxyl propane, 
acetone, rt, 51%; d) TsOH, 2,2-dimethoxyl propane, acetone, rt, 63%; e) compound 
159, PyBOP, DIPEA, dry DMF, rt, 75%. 
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Alternatively, compound 165 could be synthesised much more efficiently from 
inosine 163, thus familiar conditions furnished the acetonide protected inosine 164 in 
63% yield. 106 The azide-tethered arnine 159 was installed by activation of using 
benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) in 
the presence of N, Ný-diisopropylethylarnine (DIPEA) in dry DMF and subsequent 
displacement with amine 159 to furnish the compound 165 in 75% yield. 107 
Obviously, the second route, which contains two steps reactions in satisfactory yields, 
was much more efficient than the first route and easy to scale up. 
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With the modified N-6 azide side chain installed, the adenosine was converted into 
the SAM analogue 79 using the familiar route, including Mitsunobu reaction, Gabriel 
synthesis, twice reductive amination and deprotection (Scheme 41). Notably, there 
was a little difference in the Mitsunobu reaction to form azide-bearing 5'-amino- 
5'-deoxyadenosine 165, compared with that of 5'-amino-5-deoxyadenosine 133 
(Scheme 3 1). In this instance optimum yields were obtained using 3.5 equivalents of 
phthalimide, diisopropyl azodicarboxylate (DIAD) and triphenylphosphine 
respectively, while those three reagents were used at 1.0 equivalent in the synthesis 
of 5'-amino-5-deoxyadenosine 133. 
Briefly, the key modified adenosine, 165 was prepared over two steps in a yield of 
47%, which is better than the previous method prepared over three steps in 17% 
yield. 105 The azide-bearing SAM analogue 79 was generated successfully, following 
the preparation of nitrogen analogues 74(a-c), which will be used in the localisation 
and purification of the target protein with alkynes or Staudinger ligation in the future. 
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3.5. Attempted synthesis of (+)-sinefungin 
3.5.1. The original synthetic strategy 
The synthesis of sinefungin has been reported by numerous approacheS, 
56,57'59-63 but 
some of them produce a mixture of epimers at the C-6 position, while 
enantioselective routes to (+)-sinefungin are quite long winded requiring numerous 
steps. We envisaged a novel, rapid and efficient synthesis of (+)-sinefungin (Scheme 
42), which focused on preparation of the dihydropyridazine 170 and ideally, 
subsequent one-pot deprotection and ring opening to generate the target compound. 
It was initially conceived that the central dihydropyridazine could be generated by a 
Diels-Alder reaction, although inspection of the relative stereochernistry of 
sinefungin shows that a trans stereochernical relationship across the 
dihydropyridazine would be required. Fortunately this can be obtained by 
epimerisation adjacent to the ester functionality. 
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3.5.1.1. Preparation of the key diene by C-6 and C-7 bond formation 
In the forward direction, synthesis of the target diene 174 for the proposed 
Diels-Alder reaction by Wittig olefination to form the C-6 and C-7 alkene was 
anticipatcd, thcrcfore, dcmanding the adcnosyl 5'-ethylaldchyde 175 and 
commercially available triethyl 4-phosphonocrotonate (Scheme 43). We chose to 
ignore the geometry of the diene in the first instance, being most concerned with 
evaluation of the general strategy. The target aldehyde required one-carbon 
homologation of adenosine, which can be achieved via the protected nitrile 
compound 173. Protected adenosine 92 was converted to nitrile 173 by Mitsunobu 
reaction with acetone cyanohydrin, diisopropyl azodicarboxylate (DIAD) and 
triphenylphosphine in 73% yield. 1 08 
Scheme 43 
N NH2 N NH2 rN 
__ýNH2 r 
0 qý/ \0 Ný C) NN N 
ýý/JIN 
a) NC OHC HO -'ýD N--N 
--J 
6d0d0 
92 173 175 
b) 
N NH2 
C2H50 0N 
-ý 
N 
db 
174 
Reagents and conditions: 
a) acetone cyanohydrin, Ph3P, DIAD, dry THF, rt, 73%; b) i. DIBAL, THF, ii. triethyl 
4-phosphonocrotonate, NaH, THF; c) DIBAL, THE 
94 
Initially, a one-pot reduction and Wittig olefination to form diene 174 was attempted 
involving treatment of nitrile 173 and diisobutylaluminium hydride (DIBAL) in THIF 
to afford the crude aldehyde, which was then subject to triethyl 
4-phosphonocrotonate and sodium hydride. Unfortunately, this protocol did not 
generate the diene 174. Verification of the intermediate, adenosyl 5'-ethylaldehyde 
175 was sought by performing the reduction and isolation. Unfortunately, the 
adenosyl 5'-ethylaldehyde 175 was unstable, because the crude 1H NMR spectrum 
revealed two aldehyde containing compounds, presumably arising from a ring 
opening, ring closing sequence (Scheme 44). 
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This mixture formation can be envisaged to start with enol formation 176 and 
subsequent retro-Michael to open the ribosyl ring which may close again to scramble 
the stereochernistry at C4. Further decomposition can occur by elimination of the 
purine leading to an aldehyde 178 that may then undergo subsequent nucleophilic 
addition by methanol or water and subsequent intramolecular Michael addition to 
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give the sugar 179.109 This route was abandoned for the time being and alternative 
methods to connect C-5 and C-6 were investigated as an alternative strategy. 
3.5.1.2. Preparation of the key diene by C-5 and C-6 bond formation 
In order to form the C-5 and C-6 bond, three synthetic routes were examined: 1) SN2 
nucleophilic displacement of adenosyl 5'-tosylate 188 with an appropriate Grignard 
reagent or related cuprate (Scheme 48); 2) addition of alkynyllithium anions to the 
aldehyde modified adenosine at Y-position (Scheme 51); 3) addition of 
alkynyllithium anions to the Weinreb amide modified adenosine at Y-position 194 
(Scheme 52). 
Firstly, it was necessary to explore the formation of the target vinyl bromide 183 or 
vinyl iodide 186, ultimately required to form the respective Grignard or cuprate that 
will displace adenosyl Y-tosylate. The strategy for the formation of the vinyl bromide 
183 starting from propagyl alcohol 180 was attempted (Scheme 45). Thus, propargyl 
alcohol 180 was converted to alkyne derived alkene compound 181 via in situ 
manganese dioxide oxidation and subsequent Wittig olefination with 
(carbethoxymethylene)triphenylphosphorane, exclusively as the C-2 and C-3 trans 
isomer in 63% yield. 110 Consequently, bromination of the alkyne derived alkene 
compound 181 was achieved by treatment with N-bromosuccinimide (NBS) and 
silver nitrate in acetone to afford the bromide 182 in 83% yield. "' Attempts to reduce 
the alkyne bromide 182 by hydrogenation catalysed with Lindlar's catalyst, or 
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hydroboration with dicyclohexylborane followed by protonolysis with acetic acid' 12 
unfortunately failed to deliver vinyl bromide 183. 
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a) NaI, CH3COOH, 70T, quantitative yield; b) i. DIBAL, dry CH2CI2. ii. n-BuLi, 
triethyl phosphonoacetate, dry THF, -78'C, 62%. 
An alternative preparative route was explored as outlined in Scheme 46. Treatment of 
ethyl propynoate 184 with sodium iodide in refluxing acetic acid proceeded to give 
the vinyl ester 185 exclusively as the Z isomer in quantitative yield' 13 subsequent 
reduction of the ester 185 using diisobutylaluminium hydride (DIBAL) in dry 
CH202 gave the crude aldehyde which was immediately treated with triethyl 
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phosphonoacetate and n-butyllithium to give the vinyl iodide 186 with the desired 
configuration in a promising yield of 62%. 1 14 
Next, the model reaction was attempted in Scheme 47, with the aim of exploring the 
C-5 and C-6 bond fon-nation with SN2 nucleophilic displacement. Starting from 
2', 3'-O-isopropylideneadenosine 92, the benzoyl protecting group was installed using 
a known procedure, thus treatment with benzoyl chloride in pyridine generated N-6 
benzoyl-isopropylideneadenosine 187 in 88% yield. 76 The tosylate leaving group was 
then installed at the remaining 5'-hydroxyl using toluenesulfonyl chloride in pyridine 
to afford the adenosyl Y-tosylate 188 in 80% yield. " 
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Unfortunately, treatment of adenosyl 5'-tosylate 188 with neither vinyl magnesium 
bromide, nor the corresponding cuprate arising from in situ treatment of the Grignard 
with copper chloride, generated the model compound 189. Even though the model 
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reaction for exploring the fon-nation of C-5 and C-6 bond with nucleophilic 
displacement failed, we were keen to investigate this reaction further using model 
nucleophile 188. 
The attempt to form the C-5 and C-6 bond relied on SN2 nucleophilic displacement at 
the adenosyl 5'-tosylate 188 using alkeny1magnesates prepared from vinyl iodide 186 
following Oshima's iodine-magnesium exchange procedure (Scheme 48). 1 16 In this 
procedure '. PeBU2MgLi was prepared by mixing the isopropyl magnesium chloride 
and n-butyllithium which could then exchange with the vinyl iodide to generate the 
alkenylmagnesate with retention of the double bond configuration and the otherwise 
potentially reactive ester functionality. For our studies, 'PrBU2MgLi was first 
prepared by the treatment of isopropyl magnesium chloride and n-butyllithium in a 
1: 2 molar ratio in THIF at O'C. Vinyl iodide 186 was then treated with fresh 
'Pr`BU2MgLi at 
-78*C to fumish the desired alkenylmagnesate which was reacted 
with adcnosyl 5'-tosylate 188 in the presence of a catalytic amount of CuCN-2LiCl. 
Unfortunately, this procedure did not generate the desired diene 171. 
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Subsequently, we decided to examine a model reaction using 'PrBU2MgLi in order to 
find out why the reaction did not occur using adenosyl 5'-tosylate 188 (Scheme 49). 
Reaction between benzylaldehyde and the vinyl iodide 186 prepared using the same 
procedure as described above was attempted, but no corresponding alcohol 190 was 
observed. This model reaction showed that it was difficult to generate 
alkeny1magnesate from the vinyl iodide 186 using the iodine-magnesium exchange 
procedure. Therefore, the C-5 and C-6 bond formation could not be generated from 
the vinyl iodide 186 and adenosyl 5'-tosylate 188. 
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The unsuccessful displacement of the adenosyl 5'-tosylate 188 lead to consideration 
of an alternative route involving reaction of the alkynyllithium with the adenosyl 
5'-aldehyde to generate alcohol 193 (Scheme 51), which could be subject to 
dehydroxylation and reduction to afford the target diene 171 (scheme 42). A model 
reaction was first attempted involving deprotonation of the alkyne 181 with 
n-butyllithium and subsequent reaction with benzylaldehyde at -78'C to fumish the 
model compound 191 in 38% yield (Scheme 50). 
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Subsequently, the model reaction was applied to the formation of C-5 and C-6 bond 
of the key diene 171 and preparation of the adenosyl 5'-aldehyde was required for the 
target synthesis (Scheme 5 1). According to Moffatt's original procedure, 117 the 
adenosyl 5'-aidehyde was not stable and instead stored as 1,3-diphenylimidazolidine 
derivative 192. The N-6-benzoyl-2', 3'-O-isopropylideneadenosine 187 was oxidised 
under Moffatt's conditions of dimethyl sulfoxide (DMSO) and dicyclohexyl- 
carbodiimide (DCQ in the presence of dichloroacetic acid to afford the crude 
aldehyde. Immediately, the resulting protected aldehyde was treated with 
diphenylethylenediamine and isolated as 1,3-diphenylimidazolidine derivative 192 in 
67% yield. When required, the aldehyde functionality could be restored by treating 
the protected compound 192 with Dowex 50WX4-400 (H) in aqueous THF to 
generate the hydrated aldehyde which could be converted to the analytically pure 
aldehyde upon refluxing in benzene with Dean-Stark apparatus. The alkyne 
compound 181 was then deprotonated with n-butyllithium and reacted with the 
adenosyl 5'-aidehyde, but unfortunately no desired compound 193 was produced 
using these reaction conditions. 
101 
Scheme 51 
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Another synthetic route focused on installing a Weinreb amide in the 5-position of 
adenosine and reaction with alkynyllithium 181 to give a ketone that may later be 
reduced to the desired methylene (Scheme 52). To this end, the adenosyl 
Y-carboxylic acid 26 was generated by oxidation of the protected adenosine 187 with 
2,2,6,6-tetramethylpiperidine-l-oxyI (TEMPO) and (bis(acetoxy)-iodo)benzene 
(BAIB) system in acetonitrile and water as solvent in 86% yield. 118 The resulting 
carboxylic acid was converted to the Weinreb amide 194 by reaction with 
N, O-dimethylhydroxylamine hydrochloride, triethylarnine and benzotriazol-1-yl- 
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) in 71% yield. 119 The 
alkynyllithium compound was generated as before, and then reacted with Weinreb 
amide 194, but unfortunately this reaction did not furnish the target ketone 195. 
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In brief, some synthetic approaches were attempted to generate the key diene 171, 
which was essential for the Diels-Alder reaction to synthesise the target 
dihydropyridazine 170, including C-6 and C-7 bond formation by Wittig olefination 
form adenosyl 5'-ethylaldehyde 175 and C-5 and C-6 bond formation by nucleophilic 
displacement of adenosyl 5'-tosylate 188 with an appropriate Grignard reagent or 
related cuprate, addition of alkynyllithium anions to the adenosyl 5-aldehyde or 
adenosyl. 5'-Weinreb amide 194. Unfortunately, all of them failed, so an alternative 
synthetic route was designed. 
3.5.2. An alternative route to dihydropyridazines 
The initial Diels-Alder strategy failed because generation of the key diene 
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intermediate 171 was difficult (Scheme 42). We were intrigued by Ley's description 
of an organocatalytic procedure to access dihydropyridazines. 120 This one-pot three 
component coupling occurs between an enolisable aldehyde 196, azodicarboxylates 
197 and vinyltriphenylphosphonium salt 201 to concisely generate dihydro- 
pyridazines 203 (Scheme 53). Ley reported optimised reaction conditions that control 
the stereogenic amination using catalytic amounts of (S)-pyrrolidinyl-tetrazole 198 to 
provide the intermediate hydrazinocarbonyl compound 199 which then undergoes 
base promoted conjugate addition to the vinyltriphenylphosophonium salt 201, and 
the resulting intermediate ylide 202 then undergoes intramolecular Wittig reaction to 
generate chiral dihydropyridazines 203. 
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We set out to exploit and further develop this reaction toward a new strategy toward 
a very concise synthesis of sinefungin (Scheme 54). The planned route focuses on 
generation of a key dihydropyridazine precursor 170 from adenosyl 5'-propaldehyde 
204, commercially available azodicarboxylate derivatives 172 and an ester 
substituted vinyltriphenylphosphonium salt 205. 
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3.5.2.1. Preparation of the dihydropyridazine precursor 
We first set out to prepare the intermediates, adenosyl 5'-propaldehyde 204 and ester 
substituted vinyltriphenyl phosphoniurn bromide 205 and organocatalyst, 
(S)-pyrrolidinyl-tetrazole 198. The adenosyl 5-propaldehyde 204 could be obtained 
by Moffatt oxidation of the protected adenosine 187, subsequent one-pot Wittig 
reaction according to Wnuk's procedure 121 and then hydrogenation of the alkene 
(Scheme 55). Thus, protected adenosine was subject to Moffatt oxidation as before to 
give the crude aldehyde, which was then directly reacted with Wittig reagent, 
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(triphenylphosphoranylidene)acetaldehyde to provide the unsaturated aldehyde 206 
in 57% yield. The alkene group of the unsaturated aldehyde 206 was reduced using 
Pd/C and a hydrogen atmosphere in ethyl acetate to provide the target intermediate 
aldehyde 204 in a yield of 71%. 
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71%. 
The ester substituted vinyltriphenylphosphonium bromide 205 was generated using a 
procedure first described by Pattenden (Scheme 56). 122 Ethyl propynoate 184 was 
treated with lithium bromide in refluxing acetic acid to give the Z-vinyl bromide. 
Subsequent reaction with triphenylphosphine in toluene at room temperature 
provided the Z-vinyltriphenylphosphonium bromide 205 in 69% yield over the two 
steps. 
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Scheme 56 
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The organocatalyst, (S)-pyffo lid inyl-tetrazole 198, not commercially available, was 
prepared according to Ley's procedure (Scheme 57). 123 L-Proline 207 was converted 
to the amide 208 using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDCI), hydroxybenzotriazole (1-1013t), and ammonia aqueous 
solution in 75% yield. Subsequently, the amide 208 was converted to the nitrile 209 
using toluenesulfonyl chloride and pyridine in 72% yield. The target tetrazole 198 
was finally obtained in an overall 46% yield by [3+2] cycloaddition of nitrile 209 
with sodium azide in the presence of ammonium chloride in DMF and subsequent 
hydrogenolysis catalysed by Pd/C in acetic acid and water. 123 
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NaN3, NH4CI, DMF, ii. H2, Pd/C, CH3COOH/H20,46%. 
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Next, a series of dihydropyridazine compounds 170 were generated via Ley's method 
by using adenosyl 5'-propaldehyde 204, ester substituted vinyltriphenyl- 
phosophonium salt 205 and variant azodicarboxylatc derivatives 172, such as diethyl 
azodicarboxylate (DEAD), dibenzyl azodicarboxylate, di-terl-butyl azodicarboxylate 
and di-trichloroethyl azodicarboxylate, with the aim of selecting a good precursor for 
the deprotection and ring opening step (Scheme 59). In principle, the stereochemistry 
of the arnination at C-6 can be controlled by the organocatalyst, (S)-pyrrolidinyl- 
tetrazole 198, although the chemistry at C-9 will not be directly controlled during 
base promoted conjugate addition to the ester substituted vinyltriphenyl- 
phosophonium bromide 205. Presumably the major diastereoisomer will feature 
trans relative stereochernistry arising from facile epimerisation at C-9. 
In fact, Ley reported that the metbyl substituted vinyltriphenylphosphonium salt 211 
was involved in the formation of 1,2-oxazines 212a and 212b with a 
diastereoisomeric ratio 6: 1 (Scheme 58). 120 Ley did not report the formation of 
dihydropyridazine compounds with an ester substituted vinyltriphenylphosophonium 
salt 205, thus we sought to develop a novel application of Ley's procedure to 
synthesise the key intermediate 170. 
108 
Scheme 58 
0 
N-p 
210 
ON 
H HN-N 
198 
Reagents and conditions: 
b) NPh NPh 10+ 
co 
ý"ýP+Ph3 Br- 
211 
212a 212b 
6: 1 
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Table 2 
Entry Aminating agent Intermediate Yield(%)" 
I R= C21-15 detected 55' 
2 R=Bn detected 63 
3 R= t-Bu detected 0 
4 R= CC13CH2 detected 61 
'Yields based on isolation of a diastereomeric mixture. Single diastereoisomer could 
not be separated. bThe yield for the isolated single diastereoisomer is 33% and the 
diastereomeric mixture is 22%. 
TLC analysis revealed that all of the commercially available azodicarboxylate 
derivatives appeared to react with the adenosyl 5'-propaldehyde 204, but subsequent 
addition of the ester substituted vinyltriphenylphosphonium salt 205 appeared to 
proceed to form the dihydropyridazine for all except the di-tert-butyl 
azodicarboxylate, which may be too sterically hindred to allow the intramolecular 
cyclisation (Entry 3, Table 2). Generally, purification of the dihydropyridazine 
compounds 170(p, b and d) suffered from a number of issues including difficulty in 
removing the triphenylphosphine oxide and problem achieving separation of the 
diastereoisomers by silica gel chromatography, which ultimately complicated the 'H 
NMR spectra, thus only crude yields are reported in Table 2. In fact, the purification 
the dihydropyridazine compound with ethyl carbamate 170a (Entry 1) was better 
than the related benzyl carbamate compound 170b or trichloroethyl carbarnate 
compound 170d (Entry 2 and 4). One apparent diastereoisomer of diethyl carbarnate 
was isolated in a yield of 33%, while a further 22% yield of material was obtained as 
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a mixture of two diastereoisomers after silica gel chromatography using 
CH2CI2/MeOH (60/1) as the eluent. UnfortunatelY, the relative stereochernistry of the 
single diastereoisomer of diethyl carbamate compound 170a could not be confirmed 
using advanced NMR techniques, such as ROESY correlation spectroscopy, because 
the protons of C-6 and C-9 could not be unambiguously identified due to overlapping 
signals. Unfortunately, the apparent single diastereoisomer form of compound 170a 
proved difficult to recrystallise, which precluded X-ray crystallography. 
Nevertheless, the deprotection and ring opening conditions were investigated with 
the diastereomeric mixture of the dihydropyridazine compounds 170 with the aim of 
evaluating the overall route to sinefungin on the basis that we could return to the 
issue of stereochernistry once the entire route had been established. 
3.5.2.2. Deprotection and ring opening of the precursor 
According to Arakawa's method, 124 the N-N bond on the cyclic hydrazine 215 could 
be cleaved by platinum oxide under hydrogenation (Scheme 60). 
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Initially, base promoted cleavage of the diethyl carbarnate 170a was attempted with 
the knowledge that both the ethyl ester and benzoyl protecting group are sensitive to 
the base (Scheme 61). The main reason for examining this reaction first was the 
superior quality of the 1H NMR spectrum for the starting material. Therefore, the 
ethyl carbarnate compound 170a was treated with potassium hydroxide in 95% 
ethanol at room temperature overnight. Analysis of the reaction mixture by 
electrospray mass spectrometry suggested cleavage of the ethyl ester and benzoyl 
amide groups to form pyridazine 217 due to the major peak at 561 compared with the 
staring material parent ion at 693, but no cleavage of the carbarnates was observed. 
The same deprotection reaction was carried at reflux, but again no cyclic hydrazine 
218 was observed. 
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Subsequently, deprotection of the dibenzylcarbamate protected dihydropyridazine 
170b was examined with the aim of achieving deprotection, ring opening and 
reduction in one-pot reaction (Scheme 62). We were interested in reports from 
Micouin's and co-workers that described one-pot transformation of the cyclic 
dibenzylcarbamate 219 by carbamate deprotection and ring cleavage using 
hydrogenolysis over platinum oxide in acetic acid under a hydrogen atmosphere 
pressure in quantitative yield. 125 
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Hydrogenolysis of dibenzylcarbamate protected dihydropyridazine 170b over 
platinum oxide under one atmosphere of hydrogen in acetic acid (Scheme 63) was 
analysed by mass spectrometry which showed a major peak at 819 that suggested the 
C-7 and C-8 double bond had been reduced compared with the starting material 
parent ion at 817, but no ring opening had occurred. Consequently, the hydrogen 
pressure was increased to 10 bar, and this time analysis by mass spectrometry 
showed a large peak at 685 that suggested reduction of the C-7 and C-8 double bond 
and removal of one Cbz groups, but no ring opening was apparent. 
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These results were promising in that the alkene, and carbarnate protecting groups 
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could be cleaved, so we set out to explore formation of cyclohydrazine 222 using a 
range of conditions (Table 3) with the aim to explore the ring cleavage at a later stage. 
Attempts at transfer hydrogenolysis using Pd(OH)2/C and cyclohexene in refluxing 
methanol (Entry 1, Table 3), were analysed by mass spectrometry which showed a 
large peak at 545 and a small peak at 549, indicating a mixture compounds 
comprised of a major pyridazine 223 and a minor compound 224 where the double 
bond may have migrated, but the individual components could not be separated using 
silica gel chromatography. The possible reason for the formation of major pyridazine 
223 is that the hydrogen is transferred from intermediate 226 to cyclohexene 
promoted by conjugation with ester group at C-9 to form the aromatic ring (Scheme 
64). 
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Next, hydrogenation of the dibenzylcarbamate-protected ihydropyridazine 170b 
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with Pd/C in THF at atmosphere pressure of hydrogen over two nights yielded the 
double bond migration compound 224 which could be isolated in 28% yield (Entry 2, 
Table 3). The presumed mechanism is shown in Scheme 65, in which deprotonation 
of the intermediate 226 leads to the enolate 227, which then undergoes 
tautomerisation to give enamine 228 that may further tautomerise to give the isolated 
imine compound 224. It is likely that the ester group at C-9 of the dihydropyridazine 
helps to stabilise the product of double bond migration. 
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Examination of other transfer hydrogcnolysis conditions using Pd/C and ammonium 
formate in refluxing methanol (Entry 2, Table 3), resulted in two compounds that 
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could be separated, one of which arose from cleavage of Bz group compound 225 
and another of which could not be characterised by mass spectrometry or 1H NMR 
spectroscopy. Finally, hydrogenation of Cbz protected compound 170b with Pd/C in 
methanol at atmosphere pressure was tried, the resulting compound was analysed by 
mass spectrometry and 1H NMR, but the resulting peak at 563, could not be matched 
with the possible cyclohydrazine 223 (peak at 551) or double bond migration 
compound 224 (peak at 549), meanwhile its 114 NMR spectrum provide dift'icult to 
interpret (Entry 4, Table 3). 
Clearly, many challenges for the deprotection and ring opening of the 
dihydropyridazines were encountered: 1) it was not possible to remove the two 
ethylcarbamates from the compound 170a using base hydrolysis; 2) one-pot 
deprotection, reduction and ring opening with platinum oxide did not give the target 
compound 221; 3) transfer hydrogenolysis generated the pyridazine oxidation 
compound 223; 4) palladium catalysed hydrogenolysis apparently furnished the 
double bond migration compound 224. The cleavage of the N-N bond could not be 
achieved in order to access sinefungin. 
3.5.2.3. Modification of the second synthetic strategy 
The difficulty in cleaving the cyclohydrazine lead us to consider a modified synthetic 
strategy, generating the acyclic precursors 229 as outlined in Scheme 66. Briefly the 
same aldehyde precursor 204 could be used to perform a stereoselective amination 
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using commercial azodicarboxylate derivatives 172 which this time could be isolated 
as the aldehyde and then transformed by olefination using an appropriate 
phosphonopropanoate 230. Cleavage of these hydrazines should be easier than their 
cyclic equivalents 170. In principle, the stereochernistry at C-9 can be controlled 
independently of the C-6 centre by making it before the olefination step. It was 
therefore necessary to synthesise the substituted phosphonopropanoate 230 for the 
proposed route (Scheme 67). 
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As shown in Scheme 67, the substituted phosphonopropanoates 233(a-b) were 
synthesised with either Cbz or Boc, protecting group at nitrogen, both of which could 
be easily removed in the later stages of synthesis. Following Vederas's procedure, 126 
the stereochernically pure P-lactones 232(a-b) were synthesised from the 
commercially available N-protected L-serine derivatives 231(a-b) by intramolecular 
Mitsunobu reaction. Thus the serine derivatives 231(a-b) were treated with 
triphenylphosphine and diethyl azodicarboxylate (DEAD) at 
-78"C in THF to afford 
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the Cbz protected P-lactones 232a and Boc protected P-lactones 232b in the yields of 
33% and 32% respectively. Subsequently, the nucleophilic addition of 
triethylphosphine to the protected P-lactones 232(a-b) at 70'C generated the 
substituted phosphonopropanoates 233(a-b) as the stereochernically pure isomers in 
the yields of 81% and 62% respectively according to Smith's method. 127 
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Model reactions were performed to evaluate the ability of the substituted 
phosphonopropanoates 233(a-b) to undergo olefination (Table 4). Various bases were 
used to deprotonate the phosphonopropanoates 233(a-b), such as sodium hydride, 
potassium tert-butoxide, n-butyllithium and lithium diisopropylamide (LDA), but 
subsequent attempted reaction with benzylaldehyde or 4-methoxyl benzylaldehyde 
did not generate the expected alkene 234. Presumably deprotonation next to the 
phosphonopropanoates 233(a-b) was difficult due to deprotonation of the adjacent 
a-proton to the carbonyl. Unfortunately, we could not resolve this problem, 
undermining the value of this strategy. 
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Entry R aldehyde Base Solvent Results 
I Cbz PhCHO NaH CH2CI2 No alkene observed 
2 Cbz PhCHO t-BuOK CF12CI2 No alkene observed 
3 Cbz--, PhCHO n-BuLi THF No alkene observed 
4 Boc 
I 
4-MeOPhCHO LDA THF No alkene observed 
An alternative approach to link the C-7 and C-8 carbon bond by the addition of a 
zincate 236 to the aldehyde arising from the amination step was envisaged (Scheme 
68). 
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Following Jackson's procedure, 128 the nucleophilic a-amino acid organozinc reagent 
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236 was generated from iodoalanine 237, in which the ester group and stereocentre 
were compatible for the zinc reagent (Scheme 69). BOC-L-serine 231b was treated 
with potassium and methyl iodide in dry DMF to afford the crude protected serine, 
which was converted to the iodide 237 by reaction with triphenylphosphine, iodine 
and imidazole in THIF in 28% yield over two steps. 129 Treatment of this iodide with 
zinc dust, dibromoethane and trimethylsily1chloride in dry DMF was meant to 
generate the organozinc reagent 236, which was then added to benzyl aldehyde as a 
model reaction, but unfortunately no reaction occurred and insufficient time 
remained for further investigation of this approach. 
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Reagents and conditions: 
a) i. K2CO3, dry DMF, CH31, rt, ii. PPh39 12, imidazole, dry THF, O'C, 28%; b) Zn 
dust, BrCH2CI42Br, TMSCI, dry DMF, then PhCHO. 
In summary, our route to (+)-sinefungin relied on the rapid generation of 
dihydropyridazine compounds 170 and subsequent deprotection and ring opening 
leading to the target compound. Our efforts to extend Ley's methodology by 
employing the ester derived vinyltriphenylphosphonium salt 205 were promising, 
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although spectroscopic characterisation of the resulting dihydropyridazines was 
hindered by difficulty in separating the individual d iastereo isomers. Clearly, more 
work to solve these key problems will be valuable for establishing the level of 
stereochernical control in the reaction and deciding whether it is a viable strategy to 
sinefungin. UnfortunatelY, we were not able to establish a set of conditions to fulfill 
our ambitious strategy of simultaneously cleaving all protecting groups as well as the 
opening of cyclohydrazine. There are promising indications that the benzyl 
carbarnate protecting groups and the alkene can be manipulated under reducing 
conditions although the formation of the product where the double bond seems to 
have migrated into conjugation with the ester carbonyl appears to be a common 
problem that will need to be addressed in the future. Our failure to cleave the 
cyclohydrazine is obviously a significant barrier to the utility of this route and this 
encouraged us to explore alternative strategies that lead to acyclic precursor 229 that 
should be more easily deprotected and allow independent control of the 
stereochemistry at C-6 and C-9. Unfortunately, our initial studies into these strategies 
were frustrated by inherent problems associated with the precursors required for this 
synthetic strategy and a lack of time. Further time would allow more thorough 
investigation of new method of connecting the precursor's C-7 and C-8 carbon bond, 
such as Grubbs cross-metathesis. 
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Chapter 4 
Computational Docking and Biological Results 
4.1. Molecular docking 
Computational docking was used to visualise possible orientations of the bisubstrate 
inhibitors which have been synthesised and perhaps rationalise any inhibition. The 
crystal structure of PRMTI in complex with the cofactor product SAII (PDB 
I OR8)'6was taken as a starting point for molecular docking. Any results from these 
experiments should be treated with caution because PRMTI is believed to operate as 
a dimer, but the published crystal structure used for modelling is of the monomeric 
protein. The atoms of SAH were used as a reference to indicate the binding site for 
the bisubstrate inhibitors, and then the coordinates for SAII could be discarded. The 
receptor coordinates which remained were then taken as the input for docking 
software along with the definition of the desired binding site. The structures of the 
bisubstrate inhibitors, 74(a-c), 77 and 78 (Figure 18) were built by commercially 
available sollwarc Insightll created by Accelrys; Software Inc. 130 Docking software 
Gold 3.2 (Genetic Optimization for Ligand Docking) 131 was used to dock all 
bisubstrate inhibitors into the binding site of PRMTI. For each inhibitor, Gold docks 
the ligand 10 times starting each time from a different random population of ligand 
orientations. 
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Figure 18: Chemical structure of compounds, bisubstrate inhibitors and sinefungin, 
which are tested in vitro inhibition of PRMTI and SET7. 
Gold docking results gave 10 possible conformations with which each bisubstrate 
inhibitor bound to PRMTI. For compounds 74(a-c), there are conformations which 
can be overlapped with SAH and bind with SAM binding sites, whereas, none of the 
conformations of alkyne SAM analogue 77 or triazole derived SAM analogue 78 
(Figure 19-23) can bind with SAM binding site residues. In Figure 19, compound 
74a mainly binds to the PRMTI active site by forming hydrogen bonds with E129, 
MOO, H45, R54 and essentially the guanicline group binds to the key glutarnates 
residue E 153, and additionally to the residues W 145 and M 146. Compound 74b can 
bind with SAM binding site residues (E129, E128, EIOO) and glutamate residue 
(E153) from the Figure 20. Interestingly, the compound 74c appears to bind at the 
SAM binding site residue (V128, EIOO, H45), but does not reach either glutarnate 
residue E153 or E144, but instead appears to bind Y148 (Figure 21). In fact, the five 
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carbon linker can rotate about the alkane bonds, so it is possible that the guanidine 
group could bind with E153 after rotation. Although compounds 74(a-c) can 
potentially bind with one glutamate residue E 153, not with E 144, these experiments 
suggest that there is a good chance that the prototype bisubstrate inhibitors 74(a-c) 
might inhibit PRMTI. 
Moreover, as illustrated in Figure 22, the alkyne SAM analogue 77 can not dock with 
either SAM binding site or two key glutarnate residues (E144 or E153). The docking 
conformation of triazole derived SAM analogue 78 is quite different from SAII in 
Figure 23, in which the arginine side chain of compound 78 is overlapped with the 
amino acid side chain of SAH. Presumably, the triazole derived guanidine side chain 
is too long, so there is not enough space for it to dock with E153, therefore, it has to 
overlap with the amino acid side chain of SAM The docking results suggest that 
compounds 77 and 78 will not inhibit PRMTI. Of course, the computational docking 
just provides a graphical interpretation that may predict the relative activity of 
compounds 74(a-c), 77 and 78, and the exact biological results have to be 
demonstrated by the biological essays. 
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Figure 19: Binding conformation of bisubstrate inhibitor 74a into rat PRMTI (PDB 
IOR8) using the Gold algorithm. The tested compound 74a (tube, carbon atoms as 
cyan) were overlapped with SAH (yellow tube) and PRMTI residue were shown as 
ball and stick (carbon atoms as silver). 
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Figure 20: Binding conformation of bisubstrate inhibitors 74b into rat PRMT I (PDB 
I OR8) using the Gold algorithm. The tested compound 74b (tube, carbon atoms as 
cyan) were overlapped with SAH (yellow tube) and PRMTJ residue were shown as 
ball and stick (carbon atoms as silver). 
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Figure 21: Binding confon-nation of bisubstrate inhibitor 74c into rat PRMTI (PDB 
IOR8) using the Gold algorithm. The tested compound 74c (tube, carbon atoms as 
cyan) were overlapped with SAH (yellow tube) and PRMTI residue were shown as 
ball and stick (carbon atoms as silver). 
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Figure 22: Binding conformation of bisubstrate inhibitor 77 into rat PRMTI (PDB 
IOR8) using the Gold algorithm. The tested compound 77 (tube, carbon atoms as 
cyan) were overlapped with SAH (yellow tube) and PRMTI residue were shown as 
ball and stick (carbon atoms as silver). 
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Figure 23: Binding conformation of bisubstrate inhibitor 78 into rat PRMTI (PDB 
IOR8) using the Gold algorithm. The tested compound 78 (tube, carbon atoms as 
cyan) were overlapped with SAH (yellow tube) and PRMTI residue were shown as 
ball and stick (carbon atoms as silver). 
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4.2. Biological Results 
PRMT: s have been known to play physiologically important roles in numerous 
cellular processes, but their function in vivo is still not clear to understand, so it is 
necessary to develop specific inhibitors of PRMTs which can be used in the study of 
PRMT biological activities in vivo. In fact, only one specific inhibitor of PRMTs, 
AMI-1, was reported recently, 40 but it is a dye and resembles sulfonated ureas of the 
Suramin type which have been reported to be pleiotropic and target many proteinS. 42 
Therefore, we designed and synthesised a series of bisubstrate inhibitors and their 
biological evaluation was carried out by Professor Steve Ward and Dr Richard Parry 
in the University of Bath. 
4.2.1. In vitro evaluation of PRMT1 inhibition 
The in vitro screen of known inhibitor, (+)-sinefungin 2 and bisubstrate inhibitors 
(74(a-c), 77,78) was carried using human recombinant PRMTI, [S-3 H3C]-SAM and 
substrate recombinant Sam68 and the methyl transfer measured by scintillation 
counting. The substrate Sam68 encodes glycine- and arginine-rich sequences and is 
known to be an in vivo substrate for PRMT 1. In the P3 region (GRGVGPPR) of 
Sam68, the arginine 304 can be asymmetrically dimethylated. 133 As shown in Table 5, 
the known compound, sinefungin as a reference showed good inhibition for PRMTI 
with an approximate IC50 value of 2.0, uM. Additionally, the guanidine containing 
SAM analogues 74(a-c) appear to inhibit PRMTI with approximate IC5o values in 
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the range 2.7 to 3.3, uM. Therefore, the PRMTI inhibition activity of compounds 
74(a-c) appears to be of similar potency to sinefungin under these assay conditions. 
However, both the alkyne SAM analogue 77 and the triazole linker SAM analogue 
78 exhibited relatively weak inhibitions for PRMT1 at 100pM. Interestingly, these 
biological assay results are broadly in line with those predicted by the computational 
docking study. 
4.2.2. Evaluation of selectivity versus lysine methyltransferase SET7 
The e-amino lysine residues are another significant target for protein methylation 
within cells. 13 Lysine methyltransferases bearing SET domains can catalyse mono-, 
di- and trimethylation of lysine and are well known for their role in histone 
modification which is involved in a wide range of cellular processes, such as 
transcription regulation, chromosome inactivation and heterochromatin formation. 134 
The SAM binding site of SET domains is structurally different from that of PRMTs, 
thus it is possible to identify specific inhibitors that distinguish between these two 
types of binding site. 40 Therefore, sinefungin and novel compounds 74(a-c), 77,78 
were compared for their inhibition activity between PRMT I and SET7 (Table 5). The 
alkyne SAM analogue 77 and triazole linker SAM analogue 78 are poor inhibitors of 
either PRMTI or SET7 (43 and 27% inhibition at I OOpM respectively). As expected 
sinefungin is a potent inhibitor of both PRMTI (IC50 - 2.0, uM) and SET7 (IC5o - 
2.7pM) respectively and contains no specificity element. SAM analogue 74b also 
appears to display a lack of specificity with no more than a 5-fold reduction in 
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potency against SET7 (IC5o -I IuM). Interestingly, SAM analogues 74a, and 74c 
show much better selectivity for PRMTI OC50 
- 
3, uM) than SET7 (both 
- 
40% 
inhibition at 100, uM). Therefore, compounds 74a and 74c were identified as the 
potential selective inhibitors of PRMTI compared to the other compounds, 
presumably because these two compounds can bind with SAM binding site residues 
and key glutamate residue, E 153 (Figure 19 and 2 1). In fact, compound 74b can bind 
with SAM binding site residues and E153 (Figure 20) as well, but it exhibits poor 
selectivity for SET7. We have not performed computational docking of compounds 
74(a-c) at the SET7 binding site, so it is not possible to visualise any potential reason 
for this difference in selectivity. Ultimately, further structural binding studies by 
crystallography or NMR spectroscopy are required in order to uncover a structural 
rationale for this selectivity observed for compounds 74a and 74c. 
Table 5. In vitro inhibition of PRMTI and SET7 
Compounds PRMTI IC50a (, UM) SET7 IC5o (, uM) 
sinefungin 2.0 2.7 
75a 2.7 40% at I OOpM 
75b 3.3 11 
75c 3.3 36% at I OOpM 
78 29.5% at I OOpM 43% at I OOpM 
79 25% at 100, uM 24% at I 00, uM 
a. IC5o: the concentration of compound required to reduce the enzyme activity by 
50%. 
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However, from the biological evaluation and computational docking results, it is 
clear that compared to the alkyne analogue 77, accommodation of a guanidine group 
in the side chain of the analogues provides a substantial increase in potency against 
PRMTI and in the case of two of the analogues, provides the basis for selectivity 
over the lysine methyltransferase SET7. Furthermore, the relatively poor potency of 
the much larger and less flexible triazole based inhibitor is suggestive of 
structure-based selectivity that can be better explored and optimised in the future. 
Clearly more analogues containing guanidine isosteres will be explored using the 
synthetic route developed in this thesis in order to develop a rationale for the 
discovery of more efficient and specific inhibitors of PRMTI. 
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Chapter 5 
Summary and Future Work 
This thesis focused on improving on the very small number of chemical tools 
available for the evaluation of protein arginine methylation in cells and can be 
defined in four aims: 
1. Development of general inhibitors of methyltransferases. 
2. Design and synthesis of specific inhibitors of protein arginine methyltransferases 
(such as PRMTI). 
3. Synthesis of a N-6 modified SAM analogue for possible affinity purification of the 
target protein. 
4. Development of a novel, rapid and enantioselective synthesis of natural product 
(+)-sinefungin and its analogue. 
For the first aim, trifluoromethyl SAM analogue 69 was explored as general 
methyltransferases inhibitor based on the model compound 70 which was used as 
evaluation the reaction condition of forming trifluoromethyl sulfonium centre. 
However, it was difficult to generate the desired trifluoromethyl sulfonium 
containing model compound 70 either by trifluoromethylation of thioether 81 using 
trifluoromethylation reagent 86, or alkylation of a trifluoromethyl thioether 82 with 
Y-halogen adenosine 16 or 93. This objective was quickly abandoned in order to 
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concentrate on synthesis of more practical analogues. 
For the second aim, some guanidine containing bisubstrate SAM analogues were 
investigated with the aim of developing specific inhibitors of PRMTI. A series of 
nitrogen SAM analogues 74(a-c) were achieved in a high yield using an efficient 
four step synthesis. The reductive amination strategy offers a significant 
improvement to the overall yields obtained by Blackburn's original synthesis of 
AzoAdoMet 18 which relied on an alkylation strategy. This route offers much 
potential for the development of inhibitors of other SAM utilizing enzymes. Alkyne 
derived SAM analogue 77 was also successfully synthesised using this route and 
provides the opportunity for future exploration of protein templated synthesis of 
inhibitors of methyltransferases. The subsequent triazole derived SAM analogue 78 
was cfficiently prepared using the Cu (1) catalysed Huisgen reaction to deliver a 
potential bisubstrate inhibitor of PRMTs. 
However, synthesis of the related sulfonium-tethered guanidine SAM analogue 71 
could not be obtained successfully because of the difficulty of forming the sulfonium 
centre, but the guanidine containing thioether analogue 72 was made, although it was 
80 
claimed in a patent to be a poor inhibitor of DNA methyltransferase. In addition, 
the cycloethyl guanidine containing compounds 73 and 75 were difficult to achieve 
because of the formation of cycloethyl guanidine in an unfeasible yield. So the 
investigation of exploring the conditions for the synthesis of cycloethyl guanidine is 
necessary for the compounds 73 and 75, and improved routes to these compounds 
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must be explored in the future. 
The molecular docking results predicted that bisubstrate inhibitors 74(a-c) might 
inhibit PRMTI and that compound 77 and 78 have no inhibition for PRMTI. 
Subsequently, the bisubstrate inhibitors (74(a-c), 77,78) were evaluated for PRMTI 
inhibition by collaborators, Professor Steve Ward and Dr Richard Parry at the 
University of Bath. The biological results showed that compound 74a and 74c can 
selectively inhibit PRNff I not SET7 at ICso values 2.7pM and 3.3pM respectively, 
compound 74b can inhibit both PRMT1 and SET7 without much selectivity. It is 
very satisfying that two prototype bisubstrate inhibitors were discovered to be 
selective PRIVIT inhibitors 74a and 74c. It is hoped that they may prove to be useful 
for the study of arginine methylation or perhaps the development of candidate drugs 
for the therapeutic of some diseases, such as cancer. These preliminary results 
encourage the design of more analogues with guanidine-like functional group in 
order to discover more potent and specific inhibitors of PRMTs in the future. 
Eventually, we would like to be able to develop inhibitors that select between the 
various classes of PRMT. 
For the third aim, the azide bearing SAM analogue 79 was generated successfully, 
which may be used in the localisation and purification of the target protein with 
alkynes or Staudinger ligation in the future. It remains to be seen whether this 
compound retains potency for inhibition of PRMTI, which would clarify whether the 
location of the tether is indeed well placed to avoid repulsive steric interactions with 
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rest of the target protein. 
For the fourth aim, a novel, rapid and enantioselective route for the total synthesis of 
natural product (+)-sinefungin was investigated. The dihydropyridazine compound 
170 was successfully generated from adenosyl 5'-propaldehyde 204, commercially 
available azodicarboxylate derivatives 172 and ester substituted vinyltriphenyl- 
phosphoniurn salt 205 by extending Ley's methodology. Deprotection and ring 
opening of dihydropyridazine compounds 170b was then attempted, but this concise 
route seems difficult to generate (+)-sinefungin. The modified strategy seeking to 
generate acyclic precursor 229 was explored, but it was frustrated by inherent 
problems associated with the precursors required for this synthetic strategy and a 
lack of time. Further time would allow more thorough investigation of new method 
of connecting the precursor's C-7 and C-8 carbon bond, such as olefin cross 
metathesis. In addition, sinefungin analogue 80 will be explored as bisubstrate 
inhibitor of PRMTI in the future. 
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Chapter 6 
Experimental 
All chemicals were purchased from commercial sources and used as supplied unless 
stated, dry CH202 was distilled over calcium hydride and dry THIF was distilled over 
sodium benzophenone. TLC was carried out using silica gel 60 pre-coated 
aluminiurn plates (0.20mm thickness) from Macherey-Nagel, with visualisation by 
UV light (254nm) or cxposure to potassium permanganate solution. Flash 
chromatography was performed on silica gel (particle size 40-63pm) from Fischer 
Chemicals. I H, 13C, 19F and 3 1P NMR spectra were obtained from JEOL EX270, 
Bruker AV400, DPX400 and AV500 spectrometers. The chemical shifts, given as 8 
values, are quoted in parts per million (ppm); 1H and 13 C NMR chemical shifts were 
measured relative to internal tetramethylsi lane; 19F NMR chemical shifts were 
measured relative to neat CFC13; 3 'P NMR chemical shifts are positive downfield 
from external 85% H3PO4- Apparent coupling constants (absolute values), J, are 
measured in Hertz and multiplicities quoted as singlet (s), doublet (d), triplet (t), 
quartet (q) or combinations thereof as appropriate. Mass spectra were obtained from 
the School of Chemistry mass spectrometry service using an LC-TOF, running in an 
open-access mode. IR spectra were obtained from the solid phase using a thermo 
AVATAR 320 FT-IR or from solution samples using a Perkin Elmer FTIR 1600 and 
Bruker Tensor 27 spectrometer. Optical rotations were obtained at ambient 
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temperature using a Jasco DIP-370 digital polarimeter and ADP 440 polarimeter. 
Melting points were determined using a SMP3 melting point measurement and are 
uncorrected. 
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5'-Chloro-5'-deoxyadenosine 16 7 
f-, N 
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0 N--ý/ýý; N 
N 
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Thionyl chloride (667 mg, 5.61 mmol) was added to a solution of adenosine (500 mg, 
1.87 mmol) in CH3CN (5 mL) at 0 OC. Pyridine (296 mg, 3.74 mmol) was added to 
this mixture and stirring continued at 0 OC for 4 hr, then at room temperature 
overnight. MeOH (5 mL), aqueous ammonia solution (35%, 5 mL) and H20 (5 mL) 
were added to the yellow solution at room temperature, and stirring continued for I 
hr. The solution was then applied to Dowex Ix2 
-100 (OH') ion-exchange resin, 
eluting using H20/MeOH (1/1,100 mL) and MeOH to give chloride 16 as a white 
solid (550 mg, quantitative yield), m. p. 113-114 OC (lit., 110-111 *C); 135 11-1 NMR 
(400 MHz, DMSO-d6) 81,8.35 (s, I H, Ar-H), 8.17 (s, I H, Ar-H), 5.93 (d, J=5.1,1 H, 
I ý-H), 4.76 (app. tIH, J=5.1,2'-H), 4.22 (app. t, I H, J=S. 1,3-H), 4.09 (m, I H, 
4'-H), 3.95 (dd, I H, J, = 11.6, J2 = 5.2,5'-CH,, Hb), 3.84 (dd, I H, Ji = 11.6, J2 = 6.4, 
5'-HaHb); 13 C NMR (100 MHz, DMSO-d6) 8c 156.1 (C), 152.7 (CH), 149.4 (C), 
139.7 (CH), 119.1 (C), 87.4 (CH), 83.6 (CH), 72.6 (CH), 71.2 (CH), 44.8 (012); 
ES-MS 286.1 (M + H+); HRMS calcd for ClOH12CIN503+ 286.0662, found 286.0687. 
141 
N6-Benzoyl-2', 3'-O-isopropylidene-adenosyl-5'-carboxylic acid 26118 
0rN NHBz 
Ný ý/ N 
-ýHN HO 
N 
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Bis(acetoxy)iodo benzene (689 mg, 2.14 mmol), TEMPO (30 mg, 0.20 mmol) and 
protected adenosine 187 (400 mg, 0.97 mmol) were combined in a reaction flask and 
a solution of CH3CN/H20 (1/1,1.2 mL) was added to the mixture. The reaction 
solution was stiffed at room temperature for 3 hr. The precipitate was filtered and 
washed with successive portions of ether and acetone to give protected adenosyl 
Y-carboxylic acid 26 as a white solid (356 mg, 86%), m. p. 230-232 *C (dec) (lit., 
m. p. 208-209 'C); "g 'H NMR (400 MHz, DMSO) 81,11.19 (s, IH, NHBz), 8.70 (s, 
I H, Ar-H), 8.61 (s, I H, Ar-H), 8.06 (m, 2H, BzH), 7.64 (m, 111, BzH), 7.57 (m, 2H, 
BzH), 6.49 (m, I H, I ý-H), 5.60 (m, 2H, 2'-H and 3'-H), 4.78 (m, I H, 4'-H), 1.56 (s, 
3 H, CH3), 1.3 9 (s, 3 H, CH3); 13 C NMR (100 MHz, DMSO) Sc 170.7 (C), 165.5 (C), 
152.0 (C), 151.3 (CH), 150.2 (C), 144.1 (CH), 133.4 (C), 132.4 (CH), 128.46 (CH), 
128.45 (CH), 125.4 (C), 112.7 (C), 89.8 (CH), 85.7 (CH), 83.8 (CH), 83.4 (CH), 26.4 
(CHA 24.9 (CH3); ESI-MS 426.1 (M + H+); HRMS calcd for C2oH2ON506+ 426.1408, 
found 426.1402. 
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51-(2-Guanidinoethylthio)-5'-deoxyadenosine 72 
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TFA (5 mL) was added to a solution of protected guanidine derived thioehter 96 (240 
mg, 0.42 mmol) in CH202 (5 mL) at 0 *C and stirring continued at room temperature 
for 1.5 hr. The reaction mixture was concentrated and the residue adjusted to pH 9 
with aqueous ammonia. The resulting solution was applied to Dowex Ix2 
. 
100 
(OH-) ion exchange resin and elution using H20/CH30H (I/It 100 mL) gave 
guanidine containing compound 72 as a pale yellow solid (120 mg, 77.9%), m. p. 
145-147 "C; u a,, / cm-1 3172 (OH), 1641 (C=C, aromatic), 1036 (C-0); 111 NMR 
SH (270 MHz, D20) 8.07 (s, I H, Ar-H), 7.86 (s, I H, Ar-H), 5.77 (d, J=5.0, Ili, 
4.60 (app. t, J= 5.0, IH, T-H), 4.18 (app. t, J= 5.0, IH, Y-H), 4.12 (m, 111, 
4'-H), 3.10 (t, J=6.6,2H, CH2S), 2.87 (dd, I H, J1 = 14.4, J2 = 4.4,5'-CHHb), 2.76 
(dd, I H, J1 = 14.4, J2 = 6.7,5'-CH,, Hb), 2.54 (t, J=6.6,2fl, CH2NII); 13 C NMR (100 
MHz, D20) 8C 165.8 (C), 155.0 (C), 152.5 (CH), 148.4 (C), 139.7 (CH), 118.2 (C), 
87.4(CH), 83.3(CH), 73.2(CH), 72.2(CH), 40.5(CH2), 33.7(CI12), 31.0(CH2); 
ES-MS 369.1(M + H+); HRMS calcd for C13H2ON803S+ 369.1349, found 369.1338. 
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51-[(S-3-Amino-3-carboxypropyl)-3-guanidinopropyl-aminol-5'-deoxyadenosine 
74a 
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Protected nitrogen SAM analogue 135a (0.11 g, 0.13 mmol) was dissolved in neat 
TFA (5.4 mL) at room temperature and stiffed for 3 hr, H20 (0.60 mL) was then 
added and stiffing continued for I hr. The reaction mixture was concentrated and 
dissolved in H20 (10 mL) and extracted with EtOAc (2 x5 mL). The aqueous layer 
was condensed and dried in freezer-dryer overnight. The resulting TFA salt was 
applied to Amberlite IRA 400 (Cl-) ion-cxchange resin, eluting with H20 to give 
nitrogen SAM analogue 74a as a light yellow solid (0.06 g, 82%), m. p. 134 "C (dec); 
[CC]25D 22.75 (c 1.06 in Me0H); cm-' 1683 (C=0), 1506 (C=C, aromatic), 1049 
(C-0); lH NMR (400 MHz, D20) 8H 8.37 (s, 2H, Ar-H), 6.07 (d, J= 3.6,1 H, F-H), 
4.69 (m, I H, 2'-H), 4.42 (m, 2H, 3'-H and 4'-H), 3.92 (m, I H, CHCH2), 3.75 (dd, J, 
= 14.0, J2 = 9.6, IH, 5'-CHHb)ý 3.64 (d, J= 14.0, IH, 5'-CHaHh), 3.43 (m, 2H, 
CH2NH), 3.27 (m, 2H, CHCH2CH2N), 3.12 (m, 2H, CH2CH2CH2N), 2.30 (m, IH, 
CHCH,, Hb), 2.16 (m, I H, CHCH,, Hb), 1.90 (m, 2H, CH2CH2CH2); 13 C NMR (100 
MHz, D20) 8C 171.5 (C), 156.6 (C), 149.9 (C), 148.0 (C), 144.4 (CII), 143.5, (CH), 
119.3 (C), 90.1 (CH), 78.2 (CH), 73.0 (CH), 71.5 (CH), 54.9 (CH2)ý 51.4 (CH, 2x 
CH2), 38.0 (CHA 24.5 (CHA 22.5 (CH2); ESI-MS 467.2 (M + H+); HRMS calcd for 
C18H31NIO05+ 467.2479, found 467.2474. 
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5'-[(S-3-Amino-3-carboxypropyl)-4-guanidinobutyl-aminol-5'-deoxyadenosine 
74b 
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N 
H6 bH 
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HN y NH 
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Nitrogen SAM analogue 74b was prepared by the same procedure of nitrogen SAM 
analogue 74a as a lightly yellow solid (0.12 g, 90%), m. p. 160 "C (dec); [CC]20D 
25.97 (c 1.06 in H20); 1) max/ CM-1 1684 (C=O), 1506 (C=C, aromatic), 1047 (C-0); 
1H NMR (400 MHz, D20) 8" 8.41 (s, 2H, Ar-H), 6.11 (d, J=4.0,1 H, F-H), 4.75 (m, 
I H, 21-H), 4.44 (m, 2H, T-H and 4'-H), 3.88 (m, I H, CHCH2), 3.62 (m, 2H, 5'-CH2), 
3.44 (m, 2H, CH2NH), 3.26 (m, 2H, CHCH2CH2N), 3.08 (m, 211, C112CH2CH2N), 
2.26 (m, IH, CHCH,, Hb), 2.06 (m, IH, CHCHý, Hb), 1.68 (m, 2H, 
NCH2CH2CH2CH2NH), 1.54 (m, 2H, NCH2CH2CH2CH2NH); 13C NMR (100 Mliz, 
D20) Sc 172.0 (C), 156.7 (C), 150.0 (C), 148.1 (C), 144.5 (CH), 143.4, (Cli), 119.2 
(C), 90.0 (CH), 78.2 (CH), 73.0 (CH), 71.6 (CH), 55.0 (CH2), 51.9 (CH, 2x C112). 
40.0 (CHA 24.9 (CH2), 24.6 (CH2), 20.3 (CH2); ESI-MS 481.3 (M + H); HRMS 
calcd C18H31N, oOs+ 481.2635, found 481.2645. 
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5'-[(S-3-Amino-3-carboxypropyl)-5-guanidinopentyl-aminol-5'-deoxyadenosine 
74c 
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H2N 'k, NH 
Nitrogen SAM analogue 74c was prepared by the same procedure of nitrogen SAM 
analogue 74a as a lightly yellow solid (0.09 g, 67%), m. p. 131 T (dec); [(1]21D 23.30 
(c 1.09 in H20); 1) max/ CM-1 1685 (C=O), 1510 (C=C, aromatic), 1056 (C-0); 111 
NMR (400 MHz, D20) 51,8.41 (s, 2H, Ar-H), 6.11 (d, J=4.0,1 H, F-H), 4.75 
I H, 2-H), 4.45 (m, 2H, 3'-H and 4'-H), 3.96 (m, I H, CHCHA 3.70 (m, 211,5 I-CH2), 
3.44 (m, 2H, CH2NH, 3.23 (m, 2H, CHCH2CH2N), 3.02 (m, 2H, C112Cfl2CH2N), 
2.32 (m, IH, CHCH,, Hb), 2.20 (m, IH, CHCH,, Hb), 1.66 (m, 2H, 
NCH2CH2CH2CH2CH2NH), 1.45 (m, 2H, NCH2CH2CH2CH2CH2NH), 1.29 (m, 2H, 
NCH2CH2CH2CH2CH2NH); 13 C NMR (100 MHz, D20) 8C 171.7 (C), 156.6 (C), 
150.0 (C), 148.1 (C), 144.5 (CH), 143.5, (CH), 119.2 (C), 90.0 (CH), 78.3 (CH), 73.0 
(CH), 71.6 (CH), 54.9 (CH2), 52.6 (CH2), 51.6 (CH), 50.7 (CH2)0 40.7 (CH2), 27.3 
(CH2), 24.6 (CH2)9 22.8 (CH2), 22.5 (CH2); ESI-MS 495.3 (M + H+); HRMS calcd 
for Ci8H3, N, 005+ 495.2792, found 495.2772. 
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5'-[(S-3-Amino-3-carboxypropyl)-propargylaminol-51-deoxyadenosine 77 
NH2 N NH2 
HO, 
r)ýý 0N N jN 
N 0 
HdbH 
Protected alkyne derived SAM analogue 148 (0.18 g, 0.30 mmol) was dissolved in 
TFA (4mL) at 0 'C and stirring continued at room temperature overnight. The 
reaction mixture was concentrated and dissolved in H20 (5 mL) and extracted with 
EtOAc (2 x5 mL). The aqueous layer was condensed and dried in freezer-dryer 
overnight. The resulting TFA salt was applied to Dowex 50WX4-400 (NI-14) 
ion-exchange resin and the column was washed with 1120, and then eluted with a 
gradient NH4HCO3 (0-1.2M). Fractions from the major UV-active peak were 
collected and evaporated and then co-evaporated with water. The residue was 
Iyophilized to give alkyne derived SAM analogue 77 (0.11 g, 91%), m. p. 169 *C 
(dec); [a] 22 D 9-11 (C 1 
-0 
1 in H20); U 
,, 
/ cm" 23 60 (C-=C), 1604 (C=C, aromatic); 1H 
NMR (400 MHz, D20) St, 8.17 (s, I H, Ar-H), 8.02 (s, I H, Ar-H), 5.92 (d, J=4.8,111, 
I I-H), 4.64 (app. t, i=4.8,1 H, 2 I-H), 4.24 (m, I H, 3'-H), 4.16 (m, I H, 4'-H), 3.70 (m, 
I H, CHCHA 3.47 (dd, J, = 17.4, J2 = 2.2,1 Ht CHaHbC-=CH), 3.40 (dd, J, = 17.4, J2 
= 2.2,1 H, CHAC-ýCH), 2.86 (m, 2H, 5-CHHt. ), 2.73 (m, 2H, CH., N), 2.54 (t, i= 
2.2, IH, HC-ýQ, 1.97 (m, IH, CHCH,, Hb), 1.86 (m, IH, CHCH,, Hb); 13 C NMR (100 
N 
MHz, D20) Sc 174.1 (C), 155.4 (C), 152.6 (CH), 148.5 (C), 139.9 (CH), 118.7 (C), 
88.1 (CH), 81.3 (CH), 77.7 (CH), 75.0 (C), 73.3 (CH), 72.0 (CH), 55.7 (CHA 54.6 
(CH), 50.7 (CH2), 41.9 (CH2). 26.6 (CH2); ESI-MS 404.2 (M 
- 
H+); HRMS calcd for 
C 171422N705+ 404.1682, found 404.1694. 
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5'-[(S-3-Amino-3-carboxypropyl)-11-(2-guanidinoethyl)-111-1,2,3-triazol-4-yl]- 
methyl-aminol-5'-deoxyadenosine 78 
NH2 N NH2 
HOjr, ý, ý 
NoNN 1 
4/11, 
0N 
H6 bH 
HN 
f N, r, ýN 
H2N'ý"NH 
Triazole, derived SAM analogue 78 was prepared by the same procedure of nitrogen 
SAM analogue 74a as a yellow solid which is hygroscopic (88 mg, 92%), m. p. 
114-115 *C (dec); [a]24 D 15.79 (c 1.36 in MeOH), 1H NMR (400 MHz, D20) 8t, 8.36 
(s, I H, Ar-H), 8.34 (s, I H, Ar-H), 8.19 (s, I H, triazole-H), 6.06 (d, J=4.0,1 H, I F-M, 
4.71 (m, IH, 21-H), 4.56 (m, 2H, CH2CH2NHC=N), 4.52 (m, 2H, NCH2-triazole), 
4.474.40 (m, 2H, 3'-H and 4'-B), 3.99 (m, I H, CHCH2CH2), 3.75-3.55 (m, 4H, 
CH2NHC=N and 5'-CH2), 3.49-3.35 (m, CHCH2CH2), 2.46-2.36 (m, I H, CI]CH,, Hb)i 
2.30-2.24 (m, IH, CHCH,, Hb); 13 C NMR (100 MHz, D20) 5C 170.4 (C), 156.8 (C), 
149.8 (C), 148.0 (C), 144.3 (CH), 143.5 (CH), 135.6 (C), 128.4 (CH), 119.3 (C ), 
90.0 (CH), 78.0 (CH), 73.1 (CH), 71.5 (CH), 55.1 (CH2), 50.7 (CH), 50.2 (CHA 
49.4 (CH2), 47.2 (CH2), 40.7 (CH2), 24.3 (CH2); ESI-MS 534.3 (M + H+); HRMS 
calcd for C2oH32NI305+ 534.2649, found 534.2609. 
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5'-[(S-3-Amino-3-carboxypropyl)-3-guanidinopropyl-aminol-5'-deoxy-N6-(Il- 
azido-3,6,9-trioxaundecane)-amino adenosine 79 
H 
HO, 
NH2 
0N 
NN 
N 0 
Hd 6H 
HN 
H2N 'k, NH 
N-6 Azide tethered SAM analogue 79 was prepared by the same procedure of 
nitrogen SAM analogue 74a as a slightly yellow solid which is hygroscopic (0.13 g, 
87%); [a]23D 20.59 (c 1.02 in MeOH); 2108 N), 1737 (C=O), 1670 (C=C, 
aromatic); lH NMR (400 MHz, D20) 81,8.35 (s, 2H, ArH), 6.07 (d, J=3.2,111, 
I ý-H), 4.71 (m, I H, 2'-H), 4.39 (m, 2H, 3'-H and 4'-H), 4.02 (m, IH, CHC[12), 3.75 
(m, 2H, 5ý-CH2), 3.72 (m, 2H, adenosine-NHCH2), 3.65-3.37 (m, 14H, OCH2 x6 and 
CH2NA 3.33 (m, 2H, CH2NH), 3.27 (m, 2H, CHCH2CH2N), 3.12 (m, 2H, 
CH2CH2CH2N), 2.33 (m, 1H, CHCH,, Hb), 2.21 (m, IH, CHCHý, Hb), 1.89 (m, 2H, 
CH2CH2CH2); 13 C NMR (100 MHz, D20) 8C 170.6 (C), 156.6 (C), 149.0 (C), 146.7 
(C), 144.2 (CH), 143.1, (CH), 119.7 (C), 90.1 (CH), 78.0 (CH), 73.0 (CH), 71.5 (CH), 
70.4-68.2 (CH2 x 5), 65.1 (CHA 54.9 (CH2 x 2), 5 1.0 (CHA 50.4 (CII), 50.1 (CHA 
42.4 (CHA 38.0 (CH2), 24.3 (CH2), 22.6 (CH2); ESI-MS 668.4 (M + H); HRMS 
calcd for C26H46NI308+ 668.3587, found 668.3611. 
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5'- [2-(tert-B utoxyca rbonyla min o)ethylth io] 
-5'-d eoxyad en osi ne 8 17 
-N NH2 Fr 
BocHN, 0 Nq 
41 
jN 
N 
Hd bH 
Protected amino thiol 88 (220 mg, 1.24 mmol) was added to aIM aqueous NaOH 
solution (2.1 mL) at room temperature under nitrogen and stirring continued for 
30min. Chloride 16 (100 mg, 0.35 mmol) was then added to the solution and the 
mixture heated at 60 *C overnight. The reaction solution was cooled and extracted 
with EtOAc (3 x 10 mL). The combined organic layers were dried with Na2SO4. 
filtered and concentrated, and the residue subject to column chromatography on 
silica gel using CH2C12/MeOH (10/1, v/v) as eluent to give thioether 81 as a white 
solid (80 mg, 54%), m. p. 90-94 'C; [a] 24 D -5.67 (c 1.23 in Me011); u 
. 
/ ern»' 3355 
(OH), 1687 (C=O), 1606 (C=C, aromatic), 1530 (C=C, aromatic), 1049 (C-0); 111 
NMR (270 MHz, CD30D) 81,8.33 (s, I H, Ar-H), 8.22 (s, I H, Ar-H), 6.02 (d, 111,1 
= 
5.0, F-H), 4.80 (app. t, J=5.0,1 H, 2'-H), 4.35 (app. t, J=5.0,1 H, 3'-H), 4.23 (m, 
I H, 4 ý-B), 3.21 (t, J=6.8,2H, CH2S), 3.04 (dd, J, = 14.1, J2 = 5.6,1 Hs 5'-CHaHb), 
2.95 (dd, J, = 14.1, J2 = 6.3,1 H, 5'-CH,, Hb), 2.65 (t, J=6.8,2H, CH2NII), 1.42 (s, 
9H, C(CH; )-i); 13 C NMR Sc (68 MHz, CD30D) 157.0 (C), 155.9 (C), 152.6 (CH), 
149.3 (C), 140.1 (CH), 119.2 (C), 88.7 (CH), 84.4 (CH), 78.8 (C), 73.6 (CH), 72.6 
(CH), 40.0 (cH2), 33.9 (CHA 32.3 (CH2), 27.4 (CH3); ES-MS 427.2 (M 
HRMS calcd for C17H27N605S+ 427.1719, found 427.1799. 
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2-(tert-Butoxycarbonylamino)ethyl-trifluoromethyl-suiride 82 70 
F3CýS""^"NHBoc 
Sodium hydride (60%, 24 mg, 0.59 mmol) was slowly added in portions to a solution 
of protected amino thiol 88 (105 mg, 0.59 mmol) in dry THF (10 mL) at 0 'C under 
argon and stirred for 10min. S-(trifluoromethyl)dibenzothiophenium 
tetrafluoroborate (200 mg, 0.59 mmol) was added to the solution at 0 *C and the 
mixture warmed to room temperature and stirring continued for 30 min. The reaction 
solution was quenched by H20 (10 mL) and extracted with EtOAc (3 x 10 mL), and 
the combined organic layers dried with Na2SO4. filtered and concentrated. The 
residue was purified by column chromatography on silica gel using 
EtOAc/petroleum ether (1/10, v/v) as eluent to give trifluoromethyl thioether 82 as 
colourless oil (60 mg, 42%), 1H NMR (270 MHz, CDC13) 811 3.42 (app. q, J=6.3, 
2H, CH2NH), 3.30 (ý J=6.3,2H, CH2S), 1.47 (s, 9H, C(CH3)3); 13 C NMR (68 MHz, 
CDC13) 8C 133.2 (C), 128.7 (C), 79.9 (C), 39.8 (Cfl2), 30.3 (CH2), 28.4 (CH3); 19F 
NMR (282 MHz, CDC13) 41.08 
2-(Iert-Butoxycarbonylamino)ethanethioI 88 73 
HS 
"ýNHBoc 
Triethylarnine (889 mg, 8.8 mmol) was added to a solution of 2-arninoethanethiol 
hydrochloride (500 mg, 4.4 mmol) in CH2CI2 (25 mL) at room temperature under 
nitrogen. Stirring was continued for 30 min at'room temperature, and then 
di-tert-butyl dicarbonate (961 mg, 4.4 mmol) added to the mixture and stirring 
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continued for 1.5 hr at room temperature. The reaction mixture was quenched with 
H20 (5 mL) and extracted with Et20 (3 x 50 mL). The combined organic layers were 
washed with 0.5 M aqueous HCI, dried with Na2SO4, filtered and evaporated to give 
protected amino thiol 88 as colourless oil (660 mg, 84%), 1H NMR (270 MHz, 
CDC13) 5" 3.30 (t, J=6.3,2H, CH2SH), 2.65 (m, 2H, CH2NH), 1.45 (s, 9H, 
C(CH 3)3); 13 C NMR (68 MHz, CDC13) 8C 155.8 (C), 79.6 (C), 43.7 (CHA 28.4 
(CHA25.1 (CH2)- 
51-lodo-5'-deoxy-2', 3'-O-isopropylideneadenosine 93 76 
rN NH2 
d 
K 
Methylphenoxyphosphonium iodide (441 mg, 0.98 mmol) was added to a solution of 
21,3-isopropylideneadenosine (200 mg, 0.65 mmol) in dry C112CI2 (20 mL) at 
-70 *C under argon. The reaction mixture was warmed to room temperature and 
stirred for 2 hr, then diluted with CH202 (20 mL), washed with aqueous Na2S203 
solution and H20. The organic layer was dried with Na2S04. filtered, concentrated, 
and the residue purified by column chromatography on silica gel using 
CH2CI2/MeOH (1150, v/v) as eluent to give iodide 93 as a white solid (130 mg, 48%), 
m. p. 208-210 'C (lit., 220-225 OC); 
76 [a]25D 
-56.4 (c 1.0 in CHC13); 111 NMR 81, 
(270 MHz, CDC13) 8.35 (s, I H, Ar-H), 7.95 (s, I H, Ar-H), 6.15 (s, 2H, NH2), 6.13 
(d, J=2.0,1 H, F-H), 5.53 (dd, Ji = 6.3, J2 = 2.0,1 H, 2'-H), 5.13 (dd, J, = 6.3, J2 = 
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2.9,1 H, Y-H), 4.44 (ddd, J, = 8.4, J2 = 5.4, J3 = 2.9,1 H, 4'-H), 3.49(dd, J, = 10.2, J2 
= 8.4, IH, 5-HaHb), 3.27 (dd, J, = 10.2, J2 = 5.4, IH, 5'-H,, Hb), 1.62 (s, 3H, CH3), 
1.41 (s, 3H, CH3); 13 C NMR (100 MHz, CDC13) 8C 155.6 (C), 153.2 (CH), 149.1 (C), 
140.2 (CH), 120.3 (C), 114.6 (C), 91.2 (CH), 87.2 (CH), 84.4 (CH), 84.3 (CII), 27.0 
(CHA 25.3 (CHA 5.4 (CH2); ES-MS 418.0(M + H+); HRMS calcd for 
C13Hl6lN503+ 418.0268, found 418.0180. 
5'-12-12,3-bis-(tert-B u toxyca rbonyl)gua n idinol ethyl th io]-5-d coxyad enosi nc 96 
N NH2 
4ý11 
BocN, ý, N, 
-, 
--"s 0NN 
NHBoc 
N 
Hd 6H 
TFA (2 mL) was added to a solution of thioether 81 (62 mg, 0.14 mmol) in CH2CI2 (2 
mL) at 0 'C and stirring continued at room temperature for 2 hr. The reaction 
solution was concentrated and the residue dissolved in DMF (3 mL), triethylamine 
(0.3 mL), protected thiourea 100 (40 mg, 0.14 mmol), mercury chloride (38 mg, 0.14 
mmol) were then added to the DMF solution and stirring continued at room 
temperature for 2 hr, then EtOAc (20 mL) was added to the reaction mixture and the 
resultant solid removed by filtration. The filtrate was washed with 1-120 (2 x lOmL) 
and the organic layer was dried with Na2S04. filtered and concentrated, and the 
residue purified by column chromatography on silica gel using CH2CI2/MeOH (10/1, 
v/v) as eluent to give protected guanidine derived thioether 96 as a white solid (45mg, 
5 6%), m. p. 110- 112 oC; [(1]25D 
-9.5 (c 1.14 in CHCl3); u 
.. 
/ cm" 3411 (NH2), 3326 
(OH), 1723 (C=O), 1644 (C=C, aromatic), 1059 (C-0); 1H NMR (270 MHz, CDC13) 
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511 11.46 (bs, IH, NHBoc), 8.61 (m, IH, CH2NH), 8.13 (s, IH, Ar-H), 8.05 (s, IH, 
Ar-H), 6.00(d, J=4.8, IH, I'-H), 4.76(m, IH, 2ý-H), 4.42(m, IH, 3'-H), 4.34(m, 
I H, 4'-H), 3.60 (m, 2H, CH2S), 2.94 (m, 2H, 5-CH2), 2.76 (m, 2H, CH2NH), 1.47 (s, 
18H, C(CH3)3); 13 C NMR (100 MHz, CDC13) 8C 163.3 (C), 156.2 (C), 155.3 (C), 
153.1 (CH), 152.4 (C), 149.0 (C), 139.4 (CH), 119.5 (C), 89.3 (CH), 84.4 (CH), 83.3 
(C), 79.5 (C), 74.4 (CH), 72.8 (CH), 40.0 (CH2), 34.2 (CH2), 32.1 (CH2), 28.3 (CH3)9 
28.1 (CH3); ES-MS 569.2 (M + H+); HRMS calcd for C23H36N807S+ 569.2398, 
found 569.2343. 
S-1-tert-Butyl 2-(tert-butyloxycarbonylamino)-4-iodobutyrate 9889,91 
0 
ot-Bu 
NHBoc 
Ethyl chloroformate (0.22 mL, 2.26 mmol) was added to a mixture of protected 
aspartate 123 (0.65 g, 2.26 mmol) and triethylamine (0.32 mL, 2.26 mmol) in dry 
THF (10 mL) at 
-5 T and the reaction mixture stirred at room temperature for 30 
min. The reaction mixture was filtered and the white solid washed with Tf IF (5 mL). 
The filtrate was added to a solution of sodium borohydride (0.17 g, 4.52 mmol) in 
H20 (2 mL) at OIC and the reaction mixture stirred at room temperature for 2.5 hr. 
The reaction mixture was acidified to pH 5 with 0.5 M aqueous HCI and extracted 
with EtOAc (3 x 15 mL). The combined organic layers were dried with Na2SO4, 
filtered and concentrated, and the residue applied to the next step directly. Iodine 
(1.15 g, 4.52 mmol) was added to a solution of triphenylphosphine (1.19 g, 4.52 
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mmol) in CH2CI2 (10 mL) at 0 OC and stiffed for 20 min and the mixture solution of 
the residue from the above procedure and imidazole (0.31 g, 4.52 mmol) in CH2CI2 
(10 mL) added slowly at 0 *C, then stirred 2.5 hr. The reaction mixture was then 
filtered and the filtrate washed with Na2S203 solution (5 mL) and brine (5 mL). The 
CH2Cl2 solution was dried with Na2S04. filtered and concentrated, and the residue 
was purified by column chromatography on silica gel using Et20/Petroleum ether 
v/v) as eluent to give iodide 98 as yellow oil (0.48 g, 55%), [a]30D 18.14 (c 
2.15 in CHC13); 1H NMR (400 MHz, CDC13) SH 5.10 (d, J=6.4,1 H, NHBoc), 4.20 
(m, I H, CH), 3.20 (m, 2H, ICH2), 2.39 (m, I H, CHCHaHb), 2.18 (m, III, CHCII,, Hb), 
1.49 (s, 9H, C(CH3)-, ) 1.47 (s, 9H, C(CH3)j); 13 C NMR (100 MHz, CDC13) 8C 171.1 
(C), 155.8 (C), 83.0 (C), 80.5 (C), 55.5 (CH), 38.2 (CH2), 28.8 (013), 28.5 (CIIA 
0.0 (CH2)- 
N, IV-his-tert-Butoxycarbonylthiourea 10078 
s 
BocHN lk NHBoc 
Sodium hydride (60%, 1.2 g, 29.6 mmol) was added slowly to a solution of thiourea 
(0.5 g, 6.57 mmol) in dry THF (100 mL) at 0 OC under nitrogen and stirred for 5 min 
and then at room temperature for 10min. Di-tert-butyl dicarbonate (3.2 g, 14.5 mmol) 
was added at 0 *C and the ice bath was removed after 20 min and stirring continued 
for 1.5 hr. Saturated aqueous NaHC03 (10 mL) was then added to the resulting slurry 
solution and the mixture poured into H20 (20 mL) and extracted with EtOAc (3 x 30 
mL). The combined organic layers were dried with Na2SO4, filtered and concentrated. 
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The residue was purified by column chromatography on silica gel using U20/11exane 
(1 /3, v/v) as eluent to give protected thiourea 100 as a white sol id (1.07 g, 5 9%), m. p. 
128-129 *C (lit., 124-127 oC)78; 1H NMR 511 (270 MHz, CDC13) 1.51 (s, 9H, 
3)3); 13 C(CH C NMR (68 MHz, CDC13) SC 178.0 (C), 150.4 (C), 84.1 (C), 28.0 (CH3); 
ES-MS 277.1 (M + H+); HRMS calcd for C, 1 H2oN204S+ 277.1177, found 277.1245. 
2-[2,3-his-(tert-Butoxycarbonyl)guanidinolethanethioI 10177 
H 
HS, -,,. ý, N y NBoc 
NHBoc 
Protected thiourea 100 (121 mg, 0.44 mmol) was added to a mixture of cYsteamine 
hydrochloride (50 mg, 0.44 mmol) and triethylamine (0.18 mg, 1.32 mmol) in DMF 
(2 mL) at room temperature and stirring continued overnight. 1120 (10 mL) was 
added and the mixture was extracted with EtOAc (3 x 10 mL). The combined organic 
layers were dried with Na2SO4, filtered and concentrated. The residue was purified 
by column chromatography on silica gel using EtOAc/hexane (1/3, v/v) as eluent to 
give guanidine derived thiol 101 as a white solid (48 mg, 34%), 'H NMR (270 MHz, 
CDC13) 8H 11.47 (bs, I H, NHBoc), 8.64 (m, I H, CH2NH), 3.77 (app. q, J=6.2,2H, 
_j); 
13 
CH2NH), 2.86 (t, J=6.2,2H, CH2SH), 1.49 (s, 9H, C(CHI) C NMR (68 MHz, 
CDC13) 8C 163.5 (C), 156.1 (C), 153.1 (C), 83.3 (C), 79.5 (C), 39.2 (CH2), 37.1 
(CH2), 28.4 (CH3)3), 28.1 (CH3); ES-MS 320.1 (M + H+); HRMS calcd for 
C13H25N304S+ 320.1599, found 320.1581. 
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2-(9-FluorenyImethoxycarbonylamino)ethanethioI 10572 
clyýo--e 
H 
N--ý-SH 
N,, V-Diisopropylethylamine (0.68 mL, 3.8 mmol) was added to a solution of 
cystamine dihydrochloride (87 mg, 0.38 mmol) in DMF (5 mL) at room temperature 
and stirred for 30 min. The reaction mixture was cooled to 0 *C and 9-fluorenyl- 
methoxycarbonylchloride (200 mg, 0.77 mmol) added, and stirring continued for 30 
min. The reaction mixture was poured to H20 (30 mL) and the solution extracted 
with CHC13 (2 x 20 mL). The combined organic layers were washed with 1120 (10 
mL), dried with Na2SO4. filtered and concentrated. To the residue was added 
methanol (20 mL) and tributylphosphine (0.95 mL, 3.8 mmol) at room temperature 
and stiffed for 2 hr. The reaction solution was concentrated and the residue purified 
by column chromatography on silica gel using EtOAc/Petroleum ether (1/2, v/v) as 
eluent to give thiol 105 as a white solid (200 mg, 88%), m. p. 125-127 T; cm-1 
1721 (C=O), 1513 (C=C, aromatic); 1H NMR (400 MHz, CDC13) 8117.79 (d, J= 7.4, 
2H, Ar-H), 7.60 (d, J= 7.4,2H, Ar-H), 7.43 (t, J= 7.4,2H, Ar-11), 7.35 (ddd, J, = 7.4, 
J2 = 7.4, J3 = 1.2,2H, Ar-H), 4.43 (d, J=6.5,2H, CHCH2), 4.25 (t, J=6.5,111, 
CHCHA 3.40 (apP. q, J=6.3,2H, CH2SH), 2.67 (app. q, J=6.3,2H, CH2NH); 13C 
NMR (100 MHz, CDC13) 8C 156.3 (C), 143.9 (C), 141.4 (C), 127.6 (CH), 127.1 (CH), 
125.0 (CH), 120.0 (CH), 66.7 (CH2), 47.3 (CH), 44.0 (CH2), 24.9 (Cfl2); ES-MS 
300.1 (M+H+); HRMScalcd for C17Hl7NO2S+300.1014, found 300.1110. 
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N-tert-Butoxycarbonyl-2-thiomethyl-2-imidazoline 11,83 
SCH3 
BocN'ýN 
k-j 
Di-tert-butyl dicarbonate (0.89 g, 4.1 mmol) was added to a mixture of 
2-methylthio-2-imidazoline hydroiodide (1.0 g, 4.1 mmol) and triethylarnine (1.1 mL, 
8.2 mmol) in CH2CI2 (50 mL) at 0 'C. The reaction mixture was warmed to room 
temperature and stirring continued overnight. The reaction solution was washed with 
H20 (2 x 10 mL) and dried with Na2S04. filtered and concentrated, and the residue 
purified by column chromatography on silica gel using EtOAc/Petroleum ether (1/2, 
v/v) as eluent to give protected 2-methylthio-2-imidazoline III as a white waxy solid 
(260 mg, 98%), 'H NMR öll (270 MHz, CDC13) 3.81 (m, 4H, CH2CH), 2.36 (s, 311, 
CH3), 1.48 (9H, s, C(CH3)3); 13 C NMR (68 MHz, CDC13) Sc 159.6 (C), 150.9 (C), 
82.6 (C), 53.4 (CI42)9 47.6 (CHA 28.2 (CHA 15.1 (CH3); ES-MS 217.1 (M +f 1); 
HRMS calcd for C9Hl6N202S+ 217.0966, found 217.1055. 
N, Ný-his-tert-Butoxycarbonylimidazolidine-2-thione 113 82 
s 
BocN 
)l 
NBoc ý-j 
Sodium hydride (60%, 176.2 mg, 4.4 mmol) was added slowly to a solution of 
2-imidazolidinethione (100 mg, 1.0 mmol) in dry THF (40 mL) at 0 *C under 
nitrogen and stirred for 5 min. The reaction mixture was warmed to room 
temperature and stirring continued for 10 min. The reaction mixture was cooled to 
0 I'C. Di-lerl-butyl dicarbonate (470 mg, 2.2 mmol) was added and stirring continued 
158 
for 20 min, then warmed to room temperature and stirring continued for 2 hr. 
Saturated aqueous NaHC03 (5 mL) was added to the reaction mixture and the 
solution extracted with EtOAc (3 x5 mL). The combined organic layers were dried 
with Na2S04. filtered and concentrated. The residue was purified by column 
chromatography on silica gel using EtOAc/hexane (1/3, v/v) as eluent to give 
protected imidazolidine-2-thione 113 as a yellow solid (170 mg, 57%), m. p. 
108-110 "C (lit., 117-119 C); 82 1H NMR (270 MHz, CDC13) 511 3.88 (m, 4H, 
CH2CH2), 1.54 (s, 9H, C(CH3)3); 13 C NMR (68 MHz, CDC13) 8C 175.6 (C), 150.3 
(C), 84.0 (C), 44.6 (CH2), 28.1 ((CH3)3); ES-MS 303.1 (M + H+); HRMS calcd for 
C13H22N204S+ 303.1334, found 303.1393. 
a-Amino-l-butyrolactone hydrobromide 115 84 
0 
Cr 
NH2HBr 
Bromoacetic acid (0.93 g, 6.70 mmol) was added to a solution of methionine (1.00 g, 
6.70 mmol) in deionised water (27 mL), isopropanol (27 mL) and acetic acid (I I mL) 
at room temperature under nitrogen and then stirred at 50 OC for 2 hr and at 82-85 OC 
for 5 hr. The reaction solution was concentrated and the residue was heated at 90 -C 
in vacuum for 2 hr. 4M HCI in dioxane (13 mL) was added to the residue and 
stiffing continued at room temperature for 3 hr. Filtration of this reaction produced a 
yellow solid which was suspended in isopropanol (10 mL) and stirred for 1.5 hr at 
room temperature. Filtration gave lactone hydrobromide 115 as lightly yellow solid 
159 
(0.78 g, 65%), m. p. 209 'C; u/ cm-' 1771 (C=0); 'H NMR (400 MHz, D20) 5,1 
4.55 (m, I H, CH), 4.39 (m, 2H, OCH2), 2.74 (m, I H, CH,, HbCH), 2.38 (m, I H, 
CH,, HbCH); 13 C NMR (100 MHz, D20) 5C 174.5 (C), 67.3 (CH2), 48.5 (CH), 26.7 
(CHA 
Methionine methylsulfonium iodide 116 85 
C H3 
H3Cý S+ NH2 
COOH 
lodomethane (5.10 mL, 81.10 mmol) was added to a solution of methionine (5.00 g, 
33.50 mmol) in H20 and MeOH (93 mUl3mL) and the reaction mixture heated to 
35 oc with stirring overnight. This solution was concentrated and the resulting solid 
dissolved in H20 (minimum quantity) and EtOH added until precipitation of a white 
solid. This mixture was then allowed to stand at room temperature overnight, and 
filtration gave methylsulfonium iodide 116 as a white solid (8.40 g, 87%), m. p. 
147 *C (lit., 149-150 C); 85 1H NMR (400 MHz, D20) 81,3.79 (t, J=6.4,1 H, CH), 
3.38 (m, 2H, SCH2), 2.86 (s, 6H, CH3 x2), 2.28 (m, 2H, CHCH2); 13C NMR 8c (100 
MHz, D20) 172.5 (C), 52.7 (CH), 39.4 (CHA 25.0 (CH2), 24.7 (CH3)- 
a-Amino-y-butyrolactone hydrochloride 117 86 
0 
cr 
NH2HCI 
NaHC03 (0.58 g, 6.90 mmol) was added to a solution of mcthylsulfonium iodide 116 
(2.00 g, 6.90 mmol) in H20 (30 mL) and the reaction mixture heated at reflux 
160 
overnight. The reaction solution was concentrated, then 6M aqueous HCI (30 mL) 
added and 30% aqueous H202 (0.30 m, L) added in order to remove iodide. The 
resulting mixture was then extracted with EtOAc (3 x 20 mL) and the remaining 
acidic aqueous layer refluxed for I hr. The aqueous solution was then concentrated 
and EtOH added to the resulting residue. The resulting white solid was removed by 
filtration and the filtrate concentrated. 6M aqueous HCl (30 mL) was added to the 
residue and the solution refluxed for I hr. The aqueous solution was concentrated and 
a yellow solid precipitated which was collected by filtration. The crude product was 
then stirred in isopropanol (10 mL) for I hr. Filtration gave lactone hydrochloride 
117 as a off-white solid (0.56 g, 60%), m. p. 218 T (lit., 220-221 oC); 86 U max/ CM'I 
1780 (C=O); 1H NMR (400 MHz, D20) 8H 4.55 (m, IH, CH), 4.39 (m, 2fl, OCH2), 
2.74 (m, IH, CH,, HbCH), 2.38 (m, IH, CHACH); 13 C NMR Sc (100 Mliz, D20) 
174.5 (C), 67.4 (CH2)5 48.5 (CH), 26.7 (CHA 
S-4-Methyl aspartate hydrochloride 12088 
H3CO )ry COOH 
0 NH2HCI 
Thionyl chloride (2.30 mL, 31.50 mmol) was added dropwise to a solution of 
L-aspartic acid (3-00 g, 22.50 mmol) in anhydrous MeOH (15.60 mL) at 
-10 'C and 
then the reaction solution warmed slowly to room temperature and stirring continued 
for 25 min. Et2O (45 mL) was added to the reaction solution under cooling. 
Immediate filtration gave y-methyl aspartate 120 as a white solid (2.82 g, 68%), m. p. 
193-194 OC (dec) (lit., 190-192 OC (dec)); 89 [a]23E) 12.87 (c 1.30 in MeOH); 111 NMR 
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(400 MHz, D20) 511 4.29 (t, J=5.4, IH, CH), 3.68 (s, 3H, OCH3), 3.05 (m, 2H, 
CH2CH); 13 C NMR (100 MHz, D20) 5C 171.9 (C), 170.9 (C), 52.8 (CHA 49.3 (CH), 
33.8 (CH2). 
S-4-Methyl N-(tert-butyloxycarbonyl) aspartate 12 189 
H3CO COOH 
0 NHBoc 
y-Methyl aspartate 120 (2.00 g, 10-90 mmol) was added to a solution of Na2CO3 
(1.15 g, 10.90 mmol) in dioxane and H20 (2/1,33 mL) at 0 OC, and when the 
evolution of carbon dioxide had ceased, Na2CO3 (1.15 g, 10.90 mmol) was added 
and followed by di-teri-butyl dicarbonate (2.60 g, 12.00 mmol) at 0 "C. The reaction 
mixture was stiffed at 0 'C for I hr and then at room temperature overnight. The 
reaction mixture was concentrated and the residue poured into ice water, and the 
solution extracted with EtOAc (2 x 10 mL). The aqueous solution was acidified to 
pH 3 with 0.5 M aqueous HCI and extracted with EtOAc (3 x 20 mL). The organic 
layers were dried with Na2SO4, filtered and concentrated, and the residue purified by 
column chromatography on silica gel using EtOAc as eluent to give Boc protected 
, y-methyl aspartate 121 as colourless oil (1.50 g, 56%), [a]20D 28.48 (c 2.50 in CHC13); 
1H NMR (400 MHz, CDC13) 8H 5.60 (d, J=8.0,1 H, NHBoc), 4.63 (m, I H, CH), 
3.72(s, 3H, OCH3), 3.06(dd, Jl= 17.1, J2=4.2,1H, CHHbCH), 2.85 (dd, Jl== 17.1, 
J2 = 4.8,1 H, CH,, HhCH), 1.45 (s, 9H, C(CH3).; ); 13 C NMR (100 MHz, CDC13) 8C 
175.6 (C), 171.6 (C), 155.7 (C), 80.5 (C), 52.1 (CH3), 49.8 (CH), 36.4 (CH2), 28.3 
(CH3)- 
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S-1-tert-Butyl 4-methyl N-(tert-butyloxycarbonyl) aspartate 12290 
0 
H3CO Y---ý Ot-Bu 
0 NHBoc 
Perchloric acid (60%, 0.06 mL, 0.54 mmol) was added to a solution of y-methyl 
aspartate, 120 (0.10 g, 0.54 mmol) in lert-butyl acetate (5 mL) at 0 *C and stirring 
continued at room temperature overnight. IM aqueous NaHC03 (1.08 mL, 1.08 
mmol) was added at 0 *C and followed by a solution of di-tert-butyl dicarbonate 
(1.17 g, 0.54 mmol) in THF (5 mL), and the stirring continued at room temperature 
overnight. The reaction mixture was extracted with EtOAc (2 x 20 mL) and the 
combined organic layers dried with Na2SO4. filtered and concentrated, and the 
residue was purified by column chromatography on silica gel using Et20/hexane (115, 
v/v) as eluent to give protected methyl aspartate 122 as colourless oil (0.10 g, 61 %), 
[a]25 D 22.55 (c 1.41 in CHC13); 'H NMR (400 MHz, CDC13) 81,5.44 (d, J=7.2, Ili, 
NHBoc), 4.43 (m, I H, CH), 3.67 (s, 3 H, OCH3), 2.91 (dd, J, = 16.5, J2 = 4.4,111, 
CH,, CHbCH), 2.75 (dd, J1 = 16.5, J2 = 5.2,1 H, CHaCHbCH), 1.44 (s, 9H, C(CHj)3), 
1.43 (s, 9H, C(CH3)-; ); 13C NMR (100 MHz, CDC13) 8C 171.3 (C), 170.0 (C), 155.4 
(C), 82.3 (C), 79.8 (C), 51.8 (CH3)ý 50.5 (CH), 36.9 (CH2), 29.7 (CHA28.3 (CH3)- 
S-1-tert-Butyl N-(tert-butyloxycarbonyl) aspartate 123 89 
0 
HO Ot-Bu 
0 NHBoc 
IM aqueous NaOH (4.60 mL, 4.60 mmol) was added dropwisc to a solution of 
163 
protected y-methyl aspartate 122 (1-07 g, 3.50 mmol) in acetone (17.50 mL) and H20 
(3 mL) at 0 'C, whilst maintaining the pH between 8 and 9. The reaction mixture was 
stirred at room temperature for I hr and the acetone removed under vacuum and the 
residue diluted with H20 (20 mL). The aqueous solution was washed with Et20 (2 x 
10 mL), then adjusted to pH 6 using IM aqueous HCI and extracted with Et20 (3 x, 
20 mL). The combined ether layers were dried with Na2SO4. filtered and 
concentrated. The crude product was recrystallised from hexane to give protected 
aspartate 123 as a white solid (0.90 g, 88%), m. p. 106 IC (lit., 105-106 *C)89; [a] 25 D 
4.94(c 1.22 in CHC13); 'HNMR(40O MHz, CDC13)8H5.49(d, J=8.0,111, NHBoc), 
4.47 (m, 1 H, CH), 3.03 (dd, Ji = 17.2, J2 = 3.6,1 H, CHHbCH), 2.82 (dd, J, = 17.2, J2 
= 4.4, IH, CHýHbCH), 1.46 (s, 18H, C(CHj)3); 13 C NMR (100 MHz, CDC13) 5C 
176.5 (C), 169.8 (C), 155.5 (C), 82.6 (C), 80.1 (C), 51.7 (CH), 36.9 (CH2), 28.3 
(CH3), 27.8 (CH3)- 
N, A"-bis(tert-Butoxycarbonyl)-S-methylisothiourea 125 136 
SCH3 
BocNl)l NHBoc 
Saturated aqueous Na2C03(50 mL) was added to a solution of S-methylisothiourea 
sulfate (2.00 g, 7.20 mmol) in CH2Cl2 (50 mL) at room temperature and followed by 
di-tert-butyl dicarbonate (6.30 g, 28.80 mmol) and the reaction mixture vigorously 
stirred overnight. Layers were separated and the aqueous phase extracted with 
CH2C12 (2 x 20mL). The combined organic solution was dried with Na2SO4. filtered 
and concentrated, and the residue purified by column chromatography on silica gel 
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using Et20/hexane (1/20, v/v) as eluent to give protected methylisothiourea 125 as a 
white solid (2.59 g, 62%), m. p. 122 'C (lit., 122-123 C); 136 1H NMR (400 MHz, 
CDCIA 8H 2.41 (s, 3H, SCH3), 1.54 (s, 9H, C(CHI)3), 1.52 (s, 9H, C(CH3)3); 13C 
NMR (100 MHz, CDC13) 8C 171.4 (C), 160.7 (C), 150.8 (C), 83.2 (C), 8 1.0 (C), 28.0 
(CH3)i 14.4 (CH3); ESI-MS 313.1 (M + Na+); HRMS calcd fOr C12H22N2O4SNaý 
313.1198, found 313-1177. 
2-12,3-bis-(tert-Butoxycarbonyl)guanidinolethylamine 126 92 
NBoc 
H2N 
'-"'ý'N 
)ý 
NHBoc 
H 
A solution of protected methylisothiourea 125 (0.19 g, 0.65 mmol) in TIIF (I mL) 
was added dropwise to a solution of ethylenediamine (0.13 mL, 1.94 mmol) in 
THF/H20 (25/1,2.60 mL) at room temperature. The reaction solution was stirred at 
50 OC for I hr, then extracted with EtOAc (5 mL) and washed with 10% aqueous 
NaHC03, dried with Na2S04, filtered and concentrated. The residue was purified by 
column chromatography on silica gel using EtOAc/MeOH (4/1, v/v) with 2% 
triethylamine as eluent to give amine 126 as a white solid (0.11 g, 56%), m. p. 1900C 
(dec); 1H NMR (400 MHz, CDC13) 8H 8.66 (s, I H. CH2NHC=N), 3.50 (app. q, J= 
5.8,2H, CH2NH), 2.90 (t, J=5.8,2H, CH2NH2), 1.47 (s, 18H, C(CH3)_, ); 13 C NMR 
(100 MHz, CDC13) SC 163.6 (C), 156.4 (C), 153.2 (C), 83.1 (C), 79.2 (C), 43.4 (CHA 
41.0 (CH2), 28.3 (CHA 28.2 (CH3); ESI-MS 303.2 (M + H+); HRMS calcd for 
C13H27N404+ 303.2032, found 303.2009. 
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S-N-(Iert-Butyloxycarbonyl) homoserine terf-butyl ester 12889 
0 
HO,,,, 
-,, j, 
Jýot_Bu 
NHBoc 
Ethyl chloroformate (0.18 mL, 1.90 mmol) was added to a mixture of protected 
aspartate 123 (0.50 g, 1.73 mmol) and triethylarnine (0.30 mL, 2.08 mmol) in dry 
THF (5mL) at 
-5 `C and the reaction mixture stirred at room temperature for 30 min. 
The reaction mixture was filtered and the white solid washed with THIF (5 mL). The 
combined filtrate was added to a solution of sodium borohydride (0.13 g, 3.46 mmol) 
in H20 0 mL) at 0 "C and the reaction solution stirred at room temperature for 2.5 hr. 
The reaction mixture was then adjusted to pH 5 using 0.5 M aqueous HCI and 
extracted with EtOAc (3 x IOmL). The combined organic layers were dried with 
Na2S04. filtered and concentrated, and the residue was purified by column 
chromatography on silica gel using EtOAc/Petroleurn ether (1/3, v/v) as eluent to 
give alcobol 128 as colourless oil (0.40 g, 84%), [a]20D 13.92 (c 1.25 in CHC13); IH 
NMR (400 MHz, CDC13) SH 5.37 (d, J= 5.2, IH, NHBoc), 4.36 (m, I H, CHCH2). 
3.67 (m, 2H, CH20H), 2.14 (m, IH, CHCH,, Hb)g 1.58 (m, IH, CHCII,, Hb), 1.48 
9H, C(CHj)j), 1.46 (s, 9H, C(CH3)3); 13 C NMR (100 MHz, CDC13) SC 172.0 (C), 
156.6 (C), 82.3 (C), 80.3 (C), 58.2 (CH2)9 50.9 (CH), 36.6 (CH2), 28.3 (CHA 28.0 
(CH3)- 
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S-1-tert-Butyl-2-(tert-butyloxycarbonylamino)-4-oxobutanoate 12993 
0 
H Ot-Bu 
0 NHBoc 
Dry DMSO (1.20 mL, 17.20 mmol) was added to a solution of oxalyl chloride (0.75 
mmL, 8.60 mmol) in dry CH2C12 (25 mL) at -78 "C and stirred for 30 min. A solution 
of alcohol 128 (1.99 g, 7.20 mmol) in dry CH2CI2 (25 mL) was added to the mixture 
at 
-78 *C and stirred for 30 min. Triethylamine (5.0 mL, 36.00 mmol) was added to 
the reaction solution at -78 *C, stiffed for 30 min and then warmed to room 
temperature. The reaction solution was quenched with H20 (10 mL), separated and 
the H20 layer was washed with CH2Cl2 (2 x 10 mL). The combined CH2CI2 layers 
were dried with Na2SO4. filtered and condensed, and the residue purified by column 
chromatography on silica gel using EtOAc/Petroleum ether (1/4, v/v) as eluent to 
give aldehyde 129 as colourless oil (1.61 g, 82%), [Ct]23 D 22.64 (c 1.48 in CHCIA IH 
NMR (400 MHz, CDC13) 8H 9.74 (s, I H, CHO), 5.37 (d, J= 6.8, IH, NHBoc), 4.48 
(m, I H, CH), 3.04 (dd, il = 17.8, J2 = 4.8,1 H, CHCHbCH), 2.96 (dd, JI = 17.8, J2 = 
4.8, IH, CH,, CHtCH), 1.46 (s, 9H, C(CH3)3), 1.45 (s, 9H, C(CHj)3); 13 C NMR (100 
MHz, CDC13) SC 198.4 (CHO), 168.9 (C), 154.4 (C), 81.7 (C), 79.0 (C), 48.3 (CH), 
45.4 (CH2), 27.3 (CHA 27.0 (CH3)- 
3-[2,3-his-(tert-Butoxycarbonyl)guanidino]propanoI 131a 77 
NBoc 
HO'ýý""ýN NHBoc 
H 
Protected methylisothiourea 125 (0.60 mg, 2.06 mmol) was added to a mixture of 
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3-amino-propanol (0.16 mL, 2.06 mmol) and triethylarnine (0.58 mL, 4.12 mmol) in 
DMF (6 mL) at room temperature. Mercury chloride (0.56 mg, 2.06 mmol) was then 
added to the reaction mixture and stirring continued for 90 min. The reaction mixture 
was diluted with EtOAc (10 mL) and filtered. The filtrate was washed with brine Qx 
10 mL), dried with Na2SO4. filtered and concentrated. The residue was purified by 
column chromatography on silica gel using EtOAc/Petroleum ether (1/1, v/v) as 
eluent to give alcohol 131a as a white solid (0.65 g, 99%), m. p. I 10 OC; 11-1 NMR 
(400 MHz, CDC13) Stj 8.46 (m, 1H. CH2NHC=N), 4.74 (s, I H, CH20H), 3.58 (m, 4H, 
CH20H and CH2NH), 1.71 (m, 2H, CH2CH2CH2). 1.50 (s, 9H, C(CH3)3), 1.48 (s, 9H, 
C( )3); 13 C NMR (100 MHz, CDC13) 5C 162.9 (C), 157.2 (C), 153.2 (C), 83.4 (C), CH3 
79.5 (C), 57.7 (CHA 36.8 (CH2), 32.8 (CH2), 28.4 (CH3), 28.0 (CH3); ESI-MS 318.2 
(M + H); HRMS calcd forCl4H28N305+ 318.2029, found 318.2016. 
4-12,3-his-(tert-Butoxycarbonyl)guanidinolbutanoI 131b 77 
NBoc 
Ho'-"ýýN )ý NHBoc 
H 
Alcohol 131b was prepared by the same procedure of alcohol 131a as a white solid 
(2.10 9,92%), M. P. 120 'C; lH NMR (400 MHz, CDC13) 6H 8.39 (m, IH, 
CH2NHC=N), 3.70 (t, 2H, j=6.0, HOCH2), 3.45 (app. q, J=7.0,2H, CH2NH), 2.20 
(s, IH, CH20H), 1.65 (m, 4H, CH2CH2CH2CH2NH), 1.50 (s, 18H, C(CH3)3); 13C 
NMR (100 MHz, CDC13) SC 163.5 (C), 156.2 (C), 153.3 (C), 83.1 (C), 79.3 (C), 62.1 
(CH2), 40.4 (CH2), 29.5 (CH2), 28.5 (CH3), 28.3 (CH3) , 25.6 (CH2); ESI-MS 332.2 
(m + H); HRMS calcd C14H28N305+ 332.2186, found 332.2174. 
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5-12,3-bis-(Iert-Butoxycarbonyl)guanidinolpentanoI 131c 77 
NBoc 
H 0"ýý N lk NHBoc 
H 
Alcohol 131c was prepared by the same procedure of alcohol 131a as a white solid 
(2.10 g, 95%), m. p. 91 *C; 1H NMR (400 MHz, CDC13) 51,8.33 (m, IH, 
CH2NHC=N), 3.66 (t, J=6.4,2H, HOCH2), 3.43 (app. q, J=7.2,2H, CH2NH), 1.65 
(m, 4H, CH2CH2CH2CH2CH2). 1.51 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 1.46 (m, 
2H, CH2CH2CH2CH2CH2); 13 C NMR (100 MHz, CDC13) 8C 163.6 (C), 156.2 (C), 
153.3 (C), 83.1 (C), 79.3 (C), 62.6 (CH2), 40.8 (CH2), 32.3 (CH2), 28.8 (CH2), 28.3 
(CHA 28.1 (CH3), 23.0 (CH2); ESI-MS 346.2 (M + H+); HRMS calcd for 
C14H28N30.5+ 346.2342, found 346.2338. 
3-[2,3-his-(Iert-Butoxycarbonyl)guanidinolpropanaI 132a 93 
0 NBoc 
H"ýNýýNHBoc 
H 
Dry DMSO (0.25 mL, 3.47 mmol) was added to a solution of oxalyl chloride (0.15 
mL, 1.74 mmol) in dry CH2CI2 (10 ML) at -78 *C and stirred for 30 min under 
nitrogen and a solution of alcohol 131a (0.25 g, 0.79 mmol) in dry CH2CI2 (10 mL) 
was added and stiffed for 30 min. Triethylamine (0.88 mL, 6.31 mmol) was added to 
the reaction mixture at -78 IC and the resulting mixture stirred for 30 min. The 
reaction mixturewas warmed slowly to room temperature, then washed with brine (2 
x 10 rnL), dried with Na2S04. filtered and concentrated. The residue was purified by 
column chromatography on silica gel using EtOAc/Petroleum ether (1/3, v/v) as 
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eluent to give aldehyde 132a as colourless oil (0.11 g, 44%), 1H NMR (400 MHz, 
CDC13) 8" 9.84 (s, I H, CHO), 8.60 (m, I H, CH2NHC=N), 3.74 (app. q, J=6.0,2H, 
CH2NH), 2.80 (t, J=6.0,2H, CH2CHO), 1.51 (s, 9H, C(CH3)3), 1.50 (s, 9H, 
C(CH3)3); 13 C NMR (100 MHz, CDC13) 5c 200.7 (CHO), 163.5 (C), 156.2 (C), 153.0 
(C), 83.2 (C), 79.4 (C), 43.5 (CH2), 34.1 (CH2), 28.3 (CHA28.1 (CH3). 
4-12,3-bis-(tert-Butoxycarbonyl)guanidinojbutanaI 132b 93 
NBoc 
HN NHBoc ', ý"'ýH 
0 
Aldehyde 132b, was prepared by the same procedure of aldehyde 132a as colourless 
oil (0.78 g, 40%), 1H NMR (400 MHz, CDC13) 5H 9.80 (s, IH, CHO), 8.37 (m, 11-1, 
CH2NHC=N), 3.45 (app. q, J=7.1,2H, CH2NH), 2.54 (t, J=7.1,2H, CH2CHO), 
1.92 (app. pent, J ý-- 7.1,2H, CH2CH2CH2), 1.51 (S, 18H, C(CH3)3); 
13 C NMR (100 
MHz, CDC13) Sc 201-2 (CHO), 163.5 (C), 156.3 (C), 153.3 (C), 83.2 (C), 79.3 (C), 
4 1.1 (CH2), 40.0 (CH2), 28.3 (CHA 28.2 (CHA 21.7 (CH2). 
5- [2,3-his-(tert-B u toxyca rbonyl)gua nidinol pen tanal 132C93 
0 NBoc 
H"ý N)ýNHBoc 
H 
Aldehyde 132c was prepared by the same procedure of aldehye 132a as a white solid 
(1.30 g, 71%), M. P. 105 'C; lH NMR (400 MHz, CDC13) 8H 9.78 (t, J=1.4,111, 
CHO), 8.34 (m, I H. CH2NHC=N), 3.45 (app. q, J, = 7.0,2H, CH2NH), 2.5 0 (dt, J, = 
7.2, J2 
--'ý 1.4,2H, CH2CHO), 1.66 (m, 4H, CH2CH2CH2CH2), 1.51 (s, 9H, C(CH3)3), 
170 
1.50 (s, 9H, C(CH3)-; ); 13 C NMR (100 MHz, CDC13) 8c 202.0 (CHO), 163.6 (C), 
156.2 (C), 153.3 (C), 83.1 (C), 79.3 (C), 43.4 (CH2), 40.4 (CH2), 28.5 (CH2), 28.3 
(CHA28.1 (CHA 19.3 (CH2). 
51-Amino-5'-deoxy-2', 3'-O-isopropylideneadenosine 13395 
N NH2 
H2N ýN N 
00 N 
Diisopropylazodicarboylate (0.32 mL, 1.63 mmol) was added dropwise to a 
suspended solution of 2, Y-isopropylideneadenosine (0.50 g, 1.63 mmol), 
phthalimide (0-25 g, 1.68 mmol) and triphenylphosphine (0.43 g, 1.63 mmol) in dry 
THF (6 mL) at room temperature. The reaction mixture was stirred for 2 hr and a 
precipitate appeared. The suspension was filtered and the solid washed, with Et20 
which was used in the next step directly. Hydrazine hydrate (1.29 mL, 26.08 mmol) 
was added to a suspended solution of solid prepared from the above step in EtOll (30 
mL) at room temperature and the reaction mixture refluxed for 2 hr, then cooled to 
room temperature. The reaction mixture was filtered, the filtrate concentrated, and 
then the resulting residue purified by column chromatography on silica gel using 
MeOWCH2CI2 (15/85, v/v) as eluent to give amine 133 as a white solid (0.30 g, 
60%), m. p. 203-204 OC (lit., 204-205 OC); 95 [a]24 D -35.02 (c 1.13 in MeOH); 'H 
NMR (400 MHz, CDC13) Sli 8.35 (s, I H, Ar-H, ), 7.94 (s, I H, Ar-H), 6.04 (d, J= 3.0, 
I H, I I-H), 5.89 (s, 2H, adenosine-NH2), 5.49 (dd, il = 6.4, J2 = 3.0,1 fl, 2'-H), 5.03 
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(dd, J1 = 6.4, J2 = 3.6, IH, 3'-H), 4.27 (m, IH, 4'-H), 3.05 (dd, J1 = 13.4, J2 = 4.4, 
1H, 5'-CHHb), 2.97 (dd, J1 = 13.4, J2 = 5.8, IH, 5-'CHaHb), 1.64 (s, 3H, CH3), 
1.41 (s, 3H, CH3); 13 C NMR (100 MHz, CDC13) 5C 155.6 (C), 153.2 (CH), 149.4 (C), 
140.0 (CH), 120.4 (C), 114.6 (C), 90.7(CH), 87.5 (CH), 83.6 (CH), 81.8 (CH), 43.8 
(CH2), 27.3 (CHA25.4 (CH3); ESI-MS 307.1 (M + H+); HRMS calcd C]31119N603+ 
307.1518, found 307.1496. 
51-13-S-tert-Butyloxycarbonyl-3-(tert-butyloxycarbonylamino)-propylaminol-51- 
deoxy-2', 31-0-isopropylideneadenosine 13480 
NHBoc ýN NH2 
t-Bu0, 
tr, 
J, ý N0 
N 
----/ 
00 
K 
A solution of aldehyde 129 (0.06 g, 0.21 mmol) in 1,2-dichloroethane (2 mL) was 
added to a solution of arnine 133 (0.08 g, 0.25 mmol) in 1,2-dichloroethane (2 mL) at 
room temperature and the mixture heated slightly until complete dissolution occurred, 
then cooled to room temperature. Sodium triacetoxyborohydride (0.06 g, 0.29 mmol) 
was added portionwise to the reaction mixture and stirred at room temperature for 2 
hr. The reaction solution was then quenched with saturated aqueous Na2CO3 (2 mL), 
extracted with CH202 (2 x5 mL) and dried with Na2S04, filtered and concentrated. 
The residue was purified by column chromatography on silica gel using 
EtOAc/MeOH (25/1, v/v) as eluent to give secondary amine 134 as a white solid 
(0.09 g, 73%), m. p. 88 'C; u max/ CM-1 3414 (NH2), 1707 (C=O), 1632 (C=C, 
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aromatic), 1589 (C=C, aromatic), 1077 (C-0); [Cq23 D -34-57 (c 1.70 in CHC13); 'H 
NMR (400 MHz, CDC13) 81,8.33 (s, I H, Ar-H), 7.93 (s, I H, Ar-H), 6.06 (s, 2H, 
adenosine-NH2), 6.00 (d, J=8.4,1 H, NHBoc), 5.98 (d, J=3.6,1 H, F-H), 5.50 (dd, 
J, = 6.2, J2 = 3.6,1 H, 2'-H), 5.08 (dd, il = 6.2, J2 = 3.2,1 H, 3'-H), 4.3 7 (m, I H, 
4.30 (m, I H, CHCH2), 2.96 (dd, Ji = 12.7, J2 = 3.8,1H, 5'-CH,, Hb)g 2.80 (dd, 
il = 12.7, J2 = 5.2, IH, 5'-CH,, Hb), 2.75 (m, IH, NtiCHHb)g 2.63 (m. 111, 
NHCH, Hb), 1.94 (m, IH, CHCH,, CHb), 1.84 (m, IH, CHCHHb), 1.62 (s, 3H, CH3), 
1.51 (s, 9H, C(CH3)3), 1.40 (s, 3H, CH3), 1.38 (s, 9H, C(CHj)3); 13 C NMR (100 MHz, 
CDCI. 3) 8c 171.9 (C), 155.7 (C), 155.6 (C), 153.1 (CH), 149.5 (C), 139.9 (CII), 120.4 
4.6 (C), 91 
.1 (CH), 85.0 (CH), 83.0 (CH), 82.2 (CH), 81.7 (C), 79.4 (C), 53.0 
(CH), 51.4 (CH2), 46.3 (CHA 32.3 (CH2), 28.3 (CH3), 28.0 (CIIA 27.4 (CHA 25.5 
(CH3); ESI-MS 564.3 (M + H+); HRMS calcd for C26H42N707+ 564.3146, found 
564.3 111; Anal. Calcd for C261LiN707 - 0.51-120: C 54.53, H 7.39, N 17.12. Found C 
54.96, H 7.33, N 16.94. 
51-1[3-S-tert-Butyloxycarbonyl-3-(Iert-butyloxycarbonylamino)-propyll-3-12,3- 
bis-(tert-butoxycarbonyl)guanidinoI propyl-aminoj-5'-deoxy-2', 3'-O-isopropylide 
ne-adenosine 135a 80 
NHBoc 
N NH2 
t-BUO N0 #NýýH\p fk--ý 'ýQ N --J 
0 
d 
HN 
BocHN 'k, NBoc 
Aldehyde 132a (0-06 mg, 0.19 mmol) was added to a solution of secondary amine 
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134 (0.07 g, 0.13 mmol) in 1,2-dichloroethane (2 mL) at room temperature and 
stirred for 15 min. Sodium triacetoxyborohydride (0.04 g, 0.18 mmol) was added 
portionwise and the mixture stirred at room temperature for 2 hr. The reaction 
solution was quenched with saturated aqueous Na2CO3 (2 mL) and extracted with 
CH202 (2 x5 mL) and dried with Na2SO4. filtered and concentrated. The residue 
was purified by column chromatography on silica gel using EtOAc/MeOII (5011, v/v) 
as eluent to give protected nitrogen SAM analogue 135a as a white solid (0.10 g, 
89%), m. p. 116 'C; [a]24 D -33.27 (c 1.10 in CH30H); 1) ...... / cm" 3413 (NI12), 1711 
(C=O), 1632 (C=C, aromatic), 1095 (C-0), 1058 (C-N); 1H NMR (400 MlIz, DMSO) 
51,8.37 (t, J=5.2,1 H. CH2NH), 8.32 (s, I H, Ar-H), 8.14 (s, I H, Ar-11), 7.33 (s, 211, 
adenosine-NH2), 7-09 (d, J= 8.0,1H, CHNHBoc), 6.15 (d, J= 2.1,111, V-11), 5.48 
(d, Ji = 6.3, J2 = 2.1,1 H, 2'-H), 5.00 (dd, J1 = 6.3, J2 = 2.8,111,3'-H), 4.22 (m, I 11, 
41-H), 3.93 (m, I H, CHCH2), 3.28 (m, 2H, 5'-CH. 
-, 
), 2.80 (m, 211, CHNI), 2.33 (m, 
4H, CHCH2CH2N and CH2CH2CH2N), 1.85 (m, IH, CHCllallb)t 1.64 (m, 111, 
CHCH. Hb), 1.59 (m, 2H, NCH2CH2CH2NH), 1.53 (s, 311, CH3), 1.48 (s, 911, 
C(cH3)3), 1.39 (s, 9H, C(CH3)-; )g 1.38 (s, 9H, C(CHi)3)9 1.37 (s, 911, C(CHj)3), 1.33(s, 
3H, CH3); 13 C NMR (100 MHz, CDC13) SC 171.8 (C), 163.6 (C), 156.1 (C), 155.6 
(C), 155.5 (C), 153.13 (CH), 153.11 (C), 149.2 (C), 140.2 (CH), 120.3 (C), 114.4 (C), 
90.9 (CH), 85.5 (CH), 83.7 (CH), 83.4 (CH), 82.9 (C), 81.7 (C), 79.5 (C), 79.2 (C), 
56.1 (CH2), 52.8 (CH), 52.1 (CH2), 50.6 (CH2), 39.3 (CH2), 29.1 (012), 28.4 (CI]3)9 
28.3 (CHA 28.1 (CHA 28.0 (CH3), 27.1 (CHA 26.3 (CH2), 25.4 (013); EST-MS 
863.5 (M + H+); HRMS calcd for C4oH67NoO, I+ 863.4991, found 863-4990; Anal. 
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Calcd for C4oH66N, oOll- 0.5H20: C 55.09, H 7.74, N 16.06. Found C 55.02,117.69, 
N 15.76. 
5'-1[3-S-tert-Butyloxycarbonyl-3-(Iert-butyloxycarbonylamino)-propyll-4-[2,3- 
his-(Jert-butoxycarbonyl)guanid ino] butyl-amino]-5'-deoxy-21,3'-O-iso p ropy li den 
e-adenosine 135b8o 
NHBoc N 
NH2 
t-BuO 0 N "**ý 
N 
00 
0 
BocN y NH 
NHBoc 
Protected nitrogen SAM analogue 135b, was prepared by the same procedure of 
protected nitrogen SAM analogue 135a as a white solid (0.64 g, 82%), rn. p. 109 IIC; 
[a]21D 
-24.65 (c 1.23 in MeOH); 1) cm-1 3413 (NI12), 1713 (C=O), 1632 (C=C, 
aromatic), 1094 (C-0), 1053 (C-N); 'H NMR (400 MHz, DMSo) 8,1 8.32 (s, III, 
Ar-H), 8.24 (L J= 5.4,1 H, CH2NH), 8.14 (s, I H, Ar-H), 7.33 (s, 2f 1, adenosine-NI12), 
7.09 (d, J=7.6,1 H, CHNHBoc), 6.15 (d, J=2.1,1 H, V-H), 5.51 (dd, J, = 6.4, J2 = 
2.1,1 H, 2-H), 5.00 (dd, J, = 6.4, J2 = 2.4,1 H, 3'-H), 4.21 (m, 111,4'-11), 3.95 (m, I 11, 
CHCH2), 3.23 (m, 2H, 5-CH2), 2.76 (m, 2H, CH2NH), 2.36 (m, 2H, CHC112CI12N), 
2.30 (m, 2H, CH2CH2CH2N), 1.82 (m, IH, CHCH,, Hb)g 1.62 (rn, 111, ClIC11.11b), 
1.53 (s, 3H, CHO, 1.47 (s. 9H. C(CH3)3), 1.43 (m, 2H, NC112CH2CH2CI12NII), 1.39 
(s, 9H, C(CH3)3)i 1.38 (s, 18H, C(CH3)3), 1.34 (s, 3H, CH3), 1.29 (m, 211, 
NCH2CH2CH2CH2NH); 13 C NMR (100 MHz, CDC13) 8C 171.8 (C), 163.6 (C), 156.0 
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(C), 155.8 (C), 155.5 (C), 153.2 (CH), 153.1 (C), 149.2 (C), 140.3 (CH), 120.3 (C), 
114.4 (C), 90.9 (CH), 85.8 (CH), 83.8 (CH), 83.5 (CH), 83.0 (C), 81.6 (C), 79.4 (C), 
79.2 (C), 55.9 (CH2), 54.1 (CH2), 52.9 (CH), 50.7 (CH2), 40.8 (CI12), 29.2 (CHA 
28.4 (CHA 28.3 (CHA 28.1 (CH3), 28.0 (CHA 27.1 (CIIA 26.8 (C112), 25.4 (CI]3)9 
24.1 (CH2); ESI-MS 877.5 (M + H+); HRMS calcd for C4lH69NI001i+ 877.5147, 
found 877.5127; Anal. Calcd for C411168N, 0011*0-51120: C 56.58, H 7.85, N 15.81. 
Found C 55.79, H 7.82, N 15.53. 
51-[[3-S-tert-Butyloxycarbonyl-3-(Iert-butyloxycarbonylamino)-propyll-5-[2,3- 
his-(jert-butoxya rbonyl)guan id in ol pen tyl-am in o] 
-5 A coxy-21,3'-O-isop ropyl id en 
e-adenosine 135c 80 
A NH2 NHBoc 
Ný t-BuO N0 ý4Nrlý 
N 0 
00 
HN 
/ 
BocHN'jzý' 'NBoc 
Protected nitrogen SAM analogue 135c was prepared by the same procedure of 
protected nitrogen SAM analogue 135a as a white solid (0.27 g, 34%), m. p. log OC; 
[a]211) 
-20.55 (c 1.08 in Me0H); u .. / cm" 3413 (NH2), 1714 (C=0), 1633 (C=C, 
aromatic), 1054 (C-N); 1H NMR (400 MHz, DMSO) 8H 8.31 (s, III, Ar-H), 8.25 (t, J 
= 5.2,1H, CH2NH), 8.14 (s, I H, Ar-H), 7.33 (s, 2H, adenosine-NH2), 7.08 (d, J= 7.6, 
I H, CHNHBoc), 6.15 (d, J=2.1,1 H, V-H), 5.52 (dd, J, = 6.2, J2 = 2.1,111,2'-H), 
4.99 (dd, J1 = 6.2, J2 = 2.6, IH, 3'-H), 4.19 (m, IH, 4-H), 3.94 (m, 111, CHC112)t 
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3.23 (m, 2H, 5'-CH2), 2.73 (m, 2H, CH2NH), 2.37 (m, 2H, CHCH2CH2N), 2.28 (m, 
2H, CH2CH2CH2N), 1.81 (m, IH, CHCH,, Hb)g 1.58 (m, IH, CHCH. Hb), 1.53 (s, 311, 
CHI), 1.47 (s, 9H, C(CH3)A 1.44 (m, 2H, NCH2CH2CH2CH2CH2NII), 1.39 (s, 911, 
C(CH3)3)9 1.38 (s, 18H, C(CH3)-i), 1.34 (s, 3H, CH3), 1.26 (m, 211, 
NCH2CH2CH2CH2CH2NH), 1.19 (m, 2H, NCH2CH2CH2CF12Cf12NH); 13C NMR 
(100 MHz, CDC13) 8C 171.8 (C), 163.6 (C), 156.1 (C), 155.8 (C), 155.5 (C), 153.3 
(CH), 153.1 (C), 149.2 (C), 140.3 (CH), 120.3 (C), 114.2 (C), 91.0 (CH), 85.9 (CII), 
83.8 (CH), 83.5 (CH), 83.0 (C), 81.5 (C), 79.3 (C), 79.2 (C), 55-9 (CI]2)9 54.3 (CI12)9 
53.0 (CH), 50.7 (CH2), 40.9 (CH2), 29.3 (CH2), 28.9 (CH2), 28.4 (Cfl3), 28.3 (CI]3)9 
28.1 (CHA 28.0 (CHA 27.1 (CHO, 26.3 (CH2), 25.4 (CHA 24.6 (012); ESI-MS 
891.5 (M + H); HRMS calcd for C42H70NI001i+ 891.5303, found 891.5248; Anal. 
Calcd fbrC42H7oNio0ji-0.5H20: C 56.05, H 7.95, N 15.56. Found C 55.86,117.81, 
N 15.48. 
3-[1,3-bis-(tert-Butoxycarbonyl)-2-imidazolidinyliminoI propanol 136 82 
Boc 
I 
H 0'*'ýý N =< 
N 
N 
I Boc 
Protected imidazolidine-2-thione 113 (0.30 g, 0.99 mmol) was added to a mixture of 
3-amino-l-propanol (0.07 mL, 0.90 mmol) and triethylarnine (0.25 mL, 1.80 mmol) 
in DMF (2 mL). Mercury chloride (0.27 g, 0.99 mmol) was then added at 0 *C and 
the reaction mixture stiffed for 30 min and at room temperature overnight. The 
reaction mixture was diluted with EtOAc (10 mL) and filtered. The filtrate was 
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washed with brine (3 x 10 mL), dried with Na2S04, filtered and concentrated, and 
then the residue purified by column chromatography on silica gel using 
EtOAc/Petroleum ethcr (1/2, v/v) as eluent to give cycloethyl guanidine derived 
alcohol 136 as colourless oil (0.02 g, 5.3%), 1H NMR (400 MHz, CDC13) 8115.04 (s, 
IH, HOCH2), 4.50 (t, J=6.0,2H, HOCH2), 3.88 (app. q, j= 5.8,2fi, NCH2012N), 
3.72 (t, J=6.0,2H, CH2CH2N=C), 3.45 (app. q, J=5.8,2H, NCH2CI12N), 1.89 (app. 
pent, J=6.0,2H, CH2CH2CH2), 1.57 (s, 9H, C(CH3)3), 1.44 (s, 911, C(CH3)3); IIC 
NMR (100 MHz, CDC13) 8C 184.3 (C), 156.0 (C), 154.9 (C), 85.1 (C), 79.2 (C), 59.5 
(CH2), 48.4 (CH2), 43.5 (CH2), 39.8 (CH2), 31.6 (CH2), 28.4 (CIIA 28.0 (CH3)- 
3-[3-tert-Butoxycarbonyl-2-imidazoline-2-tert-butoxycarbonylaminoI propanol 
137 96 
N 
I Boc 
N 
Boc 
2-Methylthio-2-imidazoline (0-50 g, 2.00 mmol) was added to a solution of 
3-amino-l-propanol (0.14 mL, 1.78 mmol) in ethanol (10 mL) and the mixture 
refluxed for 16 hr. The reaction solution was concentrated and the residue dissolved 
in H20/THF (1/1,20 mL). Di-terl-butyl dicarbonate (0.80 g, 2.20 mmol) was added 
to the solution at 0 *C and stirred at room temperature overnight. The reaction 
solution was extracted with EtOAc (2 x 10 mL) and the organic layers dried with 
Na2S04. filtered and concentrated, and the residue was purified by column 
chromatography on silica gel using EtOAc/Petroleum ether (1/1, v/v) as eluent to 
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give cycloethyl guanidine derived alcohol 137 as a white wax solid (0.05 g, 8.3%), 
m. p. 96>C, u 
, 
/ CM-' 1713 (C=0), 1240 (C-0), 1150 (C-OH); 111 NMR (400 Mliz, 
CDC13) 5fl 5.32 (s, I H, HOCH2), 3.88 (t, J=5.8,2H, HOCH2), 3.67 (t, J=5.8,211, 
CH2CH2CH2N), 3.45 (app. q, J=6.0,2H, BocNCH2CH2N), 3.33 (m, 2fi, 
BocNCH2CH2N), 1.75 (app. pent, J=5.8,2H, CH2CH2CH2), 1.55 (s, 9H, C(CI13)3), 
1.51 (s, 9H, C(CH3)3); 13 C NMR (100 MHz, CDC13) 8C 156.6 (C), 156.0 (C), 154.9 
(C), 83.8 (C), 79.1 (C), 59.0 (CH2), 43.4 (CH2), 40.2 (CHA 36.7 MIA 32.7 (CI12)9 
2 8.4 (CHA 2 8.0 (CHA 
3-Hydroxypropyl tosylate 14499 
0 
H004-- 
0 
p-Toluenesulfonyl chloride (1.00 g, 5.20 mmol) was added to a solution of 
triethylarnine (0.76 mL, 5.46 mmol) and DMAP (0.02 mg, 0.16 mmol) in 
1,3-propanediol (3.00 mL, 41.60 mmol) at room temperature and stirred for 2 hr. The 
reaction mixture was diluted with CH202 (20 mL) and washed with 0.8 M aqueous 
HCI (30 mL), and then H20 (20 mL). The CH202 solution was dried with Na2S04. 
filtered and concentrated, and the residue was purified by column chromatography 
on silica gel using EtOAc/Petroleum ether (1/1, v/v) as eluent to give hydroxypropyl 
tosylate 144 as colourless oil (0.88 g, 73%); 1H NMR (400 MHz, CDC13) 5117.8 (d, J 
= 8.0,2H, Ar-H), 7.36(d, J= 8.0,2H, Ar-H), 4.19 (t, J= 6.0,211, HOCH2), 3.71 (t, J 
= 6.0,2H, CH2OTs), 2.46 (s, 3H, M), 1.89 (app. pent, J=6.0,2H, CH2CH2012); 
13 C NMR (100 MHz, CDC13) 8C 144.9 (C), 132.9 (C), 129.9 (CH), 127.9 (CH), 67.5 
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(CH2), 58.3 (CH2), 31.6 (CH2), 21.6 (CH3); ESI-MS 253.0 (M + Na); HRMS calcd 
for C, oHl4NaO4S+ 253.0505, found 253.0494. 
51-[[3-S-tert-Butyloxycarbonyl-3-(tert-butyloxycarbonylamino)propyll-propargy 
11-51-deoxy-21,31-0-isopropylidene-adenosine 148 
NHBoc rN NH2 
t-BuO 0N IN N 
N 0 
lo 
ý, 
6b 
Propargyl bromide (80% in toluene, 0.22 mL, 1.96 mmol) was added to a solution of 
secondary amine 134 (1-00 g, 1.78 mmol) and K2CO3 (0.27g, 1.96 mmol) in DMF 
(10 rnL) at room temperature and stirring continued for 3 hr. The reaction mixture 
was diluted with EtOAc (50 mL) and washed with brine (3 x 20 mL), dried with 
Na2S04. filtered and concentrated. The residue was purified by column 
chromatography on silica gel using CH2CI2/MeOH (30/1, v/v) as eluent to give 
protected alkyne derived SAM analogue 148 as a white solid (0.76 g, 71%), m. p. 
90 OC; [a]23D 
-21.67 (c 1.02 in Me0H); u/ cm-' 3413 (NH2), 3304 (C=-C-11), 1709 
1632 (C=C, aromatic), 1587 (C=C, aromatic), 1078 (C-0); 111 NMR (400 
MHz, CDC13) SH 8.34 (s, I H, Ar-H), 7.96 (s, I H, Ar-H), 6.20 (s, 2H, adenosine-NI12), 
6.07(d, J= 1.6,1H, F-H), 5.62 (d, J=8.0, I H, NHBoc), 5.49(m, IH, 2'-H), 4.99 (m, 
I H, 3'-H), 4.35 (m, I H, 4ý-H), 4.22 (m, I H. CHCH2), 3.42 (m, 2H, HC--ýCCH2N), 
2.80 (dd, J1 = 13.4, j2 = 6.0, IH, 5'-CHHb), 2.71 (dd, J, = 13.4, J2 = 6.8,111, 
5'-CH, Hb), 2.57 (t, J=6.6,2H, CH2CH2N), 2.11 (m, I H, HC=-C), 1.93 (m, III, 
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CHCH, Hb)q 1.78 (m, I H, CHCHýHt, ) 1.61 (s, 3H, CH? ), 1.43 (s, 18H, C(CI13)3)9 1.39 
(s, 3H, CHO; 13 C NMR (100 MHz, CDC13) SC 171.7(C), 155.8 (C), 155.5 (C), 153.0 
(CH), 149.2 (C), 140.0 (CH), 120.3 (C), 114.4 (C), 90.8 (CH), 85.5 (Cli), 83.9 (CII), 
83.1 (CH), 81.7 (C), 79.5 (C), 77.9 (C), 73.4 (CH), 55.3 (CHA 52.6 (CH), 50.2 
(CH2), 42.6 (CH2), 29.8 (CH2), 28.4 (CH3), 28.0 (CH3), 27.1 (CH3), 25.4 (CI13); 
ESI-MS 602.3 (M + H+); HRMS calcd for C29H44N707+ 602.3296, found 602.3317. 
2- [2,3-bis-(tert-Bu toxyca rbonyl)gua nid i no] ethanol 15077 
NBoc 
Ho"'-*ýN Ifl, NHBoc 
H 
Protected methylisothiourea 125 (300 mg, 1.03 mmol) was added to a mixture of 
arninoethanol (0.06 mL, 1.03 mmol) and triethylarnine (0-29 mL, 2.06 mmol) in 
DMF (3 mL) and followed by mercury chloride (280 mg, 1.03 mmol) at room 
temperature and stirring continued for 1.5 hr. The reaction mixture was diluted with 
EtOAc (10 mL) and filtered. The filtrate was washed with brine (3 x 10 mL), dried 
with Na2S049 filtered and concentrated. The residue was purified by column 
chromatography on silica gel using EtOAc/Petroleum ether (1/1, v/v) as eluent to 
give alcohol 150 as a white solid (3 10 mg, 99%), m. p. 118-119 *C, 1H NMR (400 
MHz, CDC13) Sn 8.70 (m, I H, CH2NHC=N), 4.56 (s, I H, C1120H), 3.78 (t, J=5.0, 
2H, CH20H), 3.58 (app. q, J= 5.0,2H, CH2NH), 1.51 (s, 9H, C(CH3)3), 1.49 (s, 9fl, 
C(CH3)3); 13 C NMR (100 MHz, CDC13) SC 162.8 (C), 157.4(C), 153.1 (C), 83.5 (C), 
79.5 (C), 63.1 (CH2), 44.4 (CH2), 28.2 (CH3), 28.0 (CH3); ESI-MS 304.2 (M + 11); 
HRMS calcd for C13H26N305+ 304.1872, found 304.1849. 
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2-(terl-B u tyloxyca bonyl)a min o-ethyl azide 15399,102 
BocHN 
N3 
p-Toluenesulfonyl chloride (3.90 g, 20.4 mmol) was added to a solution of 
Boc-amino ethanol (3.00 g, 18.6 mmol) and triethylarnine (5.20 mL, 37.2 mmol) and 
DMAP (0.23 g, 1.86 mmol) in dry CH2CI2 (50 mL) and stirring continued for 3 hr. 
The reaction solution was washed with H20 (20 mL), adjusted to pH 4 with IM 
aqueous HCI and washed with 
H20 (2 x 20 mQ, dried with Na2SO4. filtered and 
concentrated. The residue was dissolved in dry DMF (10 mL) and then NaN3 (3.60 
55.8 mmol) was added. The reaction solution was stirred at 60 "C for 4 hr, then 
diluted with H20 (50 mL) and extracted with Et20 (30 mL). The ether layer was 
washed with brine (3 x 20 mL) and dried with Na2SO4. filtered and concentrated to 
give azide 153 as colourless oil (2.46 g, 71%); 1H NMR (400 MHz, CHC13) 5114.92 
(s, I H, NH), 3.42 (t, J=5.4,2H, N3CH2), 3.31 (m, 2H, NHCH2), 1.46 (s, 9H, CII3); 
13 C NMR (100 MHz, CHC13) SC 156.8 (C), 79.8 (C), 51.2 (CHA 40.1 (012), 28.4 
(CH3)- 
2-12,3-bis-(tert-Bu toxycarbonyl)guanidinol ethyl azide 154 77 
NBoc 
BocHN 
)ý 
N ^,,.,, 
N3 
H 
TFA (I mL) was added to a solution of the azide 153 (133 mg, 0.72 mmol) in C112CI2 
(I mL) at 0 *C and stirring continued at room temperature for I hr. The reaction 
solution was concentrated, the residue dissolved in DMF (2 mL), triethylamine (0.20 
mL, 1.43 mmol), protected methylisothiourea (207 mg, 0.72 mmol), mercury 
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chloride (194 mg, 0.72 mmol) were added to this solution and stirring continued at 
room temperature for I hr, then EtOAc (20 mL) added to the reaction mixture and 
the resultant solid removed by filtration. The filtrate was washed with water and the 
organic layer was dried with Na2SO4. filtered, concentrated, and the residue was 
purified by column chromatography on silica gel using EtOAC/Petroleum ether (1/10, 
v/v) as eluent to give guanicline derived azide 154 as a white solid (183 mg, 78%), 
m. p. 82-83 <IC; u,. / cm" 2106 (N3), 1721 (C=0); 1H NMR (400 MHz, CDC13) Sil 
8.61 (m, I H, NHBoc), 3.63 (app. q, J=5.6,2H, NHCH., ), 3.54 (t, J=5.6,211, 
CH2N3), 1.52 (s, 18H, C(CH3)3); 13 C NMR (100 MHz, CDC13) 8C 163.4 (C), 156.3 
(C), 153.2 (C ), 83.4 (C), 79.5 (C), 50.5 (CH2), 40.0 (CH2), 28.3 (CHA 28.1 WIN; 
ESI-MS 329.2 (M + H+); HRMS calcd for C13H2sN604+ 329.1932, found 329.1927. 
51-[[3-S-tert-Butyloxycarbonyl-3-(tert-butyloxycarbonylamino)-propyll-[1-12-12, 
3-his-(Iert-Butoxyarbonyl)guanidinelethyll-lH- 1,2,3-triazol-4-yi] m ethylam inol. 
51-deoxy-21,31-0-isopropylidene-adenosine 155103 
NHBoc N NH2 
t-BuO 0L/ NN N 
N 06b 
HN 
f 
BocHN"ýNBoc 
Copper sulphate (41 mg, 0.16 mmol) and sodium ascorbate (163 mg, 0.82 mmol) 
were added sequentially to a suspended solution of protected alkyne derived SAM 
analogue 148 (493 mg, 0.82 mmol) and guanidine derived azide 154 (269 mg, 0.82 
183 
mmol) in MeOH/H20 (8 mL, 3/1) at room temperature and stirring continued 
overnight. The reaction mixture was diluted with CH202 0 OmL) and 1120 (10 mL), 
separated, water phase extracted with CH2CI2 (2 x 10 mL). The combined organic 
phase was dried with Na2S04. filtered and evaporated, and the residue purified by 
column chromatography on silica gel using CH2CI2/MeOH (30/1, v/v) as eluent to 
give protected triazole derived SAM analogue 154 as a white solid (530 mg, 70%), 
m. p. 105-107 "C (dec); [a] 
23 
D-2.38 (c 1.30 in CHCIA 1) max/CM" 3413 (NH2)i 1722 
1631 (C=C, aromatic), 1500 (C=C, aromatic), 1096 (C-0); 1H NMR (400 
MHZ, C6D6) 8,18.67 (s, I H, Ar-H), 8.48 (t, J=5.6,1 H, CH2NHC=N), 7.75 (s, I If, 
Ar-H), 6.84 (s, IH, triazole-H), 6.33 (s, 2H, adenosine-NH2), 6.16 (d, i=8. o, 
CHNHBoc), 6.12 (d, J=0.8, IH, F-H), 5.54 (m, IH, 2'-H), 5.13 (m, 111, Y-H), 
4.69-4.63 (m, 2H, 4'-H and CHCH2CH2), 4.09 (m, 2H, CH2CH2NHC=N), 3.87 (m, 
2H, NCH2-triazole), 3.64 (m, 2H, CH2NHC=N), 2.87-2.52 (m, 4H, 5'-CH2 and 
CHCH2CH2), 2.12 (m, IH, CHCH,, Hb), 1.92 (m, IH, CHCHHb), 1.70 (s, 311, C113), 
1.63 (s, 9H, C(CH3)3), 1.59 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CHj)3), 1.38 (s, 311, 
CH3)v 1.28 (s, 9H, C(CH3)3); 13 C NMR (125 MHz, C6D6) 8C 171.9 (C), 163.9 (C), 
156.4 (C), 155.6 (C x 2), 153.2 (CH), 152.8 (C), 149.3 (C), 143.4 (C), 140.3 (CH), 
123.0 (CH), 120.6 (C), 113.6 (C), 90.7 (CH), 86.2 (CH), 84.0 (CH), 83.5 (CH), 82.5 
(C), 80.7 (C), 78.7 (C), 78.7 (C), 55.5 (CH2), 53.2 (CH), 50.3 (CH2), 48.4 (CH2 x 2), 
40.3 (CHA 29.2 (CH2), 28.2 (CHA 28.1 (CHA 27.7 (CHA 27.4 (CH3), 27.0 (CIIA 
25.2 (CH3); ESI-MS 930.5 (M +H+); HRMS calcd for C42H68NI3011 + 930.5156, 
found 930.5185. 
184 
Tetra(ethylene glycol) ditosylate 157104 
0-S--0- 
A solution of tetraethylene glycol (10-00 mL, 57-87 mmol) in THIF (100 mL) was 
added to an aqueous solution of NaOH (8.10 g, 202.50 mmol) in H20 (100 mL) at 
0 IC. A solution of p-toluenesulfonyl chloride (24.00 g, 127.31 mmol) in THF (150 
mL) was added to the stirred mixture at 0 'C dropwise for 45 min and stirring 
continued for 2 hr at 0 'C. The reaction mixture was poured to 10% aqueous IJCI (50 
mL) at 0 *C and extracted with EtOAc (200 mL). The organic layer was washed with 
aqueous dilute NaHC03 solution (100 mL) and dried with Na2SO4. filtered and 
concentrated. The residue was purified by column chromatography on silica gel 
using EtOAc as eluent to give ditosylate 157 as colourless oil (20.70 g, 71%); 111 
NMR (400 MHz, CDC13) 8H 7.78 (d, J= 8.0,4H, Ar-H), 7.33 (d, J= 8.0,411, Ar-II), 
4.15 (t, J=4.7,4H, CH2 x 2), 3.67 (t, J=4.7,4H, CH2 x 2), 3.55 (s, 8H, CH2 x 4), 
2.44 (s, 6H, CH., x 2); 13 C NMR (100 MHz, CDC13) 8C 144.9 (C x 2), 132.9 (C x 2), 
130.2 (CH x 4), 128.2 (CH x 4), 70.7 (CH2 x 2), 70.5(CH2 x 2), 69.3 (C112 x 2), 68.6 
(CH2 x 2), 21.6 (CH3 x 2); ESI-MS 503.1 (M + H+) [Found 503.1391 C22H3109S2 
requires 503.14041. 
Tetraethylcne bis-azide 158102 
N3 
Sodium azide (6.30 g, 97.50 mmol) was added to a solution of ditosylate 157 (19.60 
g, 39.00 mmol) in dry DMF (20 mL) at room temperature and stiffing continued at 
185 
75 IC for 6 hr. The reaction mixture was diluted with EtOAc (100 mL) and washed 
with H20 (3 x 50 mL). The organic layer was dried with NaS04, filtered and 
concentrated, and the residue purified by column chromatography on silica gel using 
EtOAc/Petroleum ether (1/1, v/v) as eluent to give bis-azide 158 as lightly yellow oil 
(9.10 g, 96%), 1H NMR (400 MHz, CDC13) 8113.67 (m, 12H, CH20 x 6), 3.82 (t, J= 
5.2,4H, CH2N3 x 2); 13 C NMR (100 MHz, CDC13) 5c 70.7 (CH2 x 4), 70.0 (C112 x 2), 
50.7 (CH2N3 x 2). 
1-Amino-li-azido-3,6,9-trioxaundecane 159102 
N3, 
-,, 
-ý 0 . -ýO, ýýO, ý---, ýNH2 
Triphenylphosphine (6.84 g, 26.10 mmol) was added to a solution of bis-azide 158 
(6.06 g, 24.80 mmol) in EtOAc (50 mL) and IM aqueous HCI (50 mL) at room 
temperature and stirred overnight. The reaction solution was separated, and then the 
aqueous layer washed with EtOAc (2 x 20 mL), adjusted to pH 12 and concentrated. 
The residue was extracted with CH202 (100 mL), and the organic layer washed with 
4M aqueous NaOH (2 x 30 mL), dried with NaS04. filtered and concentrated. The 
residue was purified by column chromatography on silica gel using EtOAc/MeOl-I 
(4/1, v/v) with 2% triethylamine as eluent to give monoamine 159 as yellow oil (4.00 
g, 75%), u 
, 
/ cni-' 2108 (N3); 'H NMR (400 MHz, CDC13) 8113.67-3.59 (m, 1 Oll, 
CH20 x 5), 3.49 OJý 5.2,2H, CH2CH2NH2), 3.37 (t, J= 5.2,2H, CH2N3), 2.85 (t, J 
= 5.2,2H, CH2NH2); 
13 C NMR (100 MHz, CDC13) 8c 73.2 (CH2), 70.7 (CHA 70.63 
(CH2), 70.61 (CH2), 70.3 (CH2), 70.0 (CH2)9 50.7 (CH2N3), 41.7 (CI12NI12)- 
186 
21,31,51-Tri-O-acetyl-6-chloroinosine 161105 
rN cl 
AcO N 
N_ýN 
Ac6 bAc 
T-in tetrachloride (1 
. 
00 M in CH202,40 mL, 40.00 mmol) was added to a solution of 
P-D-ribofuranose 1,2,3,5-tri-O-acetate (6.40 g, 20.00 mmol) and 6-chloropurine 
(3.80 g, 24.60 mmol) in CH3CN (100 mL) at room temperature and stirring 
continued overnight. The reaction solution was condensed and dissolved in EtOAc 
(100 mL) and washed with saturated aqueous NaHC03 (2 x 50 mL) and 1120 (50 
mL). EtOAc was removed and the residue purified by column chromatography on 
silica gel using EtOAc as eluent to give protected 6-chloride adenosine 161 as 
colourless oil (6.42 g, 78%), [a122D -15.54 (c 1.21 in CHC13); 11-1 NMR (400 Milz, 
CDC13) St4 8.77 (s, I H, Ar-H), 8.31 (s, I H, Ar-H), 6.23 (d, J=5.2,1 H, P-H), 5.95 
(app. t, J=5.2,1H, 2-H), 5.64 (app. tJ=5.2, IH, 3'-H), 4.48-4.36 (m, 3fl, 4'-H and 
51-CH2), 2.15 (s, 3H, CHA 2.12 (s, 3H, CHA 2.08 (s, 3H, CH3); 13 C NMR (100 
MHz, CDC13) SC 170.2 (C), 169.5 (C), 169.3 (C), 152.3 (CH), 151.6 (C), 151.2 (C), 
143.6 (CH), 132.3 (C), 86.9 (CH), 80.5 (CH), 73.1 (CH), 70.5 (CH), 62.9 (CI12)9 
20.7 (CH3), 20.5 (CH3), 20.4 (CH3), ESI-MS 435.1 (M + Na); HRMS calcd for 
C16Hl7CIN4NaO7+435.0678, found 435.0679. 
187 
21,31,5'-Tri-O-acetyl-N6-(11-azido-3,6,9-trioxaundecane)-amino adenosine 162 
NN 
AcO 
Ac6 bAc 
Monoamine 159 (2.20 g, 10.08 mmol) was added to a mixture of protected 
6-chloride adenosine 161 (2.10 g, 5.04 mmol) and triethylarnine (1.37 mL, 10.08 
mmol) in dry DMF (10 mL) at room temperature and the reaction solution stirred at 
60 *C for 2 hr. The reaction mixture was diluted with EtOAc (30 mL) and washed 
with H20 (2 x 10 mL) and dried with Na2SO4, filtered and concentrated, and the 
residue purified by column chromatography on silica gel using EtOAc/MeOl-I (50/1, 
v/v) as eluent to give protected N-6 azide, tethered adenosine, 162 (1.20 g, 43%) as 
YCIIOW Oil, [U]23 D -27.12 (c 1.04 in CHCl3); U m. / cm-' 3427 (NH), 2109 (N3)9 1747 
(C=O), 1620 (C=C, aromatic), 1097 (C-0); 1H NMR (400 MHz, CDC13) 81,8.37 (s, 
I H, Ar-H), 7.91 (s, I H, Ar-H), 6.3 0 (s, I H, adenosine-NH), 6.18 (d, J=5.3,1 H, 
I I-H), 5.93 (app. t, J=5.3,1 H, 2'-H), 5.6 8 (app. t, J=5.3,1 H, 3 I-H), 4.47-4.3 7 (m, 
3H, 4-H and 5'-CH2), 3.86 (m, 2H, adenosine-NHCH2), 3.74 (t, J=5.2,2H, CH20), 
3.70-3.66 (m, I OH, CH20 x 5), 3.39 (t, J= 5.2,2H, CH2N3), 2.15 (s, 3H, CH3), 2.13 
(s, 3 H, CH3), 2.0 8 (s, 3 H, CH3); 13 C NMR (100 MHz, CDC13) 6C 170.3 (C), 169.6 
(C), 169.4 (C), 154.8 (C), 153.3 (CH), 148.9 (C), 138.1 (CH), 120.3 (C), 86.1 (CH), 
80.1 (CH), 73.1 (CH), 70.7-69.8 (CH, CH2 x 6), 63.1 (CHA 50.6 (CH2), 40.3 (CI12)9 
20.7 (CH3), 20.5 (CHA 20.4 (CH3); ESI-MS 595.2 (M + H+); HRMS calcd for 
C24H35N801o+ 595.2471, found 595.2486. 
188 
21,31-Isopropylidencinosine 16410'5 
N0 
0N NH HO 
N 
00 Xý 
p-Toluenesulfonic acid monohydrate (3.50 g, 18.66 mmol) was added to the solution 
of inosine (5-00 g, 18.66 mmol) and 2,2-dimethoxyl propane (11.50 mL, 93.28 mmol) 
in acetone (200 mL) at room temperature and stirring continued overnight. NaHC03 
aqueous solution (1.57 g in 40 ml, H20) was added to the suspension and stirred for 
15 min. The solution was concentrated and the product was recrystallised, form the 
residual water. Filtration gave isopropylideneinosine 164 as a white solid (3.60 g, 
63%), m. p. 263-265 *C (dec) (lit., 266-268 *Q'06; [a]23 D -62.81 (c 0.61 in MeOH); 
1H NMR (400 MHz, DMSO) 8H 8.31 (s, I H, Ar-H), 8.09 (s, I H, Ar-H), 6.10 (d, J= 
1.9,1 H, F-H), 5.27 (dd, J, = 5.6, J2 = 1.9,1 H, 2'-H), 4.93 (m, I H, 3'-H), 4.23 (m, I H, 
4ý-H), 3.54 (m, 2H, 5ý-CH2), 1.54 (s, 3H, CH3), 1.32 (s, 3H, CHj); 13 C NMR (100 
MHz, DMSO) 8c 156.6 (C), 147.8 (C), 146.1 (CH), 13 8.7 (CH), 124.4 (C), 113.1 (C), 
89.6 (CH), 86.6 (CH), 83.8 (CH), 81.2 (CH), 61.4 (CH2), 27.0 (CHA 25.1 (CI13); 
ESI-MS 309.1 (M + H+); HRMS calcd for C13Hl7N405+ 309.1194, found 309.1196. 
21,31-Isopropylidene-N6-(11-azido-3,6,9-trioxaundecane)-amino adenosine 165 107 
H 
N N3 
HO)NtjN 
189 
Monoamine 159 (1.59 g, 7.31 mmol) was added to a solution of 
isopropylideneinosine 164 (1.50 g, 4.87 mmol), PyBOP (3.00 g, 5.84 mmol), and 
N, N-diisopropylethylamine (1.27 mL, 7.31 mmol) in dry DMF (20 mL) at room 
temperature under nitrogen and stirring continued overnight. EtOAc (50 mL) was 
added to the reaction solution and washed with brine (3 x 20 mL), and the organic 
layer dried with Na2S04. filtered and concentrated. The residue was purified by 
column chromatography on silica gel using CH2CI2/MeOH (50/1, v/v) as eluent to 
give protected N-6 azide tethered adenosine 165 (1.85 g, 75%) as colourless oil, 
[CC]23 D 
-81.56 (c 1.28 in CHCl3); 1) inzLx/ cm" 3423 (NH), 3206 (OH), 2108 (N3)9 1626 
(C=C, aromatic), 1586 (C=C, aromatic), 1083 (C-0); lH NMR (400 MHz, CDC13) 8H 
8.30 (s, IH, Ar-H), 7.80 (s, IH, Ar-H), 6.54 (s, IH, adenosine-NH), 5.84 (d, J= 5.3, 
IH, F-H), 5.20 (app. ý J= 5.3, IH, T-H), 5.10 (m, IH, 3'-H), 4.52 (m, IH, 4'-H), 
3.98 (dd, J, = 12.8, J2 = 1.6, IH, 5'-CH,, Hb), 3.80 (m, 2H, adenosine-NHCH2), 3.78 
(m, IH, Y-CH. Hb), 3.72(t, J=5.0,2H, CH20), 3.68-3.60 (m, I OH, CH20 x 5), 3.37 
(t, J= 5.0,2H, CH2N3), 1.64 (s, 3H, CH3), 1.37 (s, 3H, M); 13 C NMR (100 MHz, 
CDC13) 8c 155.2 (C), 152.6 (CH), 147.3 (C), 139.6 (CH), 121.4 (C), 113.9 (C), 94.3 
(CH), 86.0 (CH), 83.0 (CH), 81.7 (CH), 70.7-69.7 (CH2 x 6), 63.4 (CH2), 50.7 (CH2), 
40.4 (CH2), 27.7 (CHA 25.2 (CH3); ESI-MS 509.2 (M + H+); HRMS calcd for 
C2lH33NS07+ 509.2472, found 509.2509. 
190 
51-N-Phthaloyl-2', 3'-O-isopropylidene-N6-(Il-azido-3,6,9-trioxaundecane)- 
amino adenosine 16695 
H 
o rN_, N N3 
N' 
Diisopropylazodicarboylate (2.00 mL, 10.33 mmol) was added to a solution of 
protected N-6 azide tethered adenosine 165 (1.50 g, 2.95 mmol) and 
triphenylphosphine (2.70 g, 10.33 mmol) in dry THF (50 mL) at room temperature 
and stirring continued for 30 min. Phthalimide (1.50 g, 10.33 mmol) was added to 
the reaction solution at room temperature. After 2 hr, the reaction mixture was 
concentrated and the residue purified by column chromatography on silica gel using 
EtOAc/MeOH (80/1, v/v) as eluent to give protected phthaloyl N-6 azide tethered 
adenosine 166 as yellow oil (1.42 g, 76%), [(1]22 D 5.53 (c 1.99 in CHC13); 1) max/ CM*I 
3427 (NH), 2108 (NA 1716 (C=O), 1620 (C=C, aromatic), 1584 (C=C, aromatic), 
1097 (C-0); lH NMR (400 MHz, CDC13) 8H 8.11 (s, I H, Ar-H), 7.82 (s, I H, Ar-H), 
7.78 (m, 2H, Ar-H), 7.69 (m, 2H, Ar-H), 6.37 (s, I H, adenosine-NH), 6.03 (m, I H, 
V-H), 5.54 (m, I H, T-H), 5.25 (dd, J, = 5.8, J2 = 3.4,1 H, 3'-H), 4.54 (m, I H, 4 ý-H), 
4.05 (dd, J, = 14.0, J2 = 6.2, IH, 5-CHaHb)g 3.98 (dd, J, = 14.0, J2 = 6.2,111, 
5'-CH,, Hh), 3.84 (m, 2H, adenosine-NHCH2), 3.73 (t, J=4.4,2H, CH20), 3.68-3.60 
(m, IOH, CH20 x 5), 3.38 (t, J=4.4,2H, CH2N3), 1.58 (s, 3H, CH3), 1.38 (s, 3H, 
CH 3); 13 C NMR (100 MHz, CDC13) &C 168.0 (C x 2), 154.8 (C), 152.9 (CH), 148.3 
13 9.7 (CH), 133.9 (CH x 2), 131.8 (C x 2), 123.2 (CH x 2), 120.4 (C), 114.3 (C), 
191 
90.5 (CH), 85.0 (CH), 84.1 (CH), 82.5 (CH), 70.6-69.4 (CH2 x 6), 50.6 (CH2), 40.5 
(CHA 39.5 (CH2), 27.1 (CHA 25.4 (CH3); ESI-MS 638.3 (M + H+); HRMS calcd 
for C29H36N9Os+ 638.2681, found 638.2686. 
51-Amino-5'-deoxy-21,3'-O-isopropylidene-N6-(Il-azido-3,6,9-trioxaundecane)- 
amino adenosine 16795 
H 
N0 N3 
H2N 
N 
60 
Hydrazine hydrate (1.46 mL, 30.14 mmol) was added to a solution of protected 
phthaloyl N-6 azide tethered adenosine 166 in EtOH (50 mL) at room temperature 
and the reaction mixture refluxed for 2 hr and cooled to room temperature. The 
reaction mixture was filtered and the filtrate concentrated, and the residue was 
purified by column chromatography on silica gel using MeOH/CH2CI2 (15/85, v/v) 
as eluent to give protected N-6 azide tethered adenosyl amine 167 as colourless oil 
(0.18 g, 82%), [a]22D 
- 
16.3 8 (c 1.16 in Me0H); u 
, 
/ cm" 3426 (NH2), 2107 (N3), 
1620 (C=C, aromatic), 1583 (C=C, aromatic), 1085 (C-0); 1H NMR (400 MHz, 
CD30D) 8" 8.27 (s, I H, Ar-H), 8.24 (s, I H, Ar-H), 6.15 (d, J=2.9,1 H, F-H), 5.48 
(dd, Ji = 6.2, J2 = 2.9,1 H, 2'-H), 5.03 (dd, J, = 6.2, J2 = 3.0,1 H, 3'-H), 4.26 (m, I H, 
4'-H), 3.80 (m, 2H, adenosine-NHCH2), 3.75 (m, CH0), 3.64 (m, IOH, CH20 x 5), 
3.33 (m, 2H, CH2N3), 2.93 (m, 2H, 5'-CH2), 1.62 (s, 3H, CH3), 1.40 (s, 3H, CH3); 13 c 
NMR (100 MHz, CD30D) 8c 156.3 (C), 154.0 (CH), 149.5 (C), 141.5 (CH), 121.2 
192 
(C), 115.7 (C), 91.6 (CH), 88.2 (CH), 84.9 (CH), 83.3 (CH), 71.7-70.7 (CH2 x 6), 
51.8 (CH2), 44.5 (CH2), 41.5 (CH2), 27.6 (CH3), 25.6 (CHA; ESI-MS 508.2 (M + H+); 
HRMS calcd for C2lH34N906+ 508.2627, found 508.2643. 
51-[3-S-tert-Butyloxycarbonyl-3-(tert-butyloxycarbonylamino)-propylaminol-51- 
deoxy-21,31-0-isopropylidene-N6-(11-azido-3,6,9-trioxaundecane)amino 
adenosine 168 
80 
H 
NHBoc N N3 
t-BuO 0 N- Ný !N 
H N---J 0 
60 
Protected N-6 azide tethered secondary amine 168 was prepared by the same 
procedure of secondary amine 134 as colourless oil (0.17 g, 75%), [a]20D -25.50 (c 
1.09 in CHCl3); 1) max/ cm-' 3428 (NH), 2107 (N3), 1704 (C=0), 1620 (C=C, 
aromatic), 1583 (C=C, aromatic), 1088 (C-0); lH NMR (400 MHz, CDC13) S[j 8.29 
(s, I H, Ar-H), 7.84 (s, I H, Ar-H), 6.51 (s, I H, adenosine-NH), 6.00 (d, J=8.0,1 H, 
NHBoc), 5.91 (d, J=2.4,1 H, F-H), 5.46 (m, I H, 2'-H), 5.04 (m, I H, 3'-H), 4.31 (m, 
H, 4'-H), 4.23 (m, I H, CHCH2), 3.80 (m, 2H, adenosine-NHCH2), 3.68 (t, J=4.4, 
2H, CH20), 3.63 (m, 1 OH, CH20 x 5), 3.31 (t, J=4.4,2H, CH2N3), 2.90 (dd, J, = 
12.4, J2 = 2.4,1 Hq 5'-CHiHb)g 2.75 (dd, J, = 12.4, J2 = 4.69 5'-CH,, Hb), 2.70 (m, I H, 
CH,, HbNH), 2.58 (m, IH, CH,, HbNH), 1.88 (m, IH, CHCHHb)t 1.80 (m, IH, 
CHCH,, Hb), 1.56 (s, 3H, CH3), 1.41 (s, 9H, C(CH3)3), 1.34 (s, 12H, CH3 and 
3)3); 13 C(CH C NMR (100 MHz, CDC13) 8C 171.8 (C), 155.5 (C), 154.9 (C), 153.1 
193 
(CH), 148.6 (C), 139.2 (CH), 120.6 (C), 114.5 (C), 91.0 (CH), 84.9 (CH), 83.0 (CH), 
82.1 (CH), 81.5 (C), 79.2 (C), 70.6-69.8 (CH2 x 6), 53.0 (CH), 51.4 (CHA 50.6 
(CH2), 46.3 (CHA 40.3 (CH2), 32.2 (CH2), 28.3 (CHA 28.0 (CHA 27.3 (CH3)9 25.4 
(CH3); ESI-MS 765.4 (M + H+); HRMS calcd for C34H57NioOlo+ 765.4254, found 
765.4289; Anal. Calcd for C34H56NI oOlo-0.5H20: C 52.77, H 7.42, N 18.10. Found C 
53.05, H 7.34, N 17.75. 
51-113-S-tert-Butyloxycarbonyl-3-(Iert-butyloxycarbonylamino)propyll-3-[2,3-bis 
-(tert-butoxycarbonyl)guanidinolpropyl-aminol-5'-deoxy-21,3'-O-isopropylidene 
-N6-(11-azido- 3,6,9-trioxaundecane)-amino adenosine 16980 
H 
NHBoc rN N3 
t-BuO 0N- Ný !N 
N 0 
6b 
HN 
BocHN'k'NBoc 
Protected N-6 azide tethered SAM analogue 169 was prepared by the same procedure 
of protected nitrogen SAM analogue 135a as colourless oil (0.23 g, 99%), [a]20D 
-14.77 (c 1.07 in CHC13); 1) imm/CM" 3428 (NH), 2107 (NA 1713 (C=O), 1633 (C=C, 
aromatic), 1586 (C=C, aromatic), 1093 (C-0); 1H NMR (400 MHz, DMSO) 81, 
8.41(m, IH, CH2NH), 8.32 (s, IH, Ar-H), 8. (s, IH, Ar-H), 7.74 (s, IH, 
adenosine-NH), 7.01 (d, J=4.3,1 H, V-H), 6.21 (m, I H, CHNHBoc), 5.48 (m, I H, 
5.01 (m, I H, Y-H), 4.35 (m, I H, 4'-H), 4.04 (m, I H, CHCH2), 3.60 (m, 2H, 
adenosine-NHCH2), 3.5 8 (t, J=4.8,2H, CH20), 3.52 (m, 1 OH, CH20 x 5), 3.3 7 (t, J 
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= 4.8,2H, CHA), 3.27 (m, 2H, 5-CH2), 2.83-2.30 (m, 6H, NHCH2CH2CH2N and 
CHCH2CH2N), 1.82 (m, IH, CHCH,, Hb)g 1.64 (m, IH, CHCH,, Hb), 1.62 (m, 2H, 
CH2CH2CH2), 1.53 (s, 3H, CHI), 1.48-1-38 (m, 36H, C(CH3)_, x 4), 1.33 (s, 3H, CH3); 
13 C NMR (100 MHz, CDC13) SC 171.7 (C), 163.6 (C), 156.0 (C), 155.4 (C), 154.8 
(C), 153.0 (CH and Q, 148.2 (C), 139.5 (CH), 120.5 (C), 114.5 (C), 90.7 (CH), 85.5 
(CH), 83.7 (CH), 83.4 (CH), 82.8 (C), 81.5 (C), 79.3 (C), 79.0 (C), 70.6-69.8 (CH2 
6), 56.1 (CH2), 52.8 (CH), 52.1 (CHA 50.6 (CH2 x 2), 40.3 (CH2), 39.2 (CHA 29.0 
(CHA 28.3 (CHA 28.2 (C143), 28.0 (CHA 27.9 (CH3), 27.1 (CH3), 26.3 (CH2), 25.4 
(CH3); ESI-MS 1064.6 (M + H); HRMS calcd for C48H82NI3014+ 1064.6099, found 
1064.6140; Anal. Calcd for C48H8, N]3014-H20: C 53.27, H 7.73, N 16.82, Found C 
53.20, H 7.55, N 16.99. 
N6-Benzoyl-5'-deoxy-21,3'-O-isopropylidene-51-16-(1,2,3-tricarbethoxy-3,4,5,6- 
tctrahydropyridazine)ladenosinc 170a 120 
N NHBz 
C2H50 ff 
'-- 
ýN 
0 
Lý/ 
N 
0 N-N 
N 
C2H50--ý 
0 
)--0 
ö 
0C2H5 ><ý 
(2S)-5-PYrrolidin-2-yl-IH-tetrazole (12.60 mg, 0.09 mmol) was added to a solution 
of the adenosyl T-aldehyde 204 (475 mg, 1.09 mmol) and diethyl azodicarboxylate 
(0.14 mL, 91 mmol) in dry CH2CI2 (I mL) at room temperature and stirring 
continued for I hr. The mixture was cooled to 0 'C and dry THIF added and then 
triphcnYlphosphonium bromide (600 mg, 1.36 mmol) added, followed by sodium 
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hydride (60%, 91 mg, 2.28 mmol). The reaction solution was stirred at 0 "C for 45 
min, and quenched with saturated aqueous NH4CI (I mL) and extracted with EtOAc 
(2 x5 mL). The combined organic layers were dried with Na2SO4. filtered and 
concentrated, and the residue purified with column chromatography on silica gel 
using CH2CI2/MeOH (60/1, v/v) as eluent to give the single diastereoisomer 204 (2 10 
mg, 33%) and the diastereomeric mixture (136 mg, 22%), total yield 55%, the pure 
compound 1H NMR (400 MHz, DMSO) 8H 11.25 (s, I H, NHBz), 8.79 (s, I fl, Ar-H), 
8.70 (s, IH, Ar-H), 8.06-8.05 (m, 2H, BzH), 7.66-7.55 (m, 3H, BzH), 6.32 (d, J= 2.4, 
I H, Y-B), 6.05 (m, I H, T-H), 5.63 (m, I H, 8'-H), 5.5 5 (m, I H, 2'-H), 5.05 (m, I H, 
3'-H), 4.60 (m, IH, 9'-H), 4.50 (m, IH, 6'-H), 4.43 (m, IH, 4-H), 4.14 (m, 6H, 
CH2CH3 x 3), 2.15-1-90(m, 2H, 5'-CH2), 1.57 (s, 3H, CHT), 1.35 (s, 3H, CH3), 1.18 
(M, 9H. CH2CH3 x 3); 13 C NMR (100 MHz, CDC13) 8C 168.5 (C), 164.8 (C), 156.9 
(C), 155.8 (C), 152.6 (CH), 151.1 (C), 149.8 (C), 142.8 (CH), 133.6 (C), 132.9 (CH), 
132.2 (CH), 128.9 (CH), 127.9 (CH), 123.8 (C), 121.5 (CH), 114.4 (C), 91.5 (CH), 
84.6 (CH), 84.3 (CH), 83.9 (CH), 63.1 (CH2), 62.6 (CHA 61.9 (012), 57.8 (CII), 
52.6 (CH), 36.0 (CHA 27.1 (CHA 25.3 (CHA 14.4 (CH3 x 2), 14.0 (CH3); ESI-MS 
694.3 (M + H+); HRMS calcd for C33H4ON701o+ 694.283 1, found 694.2808. 
51-Nitrile-2', 31-0-isopropylidene-adenosine 173 108 
NH2 
196 
Acetone cyanohydrin (0.06 mL, 0.67 mmol) Nvas added to a suspended solution of 2', 
3'-isopropylideneadenosine (59 mg, 0.19 mmol), and triphenylphosphine (176 mg, 
0.67 mmol) in dry THF (5 mL) at room temperature. The reaction mixture was 
stirred for 5 min, diisopropylazodicarboylate (0.13 mL, 0.67 mmol) was added at 
0 IC and stirring continued at room temperature overnight. The reaction solution was 
concentrated and the residue purified by column chromatography on silica gel using 
CH2CI2/MCOH (25/1, v/v) as eluent to give nitrile 173 as a off white solid (44 mg, 
73%), m. p. 206-208 *C (dec); [a127 D 4.41 (c 1.02 in CH30H); lH NMR (400 MHz, 
CDC13) 51,8.35 (s, I H, Ar-H), 7.91 (s, I H, Ar-H), 6.11 (d, J=1.9,1 H, V-H), 5.99 
2H, adenosine-NH2), 5A9 (dd, Ji = 63, J,, = 1.9,1 H, 2-H), 5.15 (dd, J, = 6.3, J2 = 
3.2,1 H, 3 ý-H), 4.54 (ddd, Ji = 7.1, J2 = 6.5, J3 = 3.2,1 H, 4'-H), 3.02 (dd, J, = 16.6, 
J2=6.5, IH, 5'-CHaHb), 2.90(dd, JI=16.6, J2=7.1, IH, 5'-CHaHb), 1.64(s, 3H, 
CH., ), 1.41 (s, 3H, CHI); 13 C NMR (100 MHz, CDC13) 5C 155.8 (C), 153.2 (CH), 
148.9 (C), 140.2 (CH), 120.3 (C), 116.7 (C), 114.9 (C), 91.1 (CH), 84.3 (CH), 83.9 
(CH), 83.0 (CH), 27.0 (CHA 25.2 (CHA 22.1 (CH2); ESI-MS 317.1 (M + H+); 
HRMS calcd for C14H17N603 317.1357, found 317.1353. 
Ethyl 2(E)-pcnten4-ynoate 18 110 
0 
C2H50--'ý% 
Manganese dioxide (11.80 g, 135.40 mmol) was added to a mixture of propargyl 
alcohol (0.80 MI., 13.54 mmol) and (carbethoxymethylene)triphenylphosphorane 
(5.66 g, 16.25 mmol) in dry CH2C12 (100 mL) at room temperature and stirring 
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continued 2 days. The manganese dioxide was removed by filtration through Celite 
and washed with CH2CI2 and the filtrated concentrated. The residue was purified by 
column chromatography on silica gel using Et20/Petroleum ether (1/3, v/v) as eluent 
to give alkyne derived alkene compound 181 as yellow oil (0.80 g, 63%), 111 NMR 
(400 MHz, CDC13) &16.74 (dd, J, = 16.0, J2 = 2.3, IH, EtOOCCH), 6.31 (dd, J, = 
16.0, J2 = 0.7,1 H, CHC-=CH), 4.22 (q, J=7.2,2 H, CH2CH3), 3.36 (dd, il = 2.3, J2 = 
0.7,1 H, C=-CH), 1.31 (t, J=7.2,3H, CH2CH3); 13 C NMR (100 MHz, CDC13) SC 
165.5 (C), 132.5 (CH), 123.9 (CH), 85.9 (C), 80.2 (C), 60.9 (CH2), 14.2 (CID). 
Ethyl 2(E)-penten-5-bromo-4-ynoate 1821 11 
C2H50 
Br 
Silver nitrate (38.40 mg, 0.23 mmol) was added to a solution of alkyne derived 
alkene compound 181 and NBS (470 mg, 2.64 mmol) in acetone (10 mL) at room 
temperature and stiffing continued for 2 hr. The reaction solution was evaporated and 
the residue purified by column chromatography on silica gel using Et20/11exane (1/3, 
v/v) as eluent to give alkyne bromide 182 as a white solid (381 mg, 83%), 111 NMR 
(400 MHz, CDC13) 511 6.76 (d, J= 15.8,1 H, EtOOCCH), 6.31 (d, J= 15.8,111, 
CHC-=CBr), 4.22 (q, J=7.1,2H, CH2CH3), 1.31 (t, J=7.1,3 H, CH2CH3); 13 C NMR 
(100 MHz, CDC13) 5C 165.5 (C), 132.1 (CH), 122.4 (CH), 60.9 (CHA 59.5 (C), 14.2 
(CH3). 
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Ethyl (Z)-3-iodo-propenoate 1851 13 
H3CH2CO-ýýl 
0 
Dry sodium iodide (220 mg, 1.47 mmol) was added to a solution of ethyl propynoate 
(0.10 mL, 0.98 mmol) in acetic acid (I mL) and stirring continued at 70 T overnight. 
The reaction solution was diluted with H20 (10 mL) and neutralized with K2CO3 
until no C02 was evolved and extracted with Et2O (3 x 10 mL). The combined 
organic layer was washed with 10% Na2S203 (10 mL) and brine (10 mL), dried with 
NaS04. filtered and concentrated to give vinyl iodide 185 as colorless oil in 
quantitive yield, 1H NMR (400 MHz, CDC13) 511 7.45 (d, J=8.8, IH, EtOOCCH), 
6.89 (d, J=8.8,1 H, CH=CHI), 4.26 (q, J=7.1,2H, CH2013). 1.33 (t, J=7.1,311, 
CH2CH3); 13 C NMR (100 MHz, CDC13) 8C 164.6 (C), 129.9 (CH), 94.6 (CH), 60.8 
(C"2)ý 14.2 (CH3). 
Ethyl 5-iodopenta-2E, 4Z-dienoate 1861 14 
45 
1 
ý3 ý2 
0 
H3CH2CO- 
DIBAL (IM in hexanes, 1.75 mL, 1.75 mmol) was added to a solution of vinyl 
iodide 185 (0-36 9,1.59 mmol) in dry CH2C12 (5 mL) at 
-78 *C dropwise and stirring 
continued for 15 mins. The reaction mixture was quenched with MeOH (0.30 mQ, 
followed by 15% aqueous K/Na tartrate (6.90 mL), warmed to room temperature, 
then diluted with Et20 (4 mQ, stiffed for I hr while protected from light. The 
reaction solution was separated and extracted with Et20 (3 x4 mL), dried with 
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Na2S04. filtered and concentrated. n-BuLi (1.6M in hexane, 1.04 mL, 1.67 mmol) 
was added to a solution of triethyl phosphonoacetate (0.33 mL, 1.67 mmol) in dry 
THF (5 mL) at 
-78 *C and stirring continued for 30min. The crude aldehyde in dry 
THF (5mL) was added to the reaction solution at 
-78 'C. The reaction mixture was 
warmed to room temperature over 2 hr, stirred at room temperature for I hr, diluted 
with Et2O (10 mL) and H20 (10 mL) and separated. The aqueous phase was 
extracted with Et2O (3 x 10 mL) and the combined organic extracts dried with 
Na2S04. filtered and concentrated. The residue was purified with column 
chromatography on silica gel using Et20/Hexane (1/20, v/v) as eluent to give vinyl 
iodide 186 as yellow oil (0.25 g, 62%), 'H NMR (400 MHz, CDC13) Sfj 7.42 (ddd, J, 
= 15.3, J2 = 10.3, J3 = 0.9,1 H, O-H), 6.92 (ddd, Ji = 10.3, J2 = 7.8, Ji = 0.9,111, 
C4-H), 6.84(d, J=7.8,1H, C5-H), 6.14 (d, J= 15.3,111, C2-H), 4.25 (q, J=7.0,211, 
CH2CHA 1.34 (t, J=7.0,3 H, CH2CH3); 13 C NMR (100 MHz, CDC13) SC 166.5(C), 
143.0 (CH), 136.6 (CH), 125.8 (CH), 91.9 (CH), 60.7 (CHA 14.3 (CI13)- 
N6-Benzoyl-2', 31-0-isopropylidene-adenosine 187 76 
'N 
NHBz 
N 
0 Xý 
Benzoyl chloride (0.76 mL, 6.52 mmol) was added dropwise to a solution of 2', 
31-0-isopropylideneadenosine (0.50 g, 1.63 mmol) in pyridine (5 mL) at 0 *C and the 
mixture was warmed to room temperature and stirring continued for 4 hr. The 
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reaction mixture was quenched by ice-water and evaporated. The residue was 
dissolved in CH202 (100 mL) and washed with H20 (50 mL), saturated aqueous 
NaHC03 (50 mL) and concentrated. The residue was dissolved in pyridine (4.50 mL) 
and a solution of KOH (0.65 g) in H20 (4.50 mL) was added and stirred vigorously 
for 20 min. Acetic acid (0.60 mL) was added to the cooled mixture and evaporation 
removed the solvents. The residue was dissolved in CH2CI2 (100 mL) and washed 
with H20 (50 mL), saturated aqueous NaHCO3 (50 mL) and dried with NaS04. 
filtered and evaporated. The residue was purified by column chromatography on 
silica gel using CH2CI2/MeOH (5011, v/v) as eluent to give protected adenosine 187 
as a white solid (0.53 g, 80%), m. p. 143-145 "C (lit., 146-148 (>C)76; [a]24 D -90.83 (c 
1.02 in CHC13); 1H NMR (400 MHz, CDC13) 5H 9.30 (s, IH, NHBz), 8.79 (s, III, 
Ar-H), 8.11 (s, IH, Ar-H), 8.05-8.03 (m, 2H, BzH), 7.65-7.52 (m, 311, BzH), 5.98 (d, 
J=4.4,1 H, V-H), 5.25 (m, I H, 2 ý-H), 5.13 (dd, J1 = 6.0, J2 = 1.2,1 fl, 3'-H), 4.5 6 (m, 
I H, 4-H), 4.00 (dd, J, = 12.9, J2 = 1.6,1 H, 5'-CH,, Hb), 3.81 (m, 111,5-Cl IjIb), 1.67 
3H, CH3), 1.40 (s, 3H, CH3); 13 C NMR (100 MHz, CDC13) 8C 164.6 (C), 152.4 
(CH), 150.5 (C), 150.4 (C), 142.6 (CH), 133.4 (C), 132.9 (CH), 128.9 (CII), 128.0 
(CH), 124.3 (C), 114.3 (C), 94.2 (CH), 86.3 (CH), 83.2 (CH), 81.6 (CH), 63.3 (CI12)i 
27.6 (CHA 25.2 (CI43); ESI-MS 412.2 (M + H+); HRMS calcd for C2OH22N505+ 
412.1616, found 412.1605. 
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N6-Benzoyl-51-tosylate-21,31-0-isopropylidene-adenosine 1881 15 
rN NHBz 
0N 
TSO --ýN 
N- 
60 
p-Toluenesulfonyl chloride (526 mg, 2.76 mmol) was added to a solution of 
protected adenosine 187 (453 mg, 1.10 mmol) in dry pyridine (6 mL) at 0 OC and 
stirring continued for 3 hr and then at room temperature overnight. The reaction 
solution was concentrated and dissolved in EtOAc (10 mL) and washed with 1120 (2 
x 10 mL) and dried with Na2SO4. EtOAc was removed and the residue purified by 
column chromatography on silica gel using CH2CI2/MeOH (80/1, v/v) as eluent to 
give adenosyl tosylate 188 as a white solid (494 mg, 80%), m. p. 119-120 *C; [a]23 D 
20.54 (c 0.87 in CHC13); 1H NMR (400 MHz, CDC13) 8119.27 (s, I H, NHBz), 8.71 
IH, Ar-H), 8.11 (s, IH, Ar-H), 8.06-8.04 (m, 2H, BZH), 7.66-7.60 (m, 3H, BzH), 
7.55-7.52 (m, 2H, PhH), 7.24-7.22 (m, 2H, PhH), 6.16 (d, J=2.1,1 H, F-H), 5.3 8 
(dd, J1 = 6.2, J2 = 2.1,1 H, 2'-H), 5.06 (dd, J, = 6.2, J2 = 3.0,1 H, T-H), 4.52 (m, 111, 
4.29 (dd, J, = 10.6, J2 = 4.2,1 H, 5'-CH,, Hb), 4.24 (dd, J1 = 10.6, J2 = 5.8,114, 
51-CH, Ht, ), 2.40 (s, 3H, CH, ), 1.61 (s, 3H, CH; ), 1.40 (s, 3H, CH3); 13 C NMR (100 
MHz, CDC13) SC 164.7 (C), 152.7 (CH), 150.9 (C), 149.8 (C), 145.3 (C), 142.1 
(CH), 133.5 (C), 132.9 (C), 132.2 (CH), 129.8 (CH), 128.9 (CH), 127.9 (CH), 127.8 
(CH), 123.5 (C), 114.8 (C), 91.1 (CH), 84.7 (CH), 84.2 (CH), 81.4 (CH), 68.9 (CI12)9 
27.1 (CHA 25.3 (CHA 21.6 (CH3); ESI-MS 566.2 (M + H); HRMS calcd for 
C27H28N507S+ 566.1704, found 566.1678. 
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Ethyl 6-hydroxyl-6-phenyl-2(E)-hexten-4-ynoate 191 
OH 
OCH2CH3 
0 
n-BuLi (1.6 M in hexane, 1.5 mL, 2.42 mmol) was added to a solution of alkyne 
derived alkene compound 181 (300 mg, 2.42 mmol) in dry THF (10 mL) at -78 T 
and then benzaldehyde (0.20 mL, 1.94 mmol) added, the stirring continued at -78 'C 
for I hr. The reaction solution was quenched with saturated aqueous NH4Cl and 
extracted with EtOAc (2 x 10 mL) and dried with Na2S04, filtered and evaporated. 
The residue was purified with column chromatography on silica gel using 
Et20/Petroleum ether (1/3, v/v) as eluent to give benzalcohol 191 as yellow oil (170 
mg, 38%), v cm-1 3598 (OH), 1712 (C=O), 1622 (C=C, aromatic); lH NMR (400 
MHz, CDC13) 8" 7.53 (m, 2H, Ph-H), 7.43-7.41 (m, 3H, Ph-H), 6.85 (dd, il = 15.9, 
J2 = 1.7,1 H, C=-C-CH=CH), 6.26 (d, J= 15.9,1 fi, CH=CHCOOEt), 5.63 (d, J=1.7, 
I H, PhCH), 4.21 (q, j=7.2,2H, CH2CHA 1.31 (t, J=7.2,3 H, CH2CH3); 13 C NMR 
(100 MHz, CDC13) 8C 165.8 (C), 140.0 (C), 131.0 (CH), 128.7 (CH), 128.6 (CII), 
126.7 (CH), 124.5 (CH), 98.0 (C), 83.0 (C), 64.9 (CH), 60.9 (CH2), 14.7 (CH3)- 
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N6-Benzoyl-5'-deoxy-2', 3'-O-isopropylidene-5', 5'-(NýVý-diphenylethylenedi- 
amino)adenosine 1921 17 
CN NHBz 
N, 
L%ýN 
,N N 
60 
Dichloroacetic acid (0.05 mL, 0.64 mmol) was added slowly to a solution of 
protected adenosine 187 (0.52 g, 1.27 mmol) and DCC (0.78 g, 3.80 mmol) in dry 
DMSO (3 mQ with ice cooling and the mixture stirred at room temperature for 1.5 
hr. A solution of oxalic acid dihydrate (0.32 g, 2.54 mmol) in MeOH (3 mL) was 
added slowly to the mixture and stirring continued at room temperature for 30 min. 
The mixture was filtered and the white solid washed with cold MeOll. 
N,,, V-Diphenylethylenediamine (0.31 g, 1.46 mmol) was added to the combined 
filtrate and stirring continued at room temperature for I hr. The reaction mixture was 
diluted with EtOAc (20 mL) and washed with brine (2 x5 mL) and dried with 
Na2S04. filtered and concentrated. The residue was recrystallised from Doll to give 
protected adenosyl 5'-aidehyde 192 as off white solid (0.51 g, 67%), m. p. 134 OC (lit., 
132-135 OC); 117 [a]24 D 13.96 (c 0.73 in CHC13); 1H NMR (400 MHz, CDC13) 8119.25 
(s, IH, NHBz), 8.73 (s, IH, Ar-H), 8.05-8.03 (m, 2H, BzH), 7.83 (s, 111, Ar-H), 
7.63-7.52 (m, 3H, BzH), 7.28-7.16 (m, 4H, PhH), 6.83-6.73 (m, 6H, PhH), 6.18 (d, J 
= 2.4,1 H, V-H), 5.76 (m, I H, 2-H), 5.23 (m, I H, 3-H), S. 18 (dd, J, = 6.4, J2 = 2.4, 
H, 4ý-H ), 4.65 (dd, J, = 4.8, J2 = 2.4,2H, 5'-H), 3.77-3.5 8 (m, 4H, NCH2CH2N), 
1.51 (s, 3H, CHA 1.35 (s, 3H, CH4; 13C NMR (100 MHz, CDC13) SC 164.8 (C), 
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152.8 (CH), 151.3 (C), 149.6 (C), 146.5 (C x 2), 141.8 (CH), 133.6 (C), 132.8 
(CH), 129.4 (CH), 129.2 (CH), 128.8 (CH), 128.0 (CH), 123.1 (C), 118.4 (CH), 
118.3 (CH), 115.0 (C), 113.7 (CH), 113.5 (CH), 88.4 (CH), 87.0 (CH), 83.8 (CH), 
80.1 (CH), 73.3 (CH), 47.7 (CH2), 46.9 (CH2), 27.4 (CHA 25.8 (CH3); ESI-MS 
604.3 (M + H+); HRNIS calcd forC34H33N704+ 604-2667, found 604.2650. 
N6-Benzoyl-2', 3'-O-isop ropylidene-ad enosyl-5'-ca rboxa mid eýV- methoxyýV- 
methyl 194 119 
0rN NHBz 
H3CO- 
N0N 
1ý1ýjN 
6 
ýý 
N H3 
- 
-ý 
db Xý 
PyBOP (72 mg, 0.14 mmol) was added to a solution of protected adenosyl 
5ý-carboxylic acid 26 (54 mg, 0.13 mmol) and NO-dimethylhydroxylamine 
hydrochloride (15 mg, 0.15 mmol) in dry DMF (2 mL) and stirring continued at 
room temperature for 1.5 hr. The reaction solution was diluted with EtOAc (10 mL) 
and washed with 5% aqueous KHS04 (5 mL), saturated aqueous NaHC03 (5 mL), 
brine (5 mL) and dried with Na2SO4. filtered and concentrated. The residue was 
purified with column chromatography on silica gel using CH2CI2/MeOH (70/1, v/v) 
as eluent to give protected adenosyl 5'-amide 194 as a white solid (178 mg, 71%), 
m. p. 73-75 "C; [a] 21 D 48.39 (c 1.12, CHC13); lU max/ CM-1 3408 (NH), 1708 (C=O), 
1612(C=C, aromatic), 1588 (C=C, aromatic), 1087 (C-0); 1H NMR (400 MHz, 
CDC13) 5H 9.12 (s, I H, NHBz), 8.84 (s, I H, Ar-H), 8.47 (s, I H, Ar-H), 8.05-8.03 (m, 
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2H, BzH), 7.65-7.61 (m, I H, BzH), 7.56-7.52 (m, 2H, BzH), 6.49 (d, J=1.7,1 H, 
F-H), 5.48 (dd, J, = 5.6, J2 = 1.7, IH, 21-H), 5.32 (m, 2H, 3-H and 4-H), 3.76 (s, 
3 H, OCH3), 3.17 (s, 3 H, NCH3), 1.69 (s, 3 H, CH3), 1.46 (s, 3 H, CH3); 13 C NMR (100 
MHz, CDC13) 8c 169.5 (C), 164.6 (C), 152.8 (CH), 151.8 (C), 149.5 (C), 142.3 
(CH), 133.8 (C), 132.8 (CH), 128.9 (CH), 127.8 (CH), 122.8 (C), 114.2 (C), 91.8 
(CH), 85.1 (CH), 83.8 (CH), 83.3 (CH), 61.9 (CHA 32.3 (CH3)ý 27.0 (CHA 25.3 
(CH3); ESI-MS 469.2 (M + H+); HRMS calcd for C22H25N606+ 469.1830, found 
469.1824. 
(2S)-5-Pyrrolidin-2-yl-IH-tetrazole 198 123 
H HN-N 
Sodium azide (0.34 g, 5.2 mmol) and NH4CI (0.29 g, 5.5 mmol) were added to a 
solution of nitrile 209 (1.15 g, 5.0 mmol) in DMF (10 mL) and the reaction mixture 
stirred at 90 "C for 8 hr. After cooling down, the reaction solution was acidified to 
pH 2 with IM aqueous HCI and extracted with CHC13 (3 x 30 mL), and the 
combined organic layers were washed with brine (50 mL) and dried with Na2SO4. 
filtered and concentrated to give crude product as slightly yellow oil. The crude oil 
and Pd/C (10%, 0.27 g) in acetic acid/H20 (9: 1,75 mL) were stirred under an 
atmosphere Of H2 at room temperature for 4hr. The reaction mixture was filtered and 
the filtrate concentrated, the residue was rccrystallised with MeOH/Et2O to give 
tetrazole 198 as a off-white solid (0.32 g, 46%), m. p. 267-268 *C (lit., 269-271 "C); 137 
[a]20D 
-23.41 (c 0.62 in MeOH), 1H NMR SH (400 MHz, CD30D) 4.99 (t, J=7.8,1 H, 
206 
NHCH), 3.52 (m, 2H, CH2NH), 2.60-2.29 (m, 4H, CH2CH2CH); 13 C NMR 5c (100 
MHz, CD30D) 159.6 (C), 56.3 (CH), 46.6 (CH2), 3 1.1 (CHA 24.8 (CH2)- 
N6-Benzoyl-2', 3'-O-isopropylideneadenosyl-5'-propanaI 204 
ý--- N NHBz 
0 N--ýý 
_ýN N- 
6b 
Pd/C (2.7 g) was added to a solution of unsaturated adenosyl T-aldehyde 206 (5.40 g, 
12.40 mmol) in EtOAc (500 mL) and stirred under 112 (balloon) for 5 hr. The reaction 
solution was filtered and the filtrate concentrated, then the residue was purified with 
column chromatography on silica gel using CHC13/MeOH (70/1, v/v) as eluent to 
give adenosyl 5'-propaldehyde 204 as slightly yellow solid (3.85 g, 71%), m. p. 
70-7 VC; [a]20D-1.40 (c 1.21 in CHC13), 1) max/Ctn-' 3407 (NH), 1711 (CIIO), 1612 
(C=C, aromatic), 1587 (C=C, aromatic), 1091 (C-0); 'H NMR (400 MHz, CDC13) 811 
9.70 (t, J=0.9,1 H, CHO), 9.25 (s, I H, NHBz), 8.80 (s, III, Ar-H), 8.10 (s, III, 
Ar-H), 8.03 (m, 2H, BzH), 7.62 (m, I H, BzH), 7.52 (m, 2H, BzH), 6.10 (d, J=2.4, 
I H, P-H), 5.50 (dd, J, = 6.5, J2 = 2.4,1H, 2-H), 4.92 (dd, J, = 6.5, J2 = 4.2,111, 
3 ý-H), 4.23 (ddd, J, = 10.2, J2 = 6.2, J3 = 4.2,1 H, 4-H ), 2.5 6 (dt, J, = 7.1, J2 = 0.9, 
2H, 6'-CH2), 2.08 (m, 2H, 5'-CH2), 1.62 (s, 3H, CHI), 1.41 (s, 3H, CHj); 13 C NMR 
(100 MHz, CDC13) Sc 200.9 (CHO), 164.8 (C), 152.7 (CH), 151.3 (C), 149.9 (C), 
142.4 (CH), 133.6 (C), 132.8 (CH), 128.9 (CH), 128.0 (CII), 123.8 (C), 115.0 (C), 
90.3 (CH), 86.0 (CH), 84.0 (CH), 83.9 (CH), 39.8 (CH2), 27.2 (CHA 25.6 (CH2)9 
207 
25.4 (CH3); ESI-MS 438.2 (M + H+); HRMS calcd for C22H24N505+ 438.1772, found 
438.1768; Anal. Calcd for CMH23NA-0.51-120: C 59.19, H 5.42, N 15.69. Found C 
59.07, H 5.25, N 15.32. 
Cis-2-Ethoxycarbonylvinyltriphenylphosphonium bromide 205 122 
+0 
Ph3 P\----A 
OC2H5 Br- 
Lithium bromide (2.50 g, 29 mmol) was added to a solution of ethyl propynoate 
(2.00 mL, 19.6 mmol) in acetic acid (20 mL) and stirring continued at 70 *C 
overnight. The reaction solution was diluted with H20 (100 mL) and neutralized with 
K2CO3 and extracted with Et20 (3 x 50 mL). The combined organic layer was 
washed with brine (50 mL), dried with NaS04. filtered and concentrated. The residue 
was dissolved in toluene (60 mL), and triphenylphosphine (6.10 g, 23.50 mmol) was 
added at room temperature and stiffing continued for 2 days. The precipitate was 
filtered and the filtrate was concentrated. The residue was washed by ether to give 
phosphonium bromide 205 as white powder (5.90 g, 69%), m. p. 106-108 *C; 1H 
NMR (400 MHz, CDC13) 5fj 8.29 (dd, JIH- P= 19.6, J2 = 16.8,1H, CH=CHCOOEt), 
7.96-7.90 (m, 3H, Ph-H), 7.85-7.80 (m, 6H, Ph-H), 7.75-7.69 (m, 6H, Ph-H), 6.57 
(dd, JIH-p = 20.4, J2 = 16.8, IH, CH=CHCOOEt), 4.36 (q, J=7.2,211, CH2CH3)- 
1.3 8(t, J=7.2,3 H, CH2CHI); 13 C NMR (100 MHz, CDC13) SC 162.3 (d, f'p = 24.0, 
C=O), 145.4 (d,. f'p = 4.0, CH), 136.30 (d,. f'p = 3.0, CH-Ph), 134.1 (d,. f-P = 11.0, 
CH-Ph), 131.2 (d,. f*p = 13.0, CH-Ph), 125.0 (d, f-P = 82.0, CH), 116.0 (d,. f"P = 
91.0, C-Ph), 63.03 (CHA 14.13 (CH3)- 
208 
N6-Benzoyl-2', 3'-O-isopropylideneadenosyl-5'-(E)-propenaI 206 121 
-: 
_- 
N NHBz 
N 
'ý/ 
"N 
N 
Dichloroacitic acid (0.52 mL, 6.25 mmol) was added to a solution of protected 
adenosine 187 (5.14 g, 12.50 mmol) and DCC (7.70 g, 37.50 mmol) in dry DMSO 
(29 mL) at 
-5 *C under argon and stirring continued at room for 1.5 hr. The 
(triphenylphosphoranylidene)acetaldehyde (4.00 g, 13.0 mmol) was added and the 
resulting solution stiffed at room temperature for 5 hr. The reaction solution was 
filtered and the filtrate diluted with EtOAc (60 mL) and washed with brine (2 x 30 
mL) and dried with Na2SO4, filtered and concentrated. The residue was purified with 
column chromatography on silica gel using CHC13/MeOH (90/1, v/v) as elucnt to 
give unsaturated aldehyde 206 as a yellow solid (5.98 g, 57%), m. p. 98-100 T; 
[a]23 D 32.22 (c 1.17 in CHC13). 1) inax/cm-1 3408 (NH), 1696 (CHO), 1612 (C=C, 
aromatic), 1589 (C=C, aromatic), 1089 (C-0); 1H NMR (400 MHz, CDC13) 81,9.40 
(d, J=7.6,1 H, CHO), 8.69 (s, I H, Ar-H), 8.12 (s, I H, Ar-H), 8.00 (m, 211, Bzll), 
7.56 (m, I H, BzH), 7.46 (m, 2H, BzH), 6.81 (dd, J, = 15.8, J2 = 5.4,1 H, 5'-fl), 6.22 
(d, J=1.3, IH, I'-H), 6.07(ddd, JI=15.8, J2=7.6, J; =1.4, IH, 6'-H), 5.54(dd, J, 
= 6.3, J2 = 1.3,1 H, 2-H), 5.23 (dd, J1 = 6.3, J2 = 3.8,1 H, 3, -H), 4.91 (m, I H, 4'-H), 
1.62 (s, 3H, CH3), 1.39 (s, 3H, CH3); 13 C NMR (100 MHz, CDC13) 8C 192.5 (C), 
165.0 (C), 152.6 (CH), 151.5 (CH), 151.1 (C), 150.0 (C), 142.7 (CH), 133.9 (C), 
132.8 (CH), 132.2 (CH), 128.8 (CH), 128.0 (CH), 123.8 (C), 115.0 (C), 90.6 (CH), 
209 
86.5 (CH), 84.4 (CH), 84.1 (CH), 27.1 (CHA 25.4 (CH3); ESI-MS 436.2 (M + H+); 
HRMS caled for C22H22N505+ 436.1615, found 436.1612. 
(2S)-2-Carbamoyl-pyrrolidine-l-carboxylic acid benzyl ester 208 123 
Qýo 
6bz NH2 
1-Hydroxybenzotriazole (8.00 g, 52 mmol) and EDCI (6.70 g, 35 mmol) were added 
to a solution of Cbz-L-proline (8.64 g, 35 mmol) in THIF (200 mL) at room 
temperature and stirring continued for 30 min. The aqueous ammonia (23 mL) was 
added slowly and the reaction mixture was stirred for 24 hr. The saturated aqueous 
NH4CI (200 mL) was added and extracted with EtOAc (3 x 100 mL). The combined 
organic layers were dried with Na2SO4. filtered and concentrated, and the residue 
purified with column chromatography on silica gel using EtOAc/MeOH (100/1, v/v) 
as eluent to give amide 208 as colourless oil (6.48g, 75%), [a]29D -88.08 (ic 1.06, 
CHC13); lH NMR (400 MHz, CDC13) 8H 7.37 (m, 5H, Ph-H), 6.74-5.84 (m, 2H, 
NH2), 5.19 (d, J= 12.6,1H, PhCHaHb)v 5-15 (d, J= 12.6,1H, PhCHaHb), 4.37(m, 
IH, NCH), 3.56-3.48 (m, 2H, NCH2), 2.34-1.90 (m, 4H, CH2CH2CH); 13 C NMR 
(100 MHz, CDC13, as a mixture of rotamers) 8c 175.3/174.4 (C), 156.11155.1 (C), 
136.4 (C), 128.6 (CH x 2), 128.2 (CH), 127.9 (CH x 2), 67.4 (CH2), 60.7/60.2 (CH), 
47.5/47.1 (CH2), 31.1/28.5 (CHA 24.6/23.7 (CH2). 
210 
(2S)-2-Cyano-pyrrolidine-l-carboxylic acid benzyl ester 209 123 
C)-'CN 
N 
6bz 
p-Tolucnesulfonyl chloride (9-20 g, 48 mmol) was added to a solution of amide 208 
(6.00 g, 24 mmol) and pyridine (9.78 mL, 120 mmol) in CH2CI2 (60 mL). The 
reaction mixture was stirred at room temperature for 72 hr, and then saturated 
aqueous N114CI (45 mL) was added. The aqueous solution was extracted with EtOAc 
(3 x 100 mL) and combined organic layers dried with Na2S04, filtered and 
concentrated. The residue was purified with column chromatography on silica gel 
using EtOAc/Petroleum ether (1/1, v/v) as eluent to give nitrile 209 as yellow oil 
(4.00 g, 72%), [a, 21D 
-74.27 (c 2.25 in CHC13); 1H NMR (400 MHz, CDC13) 8H 
7.45-7.33 (m, 5H, Ph-H), 5.26-5.16 (m, 2H, PhCH2), 4.65-4.57 (m, Ili, CHCN), 
3.66-3.58 (m, IH, NCHHb), 3.50-3.40 (m, IH, NCH. Hb), 2.29-2.07 (m, 4H, 
CH2CH2CH); 13 C NMR (loo MHz, CDC13, as a mixture of rotamers) Sc 154.3/153.7 
(C), 136.1/136.0 (C), 128.6 (CH x 2), 128.3 (CH), 128.2 (CH x 2), 118.9/118.8 (C), 
67.8/67.7 (CH2), 47.6/47.0 (CH), 46.4/46.0 (CH2), 31.8/30.8 (CH2), 24.7/23.8 (CI12)- 
N6-Benzoyl-S'-deoxy-2', 3'-O-isopropylidene-51-[6-(3-carbethoxy-1,4,5,6-tetra- 
hydropyridazine)ladenosine 224 
C2H50 
N NHBz 
0 \, IN 
0 N-NH N 
--J 
6o ýK 
Pd/C (10%, 53 mg) was added to a solution of crude Cbz protected dihydro- 
211 
pyridazine 170b (106 mg) in THIF (5 mL) and stirred under H2 (balloon) over 2 
nights. The reaction solution was filtered and the filtrate concentrated, the residue 
purified with column chromatography on silica gel using CH2CI2/MeOH (70/1, v/v) 
as eluent to give tetrahydropyridazine 224 as colourless oil (20 mg, 28%), lH NMR 
(400 MHz, CDC13) SH 9.17 (s, IH, NHBz), 8.82 (s, IH, Ar-H), 8.10 (s, IH, Ar-H), 
8.06-8.04 (m, 2H, BzH), 7.65-7.52 (m, 3H, BzH), 6.60 (s, IH, NHCH), 6.09 (d, J= 
2.4,1 H, I ý-H), 5.50 (dd, J, = 6.6, J2 = 2.4,1 H, 2'-H), 5.00 (dd, J, = 6.6, J2 = 4.8, Ili, 
3'. H), 4.334.25 (m, 3H, 4W and CH2CHA3.37(m, IH, 6-H), 2.46(t, J=6.8,2f1, 
8'-CH2), 1.99-1.87 (m, 3H, Y-CH2 and T-CH,, Hb), 1.64 (s, 3H, CH3), 1.60 (m, I H, 
T-CH. Hb), 1.41 (s, 3 H, CH3), 1.34 (t, J=7.2,3 H, CH2CH3); 13 C NMR (100 MHz, 
CDC13) 8C 165.7 (C), 165.3 (C), 153.5 (CH), 151.8 (C), 150.6 (C), 143.0 (CII), 134.2 
(C), 133.5 (C), 133.2 (CH), 129.6 (CH), 128.6 (CH), 124.4 (C), 116.0 (C), 90.7 (CII), 
84.8 (CH), 84.6 (CH), 84.5 (CH), 61-5 (CH2), 48.8 (CH), 37.9 (012), 27.9 (Cfl3)9 
26.1 (CHA 24.2 (CH2), 20.9 (CHA 15.1 (CH3); ESI-MS 550.2 (M + li) [Found 
550.2407 C27H32N706 requires 550.2409]. 
N-(Benzyloxycarbonyl)-L-serine P-lactone 232a 126 
00 ýj CbzHN 
DEAD (0.66 mL, 4.18 mmol) was added dropwise to a solution of 
triphenylphosphine (1.1 g, 4.18 mmol) in dry THF (10 mL) at 
-78 T under argon. 
After 10min a solution of Cbz-L-serine (1.0 g, 4.18 mmol) in dry THIF (30 mL) was 
added dropwise over 10 min at -78 'C, and stirring continued for 20 min and at room 
212 
temperature for 2.5 hr. The reaction solution was concentrated and the residue 
purified with column chromatography on silica gel using EtOAc/Petroleum ether 
(1/2, v/v) as eluent to give P-lactone 232a as a white solid (303 mg, 33%), m. p. 
133-134 'C (lit., 133-134 oC); 126 [a]24 D 
-4.47 (c 1.3 in CHC13); 1H NMR (400 MHz, 
CD3CN) 51,7.40 (m, 5 H, Ph-H), 6.41 (s, I H, NH), 5.15 (s, 2H, PhCH2), 5.10 (m, I H, 
CHCH2), 4.43 (d, J=6.4,2H, CHCH2); 13C NMR (100 MHz, CD3CN) 5c 169.6 (C), 
155.2 (C), 136.3 (C), 128.2 (CH), 127.9 (CH), 127.7 (CH), 66.5 (CH2), 65.5 (CH2)ý 
59.1 (CH). 
N-(tert-Butoxycarbonyl)-L-scrine P-lactone 232b 126 
00 Ij 
BocHN 
P-Lactone 232b was prepared by the same procedure of P-lactone 232a as a white 
solid (290 mg, 32%), m. p. 119-120 *C (dec) (lit., 119.5-120.5 OC (dec)); 
126 ICE] 24 D 
-5.02 (c 0.69 in CHC13); 1H NMR (400 MHz, CD3CN) SH 6.05 (s, I H, NH), 5.02 
(app. q, J=5.9,1 H, CHCHA 4.39 (d, J=5.9,2H, CHCH2), 1.45 (s, 9H, C(CH3)3); 
13 C NMR (100 MHz, CD3CN) Sc 170.3 (C), 154.9 (C), 80.2 (C), 65.9 (012), 59.2 
(CH), 27.4 (CH3)- 
(S)-Ethyl-N-(benzyloxycarbonyl)-2-amino-3-(diethylphosphono)propanoate 
233a 127 
Cbz, 
NH 0 
11 C2H50 PI-OC2H5 Y' 
OC2HS 
0 
213 
Triethyl phosphite (1.7 mL, 9.6 mmol) and P-lactone 232a (212 mg, 0.96 mmol) 
were combined and heated at 70 *C under argon for 2 days. The reaction solution 
was concentrated and the residue was purified with column chromatography on silica 
gel using CH2CI2/CH30H (70/1, v/v) as eluent to give phosphonopropanoates 233a 
as colourless oil (300 mg, 81%), [aj24D 8.43 (c 0.45 in CHC13); 1H NMR (400 MHz, 
CDCI-3) 81,7.35 (m, 5H, Ph-H), 5.96 (d, J=7.6,1 H, NH), 5.15 (s, 2H, PhCH2), 4.62 
(m, CHCH2), 4164.06(m, 6H, CH2CH3 x 3), 2.38 (m, 2H, CHCH2), 1.35-1-29 (m, 
CH2CH3 x 3); 13 C NMR (100 NIHZ, CDC13) SC 170.6 (d, f-P = 8.7, C=O), 155.8 
(C=O), 136.3 (C), 128.5 (CH), 128.1 (CH), 128.1 (CH), 67.0 (CH2), 62.2 (d, f-" = 
7.5, CH2), 62.0 (d, f'p = 13.1, CHA 49.6 (d, f'p = 6.5, CH), 28.5 (d, fp = 141.3, 
CH2)v 16A (CH3), 16.3 (CHA14.1 (CH3); 31 P NMR (162 MHz, CDC13) 8p 26.60. 
(S)-Ethyl-N4tert-butoxycarbonyl)-2-amino-3-(diethylphosphono)propanoate 
233b 127 
Boc, 
NH 0 
11 C-2HSO P, 
-OC2H5 
0 
OC2HS 
Phosphonopropanoates 233b, was prepared by the same procedure of 
phosphonopropanoates 233a as colourless oil (210 mg, 62%), [a]24 D 8.35 (c 1.02 in 
CHC13); 111 NNIR (400 Niliz, CDC13) 8" 5.69 (d, J=7.6, IH, NH), 4.54 (m, IH, 
CHC112), 4.25-4-11 (m, 611, CH2CH3 x 3), 2.36 (m, 2H, CHCH2), 1.47 (s, 9H, 
C(CHj)j), 1.37-1.30 (m, 9H, CH2CHj x 3); 13 C NMR (100 MHz, CDC13) SC 17 1.0 (d, 
. 
f-P 
= 10.0, C=O), 155.2 (C=O), 80.0 (C), 62.1 (d, f- p=5.0, CHA 62.0 (d, f-P = 
214 
6.0, CHA 61.7 (CH2), 49.2 (d, JFP = 6.0, CH), 28.5 (d, fp = 142.0, CH2), 28.3 
(CH3)9 16.4 (d,. f-P = 2.0, CH3)i 16.3 (d,. f'p = 2.0, CHA 14.1 (CH3); 31 P NMR (162 
MHz, CDC13) 8p 26.90. 
S-1-Methyl-2-(Iert-butyloxycarbonylamino)-3-iodopropyrate 237 129 
NHBoc 
MeO I 
0 
K2CO3 (0.74 g, 5.36 mmol) was added to a solution of BOC-L-serine (1.0 g, 4.87 
mmol) in dry DMF (5 mL) at 0 "C and stirring continued for 10 min. Methyl iodide 
(0.61 mL, 9.74 mmol) was added to this mixture at 0 *C and stirring continued for 30 
min and then at room temperature for 2 hr. The reaction solution was filtered and the 
filtrate diluted with EtOAc (50 mL) and washed with brine (3 x 20 mL). The organic 
layer was dried with Na2S04. filtered and concentrated. Iodine (2.47 g, 9.74 mmol) 
was added to a solution of triphenylphosphine (2.55 g, 9.74 mmol) in dry CH2CI2 (10 
mL) at O'C and stirring continued for 20 min. A mixed solution of the crude serine 
and imidazole (0.66 g, 9.74 mmol) was added to the iodine solution at 0 'C and 
stirring continued for 3 hr. The reaction solution was diluted with Et20 (20 mL) and 
washed with saturated aqueous Na2S203 (10 mL) and H20 00 mL), dried with 
Na2S04. filtered and concentrated. The residue was purified with column 
chromatography on silica gel using EtOAc/Petroleurn ether (1/10, v/v) as eluent to 
give iodide 237 (439 mg, 28%) as yellow oil, [a]21D 41.28 (c 1.02 in CHC13); 1H 
NMR (400 MHz, CDC13) 8H 5.3 8 (d, J=6.4,1 H, NHBoc), 4.55 (m, I H, CHCHA 
3.83 (s, 3H, CH3), 3.60 (m, 2H, CHCH2), 1.48 (s, 9H, CH3); 13 C NMR (100 MHz, 
215 
CDC13) SC 170.1 (C), 154.9 (C), 80.5 (C), 53.7 (CH), 53.0 (CHA 28.3 (CH3), 7.9 
(CH2). 
Biological assays 
Determination of ICso values were carried out by Dr Richard Parry at the Department 
of Pharmacy and Pharmacology, University of Bath. 
In vitro methylation reactions were carried out as detailed by Cheng and 
co-workers 
. 
40 All methylation reactions were carried out in the presence of 0.5 gM 
S-adenoSyl-L-[S_3 H3C] methionine (85 Ci/mmol from a 12.6 pM stock solution; 
Amersharn Biosciences) and a final volume of 30 pL of PBS (137 mM NaCl, 2.7 
mM KCI, 4.3 mM Na2HP04,1.4 mM KH2PO4. pH 7.4). The reactions contained 
0.1-0.2 pg of recombinant PRMTI or SET7 and 0.5-1.0 pg of substrate (recombinant 
Sam68 and histone H3 (Sigma Aldrich) respectively) with various concentrations of 
inhibitor (e. g. 74a). The reactions were incubated at 30 'C for 90 min and terminated 
by addition of 20 pL SDS-PAGE sample buffer and boiling for 5 min. Proteins were 
separated by SDS/PAGE, transferred to nitrocellulose membrane, and stained by 
Ponceau S. The visualised bands of substrate protein were excised and counted by 
liquid scintillation. 
Computational docking 
Computational docking was carried out by Dr Hao Wang at the School of Pharmacy, 
University of Nottingham. 
216 
The structures of the bisubstrate inhibitors, 74(a-c), 77 and 78 were built by 
commercially available sofhvare Insight 11 created by Accelrys; Software Inc. 130 The 
docking sofh%-arc Gold 3.2 (Genetic Optimization for Ligand Docking) 131 was used 
to dock all bisubstrate inhibitors into the binding site of PRMTI. During the Gold 
docking process. the crystal structure of PRMTI in complex with the cofactor 
product SAH (PDB I ORS)16, vvas taken as a starting point for molecular docking. The 
atoms of SAII %%-crc used as a reference to indicate the binding site (all protein atoms 
within 5A of SAH) for the bisubstrate inhibitors, and then the coordinates for SAH 
could be discarded during the docking process. The coordinates that remained were 
then taken as the input protein receptor for the docking along with the definition of 
the desired binding site. 
217 
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